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1. List of abbreviations 
Table 1. List of abbreviations. 
Abbreviation Full name 
2YT 2X-Yeast extract-tryptone 
4-IPP 4-Iodo-6-phenylpyrimidine 
A.U. Arbitrary units 
aa Amino acids 
ABCA1 ATP-binding cassette sub-family A member 1 
ANOVA Analysis of variance 
AP2 Adaptor protein complex 2 
APS Ammonium peroxodisulfate 
ARP2/3 Actin-related protein 2/3 [complex] 
ARPC3, 4 Actin-related protein 2/3 complex subunit 3, 4 
AS Ammonium sulphate 
ATP Adenosine triphosphate 
birA Biotin protein ligase A 
BMDM Bone marrow-derived macrophage 
CCD Charge-coupled device 
CCL2 C-C motif chemokine 2 
ccRCC Clear cell renal cell carcinoma 
CD Cluster of differentiation 
Cdc42 Cell division control protein 42 homolog 
CHO Chinese hamster ovary 
CME Clathrin-mediated endocytosis 
COP9 Constitutive photomorphogenesis 9 
COS CV-1 in origin, carrying SV40 
COX-2 Cyclooxygenase-2 
CPZ Chlorpromazine 
CREB 3’,5’-cyclic adenosine monophosphate-responsive element-binding protein 
CSN5 COP9 signalosome subunit 5 
CXCL8/12/14 C-X-C motif chemokine ligand 8/12/14 
CXCR2/4/7 C-X-C motif chemokine receptor type 2/4/7 
DAPI 4’,6-Diamidino-2-phenylindole 
D-DT D-Dopachrome tautomerase 
D-DTL D-Dopachrome tautomerase-like 
DMEM Dulbecco’s modified Eagle’s medium 
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DMSO Dimethyl sulfoxide 
DTT Dithiothreitol 
DYN Dynasore 
E. coli Escherichia coli 
EC Enzyme Commission 
ECL Enhanced chemiluminescence 
ECM Extracellular matrix 
EDTA 2,2’,2’’,2’’’-(Ethane-1,2-diyldinitrilo)tetraacetic acid 
EGF Epidermal growth factor 
EGFP Enhanced green fluorescent protein 
EGFR Epidermal growth factor receptor 
EGTA Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid 
Ena/VASP Protein enabled homolog/vasodilator-stimulated phosphoprotein 
ERK1/2 Extracellular signal-regulated kinase 1/2 
ERM Ezrin-radixin-moesin (family) 
EtOH Ethanol 
F Focus 
F-actin Filamentous actin 
FCS Foetal calf serum 
FIL Filipin 
For Forward primer 
FPLC/HPLC Fast protein/high-performance liquid chromatography 
fps Frames per second 
g G-force (gravitational force) 
G-actin Globular actin 
GAP GTPase-activating protein 
GDP Guanosine 5’-diphosphate 
GEF Guanine nucleotide exchange factor 
GFP Green fluorescent protein 
GILZ Glucocorticoid-induced leucine zipper 
GPCR G-protein coupled receptor 
GR Glucocorticoid receptor 
GST Glutathione S-transferase 
GTP Guanosine 5’-triphosphate 
HA Hyaluronic acid 
HCC Hepatocellular carcinoma 
HCl Hydrochloric acid 
hD-DT Human D-DT 
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HED 2-Hydroxyethyldisulfide 
HEK293 Human embryonic kidney 293 cells 
HIF-1α Hypoxia-inducible factor-1α 
hMIF Human MIF 
HPP p-Hydroxyphenylpyruvate 
HRP Horseradish peroxidase 
IB Immunoblot 
IF Intermediate filament 
IGF-I Insulin-like growth factor I 
IgG Immunoglobulin G 
IL Interleukin 
IP Immunoprecipitation 
IPTG Isopropyl-β-D-thiogalactopyranoside 
ISO-1 (S,R)-3-(4-Hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid 
JAB1 Jun activation domain-binding protein 1 
LAS Lysis and F-actin-stabilising [buffer] 
LB Lysogeny broth 
MAPK Mitogen-activated protein kinase 
MCP-1 Monocyte chemotactic protein 1 
mD-DT Murine D-DT 
MDSC Myeloid-derived suppressor cell 
MEF Mouse embryonic fibroblast 
MHC Major histocompatibility complex 
MIF Macrophage migration inhibitory factor 
MIP MIF- and D-DT-interacting protein 
miRNA MicroRNA 
MLCK Myosin light chain kinase 
MMP Matrix metalloproteinase 
MT Microtubule 
NaOH Sodium hydroxide 
NDPK Nucleoside diphosphate kinase 
NET Neutrophil extracellular trap 
NF-κB Nuclear factor of kappa light polypeptide gene enhancer in B cells 
NYS Nystatin 
OD600 Optical density at 600 nm 
Opti-MEM Optimal minimal essential medium 
p27Kip1 p27/kinesin-related protein 1 
PBMC Peripheral blood mononuclear cell 
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PBS or DPBS Phosphate-buffered saline (or Dulbecco’s phosphate-buffered saline) 
PCR Polymerase chain reaction 
PDGF Platelet-derived growth factor 
PDGF-BB Platelet-derived growth factor chain BB 
pH Power of hydrogen (or negative log of the hydrogen ion concentration) 
PMSF Phenylmethyl sulfonyl fluoride 
PtK1 Female rat-kangaroo kidney epithelial [cell] 
RA Rheumatoid arthritis 
Rac1 Ras-related C3 botulinum toxin substrate 1 
Rev Reverse primer 
RhoA Ras homolog gene family, member A 
RhoGDI Rho GDP-dissociation inhibitor 
RNAi RNA interference 
ROS Reactive oxygen species 
rpm Revolutions per minute 
SDF-1 Stromal cell-derived factor 1 
SDS Sodium dodecyl sulphate 
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
siRNA short interfering RNA 
SOB Super optimal broth 
SOC Super optimal broth with catabolite repression 
STAT5 Signal transducer and activator of transcription 5 
TAE Tris base, acetic acid, EDTA 
TBST Tris-buffered saline/Tween-20 
TCA Trichloroacetic acid 
TEMED N,N,N′,N′-Tetramethylethylenediamine 
TEV Tobacco etch virus 
TFB Transformation buffer 
TH T helper [cell] 
THP-1 Human monocytic leukaemia cell line 
TIFF Tagged Image File Format 
TNF-α Tumour necrosis factor alpha 
VEGF Vascular endothelial growth factor 
VSMC Vascular smooth muscle cell 
WAVE WASP (Wiskott-Aldrich syndrome protein)-family verprolin-homologous protein 
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2. Introduction 
This thesis focuses on cell motility and two paralogous cytokines, macrophage migration 
inhibitory factor (MIF) and D-dopachrome tautomase (D-DT). MIF’s eponymous function 
was first demonstrated when it was shown to inhibit random migration of peritoneal 
macrophages in the delayed-type hypersensitivity reaction (Bloom and Bennett, 1966). In 
the next decades, it turned out to mediate a number of processes in healthy as well as 
diseased cells and tissues. The essential role of MIF in a number of inflammatory 
conditions such as wound healing (Gilliver et al., 2011) or acute respiratory distress 
syndrome (ARDS) (Donnelly et al., 1997; Lai et al., 2003) is well documented. 
Depending on its tissue of origin, MIF may act as a stress-induced hormone and cytokine 
(Bernhagen et al., 1993), chemokine (Bernhagen et al., 2007), tumour promoter (Mitchell, 
2004; Bucala and Donnelly, 2007; Du et al., 2012), tumour suppressor (Tarnowski et al., 
2010), redox modulator (Koga et al., 2011), inducer of epithelial-to-mesenchymal 
transition (Funamizu et al., 2012), pro-angiogenic factor (Ren et al., 2003), pro-
proliferative factor (Ohta et al., 2012), and pro-survival agent (Mitchell et al., 2002). 
Particularly, as a modulator of cell motility, it plays a differential role in wound healing 
(Gilliver et al., 2011), chemotaxis and invasion. D-DT is a structural and functional 
homologue of MIF that likely arose due to MIF gene duplication (Kamir et al., 2008). 
Similar to MIF, D-DT binds CD74 and upregulates mitogen-activated protein kinase 
(MAPK)/extracellular signal-regulated kinase 1/2 (ERK1/2), a pathway responsible for 
mitogen-mediated transduction of signalling from the extracellular environment, via CD74 
as well as G-protein coupled receptors (GPCRs), through a cascade of cytoplasmic kinases 
to the nucleus where it activates target genes including cyclin D1 (Merk et al., 2011). In 
A549 adenocarcinoma cells, MIF/D-DT promote two pro-angiogenic factors – C-X-C motif 
chemokine ligand 8 (CXCL8)/interleukin-8 (IL-8) and vascular endothelial growth factor 
(VEGF) (Coleman et al., 2008). Moreover, MIF/D-DT regulate the migration of human clear 
cell renal cell carcinoma (ccRCC) cells (Pasupuleti et al., 2014). Clinically, D-DT and S-
nitros(yl)ated MIF are cardioprotective (Luedike et al., 2012; Qi et al., 2014) and serve as 
markers of sepsis severity (Merk et al., 2011).  
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2.1. MIF/D-DT play a role in immunity and inflammation 
The immune system endows us with protection against viruses, parasites and bacteria by 
means of non-specific innate immunity (section 2.1.1) and antibody-based adaptive 
immunity (section 2.1.2).  
2.1.1. Innate immunity 
Innate immunity is triggered within a matter of minutes and hours after an encounter of a 
variety of extracellular compounds known as danger-associated molecular patterns 
(DAMPs) – DNA, RNA, or adenosine triphosphate (ATP) – and pathogen-associated 
molecular patterns (PAMPs) – foreign DNA or RNA, endotoxin, or CpG motifs. 
A key part of innate immunity is the release of neutrophil extracellular traps (NETs) – 
composed of neutrophil-derived DNA and histones, neutrophil elastase, and cathepsin G – 
in order to encapsulate and digest large bacteria and fungi through a specialised cell death 
phenomenon known as NETosis (Branzk et al., 2014). Via MAPK and reactive oxygen 
species (ROS), MIF promotes NET release upon infection with Pseudomonas aeruginosa 
(Dwyer et al., 2014). In the context of cystic fibrosis, prolonged MIF-triggered NETosis 
aggravates the disease (Dwyer et al., 2014), a finding supported by the fact that MIF–/– 
mice exhibit better P. aeruginosa clearance than their WT littermates (Bozza et al., 1999). 
There are a number of cell types associated with innate immunity: certain subsets of 
T cells, eosinophils and basophiles, dendritic cells, mast cells, monocytes/macrophages, 
and neutrophils. MIF was shown to: (a) promote eosinophil accumulation via C-X-C motif 
chemokine receptor 4 (CXCR4) (de Souza et al., 2015); (b) enhance mast cell recruitment 
via signal transducer and activator of transcription 5 (STAT5) and possibly CXCR4 (Põlajeva 
et al., 2014); (c) promote chemotaxis and cause a subsequent arrest of 
monocytes/macrophages (Bernhagen et al., 2007); (e) affect lung neutrophil recruitment 
(Rajasekaran et al., 2014); and (f) induce chemotaxis of interstitial monocytes and 
neutrophils in sterile inflammation (Stark et al., 2013). 
Although MIF is not known to be directly involved in danger or pathogen recognition, its 
key function seems to be the induction of the expression of tumour necrosis factor (TNF)-
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α, interleukins, and cyclooxygenase-2 (COX-2) (Xin et al., 2010) in macrophages. Indeed, 
the basis of the resolution of acute, early inflammation is that macrophages phagocytose 
foreign material and secrete cytokines. Overall, one report suggested that MIF is an early 
modulator of inflammation rather than a pro-inflammatory cytokine (Kudrin et al., 2006). 
2.1.2. Adaptive immunity 
The adaptive immune system is comprised of B and T cells that generate antibodies 
against foreign peptides and proteins over the course of a few days. MIF-dependent 
chemotaxis is essential for the migration of circulating B and T cells (adaptive immunity) 
but also neutrophils and monocytes/macrophages (innate immunity) (Bernhagen et al., 
2007; Klasen et al., 2014; Alampour-Rajabi et al., 2015) (section 2.6). Both B and T cells are 
regulated by many factors including regulatory B and T (Breg and Treg) cells. 
The T cell-mediated responses are further modulated by type 1 (TH1) and type 2 (TH2) 
T helper (Th) cells. Briefly, TH1 are associated with pro-inflammatory, cell-mediated 
responses, and TH2 with anti-inflammatory, humoral responses. MIF is known to promote 
TH1-mediated immunity after cardiovascular surgery and may contribute to multiple organ 
dysfunction syndrome (de Mendonça-Filho et al., 2006; Larson and Horak, 2006). TH2 cells 
can also release MIF (Bacher et al., 1996). 
In concert with other cytokines, MIF is known to be responsible for the following chain of 
inflammation-potentiating events in monocytes/macrophages and fibroblasts: activation 
of ERK1/2 by phosphorylation, activation of cytosolic phospholipase A2 (cPLA2) and COX-2, 
and the production of prostaglandins (Xin et al., 2010). 
Therapeutically, such inflammation may be treated with immunosuppressants such as 
glucocorticosteroids, and MIF is involved at this stage as well. 
Binding of glucocorticosteroids to their cytoplasmic glucocorticoid receptor (GR) elicits 
(a) inhibition of cPLA2 as well as (b) GR translocation to the nucleus to (c) trigger anti-
inflammatory gene expression including mitogen-activated protein kinase phosphatase-1 
(MKP-1). At the same time, glucocorticoid-induced leucine zipper (GILZ) facilitates the 
expression of MKP-1. Overall, ERK1/2 dephosphorylation by MKP-1 and the GC-mediated 
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inhibition of cPLA2 diminishes immune responses as well as the synthesis of 
prostaglandins. One of the most prominent features of MIF is that it counteracts the anti-
inflammatory action of glucocorticosteroids (Alourfi et al., 2005) by: (a) upregulating 
ERK1/2 phosphorylation which leads to COX-2 activation, as well as (b) inhibiting GILZ in a 
mitogen-activated protein kinase phosphatase-1 (MKP-1)-dependent manner (Roger et 
al., 2005; Fan et al., 2014). One example of an autoimmune disorder treated with 
glucocorticosteroids is chronic joint inflammation known as rheumatoid arthritis (RA). In 
RA, prolonged MIF exposure is known to exacerbate the symptoms, as it overrides the 
glucocorticosteroid effect. 
In summary, MIF is important in human immunity by keeping the homeostasis of tissues 
by inhibiting the anti-inflammatory responses of glucocorticoids, thereby potentiating the 
inflammation to fight the disease. Nonetheless prolonged inflammation aggravates tissue 
damage, so that the development of novel MIF inhibitors such as MIF DNA vaccines is 
much needed (section 2.5). 
2.2. MIF/D-DT: gene and protein 
Human MIF and D-DT genes are located at chromosome 22q11.23 and are conserved 
across a broad range of species including humans, rodents, bacteria, parasitic nematodes 
(Qu et al., 2014), plants (Panstruga et al., 2015), and others (Fingerle-Rowson et al., 2003). 
Following cleavage of the first methionine, the first amino acid in the mature full-length 
MIF (and D-DT) protein is Pro-2 encoded by the triplet CCT for MIF and CCG for D-DT 
(Figure 1A-B). Conserved among species, Pro-2 is required for MIF/D-DT 
isomerase/tautomerase enzymatic activities (section 2.4) (Bendrat et al., 1997; Nishihira 
et al., 1998). 
MIF and D-DT genes both contain three exons and two introns (Calandra and Roger, 2003; 
Merk et al., 2012). Within their promoters various transcription factor-binding elements 
can be found including: (a) NF-κB (for MIF); (b) 3’,5’-cyclic adenosine monophosphate-
responsive element-binding protein (CREB) (for both MIF and D-DT), and (c) hypoxia-
responsive elements (HREs) (for both MIF and D-DT) (Pasupuleti et al., 2014). Upon 
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oxygen depletion, hypoxia-inducible factor-1α (HIF-1α) potently induces MIF expression 
which is further promoted by concomitant hypoxia-driven CREB degradation (Baugh et al., 
2006). 
Two gene promoter polymorphisms for MIF are documented in a number of autoimmune 
diseases and cancer: a single-nucleotide polymorphism (SNP) -173 G>C (guanine-to-
cytosine) (rs755622) and a short tandem repeat (STR) -794 CAAT5-8 (5-8 repeats of 
cytosine-adenine-thymine-thymine) (rs5844572) (Grieb et al., 2010). Their identification 
helps to improve disease risk assessment by validating MIF as a biomarker. 
At the protein level human MIF is a 12.5-kDa single-chain polypeptide composed of 
114 amino acids whereas human D-DT (12.7 kDa) is 118-amino-acid in length. MIF and D-
DT monomers contain two α-helices and six β-sheets (Figure 1A-B). Deletions and 
substitutions of select MIF residues were a basis for much research on MIF’s enzymatic 
activities and secondary structure in the past (section 2.5). Δ4 MIF (deletion of the first 
four amino acids at the N-terminus: Pro-2, Met-3, Phe-4 and Ile-5) exhibits an increase in 
random coil structure. 
In solution as well as in tissues, MIF monomers are capable of forming higher oligomers 
including trimers. An MIF homotrimer – which possesses a negatively-charged channel, 
akin to a barrel – exerts most if not all of its physiological effects (Fan et al., 2013). An Asn-
110 substitution (N110C) results in an artificially locked MIF trimer (Ouertatani-Sakouhi et 
al., 2010; Reidy et al., 2013). Leu-46 was reported to play a role in the maintenance of the 
secondary/tertiary structure of MIF (El-Turk et al., 2012). 
An ELR motif, composed of Glu (E), which be substituted for Asp (D) by a conserved 
exchange, and Arg (R), is necessary for chemokine-chemokine receptor interactions. In 
MIF there is no genuine ELR motif but there is a pseudo (E)LR motif composed of Arg-12 
(R) and Asp-45 (D) (Figure 1A). Physiologically, this pseudo (E)LR motif is responsible for 
the interaction between MIF and one of its receptors, CXCR2 (Weber et al., 2008). Such an 
ELR or pseudo (E)LR motif is absent from human and murine D-DT (Figure 1B). 
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MIF has a Cys-Xaa-Xaa-Cys (CXXC)-based thiol-protein oxidoreductase activity (Figure 1A). 
In case of MIF, the CXXC motif is a Cys-57-Ala-Leu-Cys-60 (CALC) motif. The two cysteines 
within CALC are indispensable for enzymatic activity. Out of the three conserved cysteines 
(Cys-57, -60 and -81) in MIF across species, D-DT retains only one (Cys-57) (Figure 1A and 
B), which is insufficient for D-DT to catalyse oxidoreduction. Physiologically, S-
nitros(yl)ation of Cys-81 increases the oxidoreductase activity and is cardioprotective by 
decreasing apoptosis (Luedike et al., 2012). 
O-linked β-N-acetylglucosamine (O-GlcNAc) modifies MIF at Ser-112/Thr-113. O-GlcNAc-
MIF binds epidermal growth factor receptor (EGFR) and has implications in tumour 
invasion (Zheng et al., 2015). 
MIF may be putatively cleaved by kallikrein-related peptidases (Shahinian et al., 2014). In 
a mass spectrometry-based proteomics screen two other putative post-translational 
modifications of MIF were identified: cysteinylation and glycation (Sherma et al., 2014). 
An oxidised form of MIF exists in tumour tissues (Thiele et al., 2015b) and is essential for 
triggering glomerulonephritis (Thiele et al., 2015a). 
Based on a study with a series of MIF-derived synthetic peptide fragments, the region 
spanning MIF amino acids 50-65 (MIF50-65) (Figure 1A) was described as physiologically-
relevant because it was capable of mediating most of full-length MIF’s biological functions 
including redox (CALC motif), pro-proliferative, and glucocorticoid overriding activities 
(Nguyen et al., 2003). Taken together, it appears that all the many post-translational 
modifications of MIF generate a variety of MIF molecules which might be tissue-, cell-, and 
disease-specific. 
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Figure 1. MIF/D-DT monomers share similarities in their primary and secondary structures. (A and B) 
MIF/D-DT crystal structures are shown as false colour-coded ribbons (made with PyMOL) and based on data 
deposited under Protein Database identifiers 1MIF and 1DPT, respectively. The amino acid sequence identity 
between human MIF and human D-DT is 37% based on Blocks Substitution Matrix 62 (BLOSUM62). For 
clarity only some of the identical amino acids are shown (Pro-2, Cys-57). Each MIF/D-DT monomer is 
composed of two α-helices and six β-sheets. (A) The first four amino acids of the N-terminus (Pro-2, Met-3, 
Phe-4 and Ile-5) in MIF (red) are deleted in the MIF Δ4 mutant (Materials and Methods). Pro-2 (red, stick 
structure) is required for the tautomerase activity. Arg-12 and Asp-45 (magenta, stick structures) form a 
pseudo-(E)LR motif responsible for the MIF-CXCR2 interaction. MIF’s CALC (Cys-Ala-Leu-Cys) oxidoreductase 
motif contains three cysteines (Cys-57, -60, and -81). Cys-60 is mutated to Ser in the oxidoreductase-null MIF 
mutant (Materials and Methods). The MIF50-65 polypeptide is marked in black. (B) Pro-2 (red) and Cys-57 
(green) of D-DT are conserved in both proteins. 
 
2.3. MIF/D-DT are distributed among various tissue 
At the cellular level MIF can be nuclear, cytoplasmic, or secreted. Though MIF localises to 
the nucleus (Pyle, 2003), a nuclear localisation signal is missing from its sequence, and its 
nuclear function remains undetermined. Within the cytoplasm, MIF localises to the cell 
periphery (Kleemann et al., 2000a; Filip et al., 2009) where it complexes with Jun 
activation domain-binding protein 1 (JAB1)/COP9 signalosome complex subunit 5 (CSN5). 
Current knowledge holds that JAB1 and MIF bind and mutually inhibit one another. On the 
one hand JAB1 binds MIF, inhibits its secretion, and as such inhibits secreted MIF-
mediated AKT phosphorylation in human HEK293 cells (Lue et al., 2007). On the other 
hand, MIF binds and inhibits JAB1 leading to p27Kip1 stabilisation and fibroblast growth 
arrest (Kleemann et al., 2000a). JAB1 regulates both transient and sustained ERK1/2 
activation by MIF (Lue et al., 2006). In HCT116 human adenocarcinoma cells, a ternary 
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complex composed of MIF, JAB1 and HIF-1α plays a role in stabilising the latter (No et al., 
2015). D-DT has also been recently described to bind JAB1 (Merk et al., 2011). 
Although MIF and D-DT lack a cleavable N-terminal or internal secretion signal, MIF is 
secreted in a non-classical manner by binding to the Golgi complex-associated protein 
p115 (Eickhoff et al., 2001; Flieger et al., 2003; Merk et al., 2009). In LPS-stimulated 
monocytes, MIF co-localises with the Golgi-associated protein p115 in the cytoplasm as 
well as at the Golgi, and both are secreted as a complex, but competition binding assays 
do not exclude the possibility that additional proteins are present within such a complex 
(Merk et al., 2009). 
Because MIF does not enter the endoplasmic reticulum and Golgi apparatus (Merk et al., 
2009) it cannot be N-glycosylated. On the other hand, since O-glycosylation takes place in 
the MIF-containing nucleus and cytoplasm, a secreted O-GlcNAcylated MIF species have 
been described in human cells (Zheng et al., 2015). Zheng et al. identified two enzymes – 
O-GlcNAc transferase and O-GlcNAcase – as mediating this post-translational 
modification. How secreted MIF can acquire O-linked glycosylation within the cytoplasm in 
vivo, and whether O-glycosylated MIF specifically affects cell migration or invasion, 
remains currently unknown. 
In human monocytic leukaemia THP-1 cells, the export of MIF is mediated by a 12-
transmembrane anion transporter known as ATP-binding cassette sub-family A member 1 
(ATP-binding cassette transporter 1, ABCA1) based on a report using ABCA1 inhibitors 
glyburide and probenecid (Flieger et al., 2003). However, in human renal cell carcinoma 
RCC4 cells shRNA-mediated knockdown of ABCA1 did not impair radiation-induced MIF 
secretion (Gupta et al., 2016), suggesting MIF secretion pathways vary between cell types. 
MIF is constitutively expressed and is believed to be released into the extracellular milieu 
upon stimulation with various substances including endotoxin. However, human foreskin 
fibroblasts produce MIF de novo upon human cytomegalovirus infection (Bacher et al., 
2002). In quiescent NIH 3T3 – used by many laboratories including ours to study the 
physiology of MIF – adhesion to fibronectin triggers MIF release and subsequent cyclin D1 
expression and DNA synthesis (Liao et al., 2003). 
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MIF and D-DT are ubiquitously produced by resident as well as circulating cells. The 
sources of MIF include the hypothalamic-pituitary-adrenal axis (Fingerle-Rowson and 
Bucala, 2001), activated monocytes/macrophages, T cells, platelets (Strüßmann et al., 
2013), B cells (Rocklin et al., 1974), eosinophils (Rossi et al., 1998), epithelium (Lan et al., 
2000; Rice et al., 2003), endothelium (Hu et al., 2015), Leydig cells (Meinhardt et al., 1996) 
and Sertoli cells after Leydig cell depletion (Meinhardt et al., 2000), fibroblasts (Selvi et al., 
2003), and a plethora of others (Fingerle-Rowson and Bucala, 2001). A number of 
immortalised fibroblast-like cell lines produce and secrete MIF – high levels of intracellular 
MIF are found in NIH 3T3 of murine origin (Mitchell et al., 1999) and low levels of 
intracellular MIF are found in the M6 clone of CV-1 cells derived from Green African 
monkey kidney fibroblasts – COS-7/M6 (Figure 22A). Upon secretion, MIF is found in saliva 
(de Souza et al., 2014), serum (Sobierajski et al., 2013), synovial fluid (Onodera et al., 
1999), urine (Hong et al., 2012), follicular fluid (Wada et al., 1999), and testicular 
interstitial fluid (Meinhardt et al., 1998) in a concentration range between 0.1-150 ng/ml. 
2.4. MIF/D-DT have enzymatic activities 
As mentioned earlier, MIF/D-DT catalyse the isomerisation (a reaction of one substrate 
yielding one product) and tautomerisation (a keto/enol conversion) of various 
compounds. Additionally MIF catalyses an oxidoreduction (a disulphide reduction). All of 
these reactions may play a role in signal transduction including redox signalling. 
As L-dopachrome isomerase/tautomerase (EC 5.3.3.12), MIF catalyses in vitro the 
following reaction: L-dopachrome ↔ 5,6-dihydroxyindole-2-carboxylate (Rosengren et 
al., 1996). D-DT catalyses the tautomerisation of the non-naturally occurring D-
dopachrome (D-dopachrome ↔ 5,6-dihydroxyindole + CO2). As this reaction is 
accompanied by a simultaneous decarboxylation, D-DT is additionally referred to as a D-
dopachrome decarboxylase (EC 4.1.1.84) (Rosengren et al., 1996). As phenylpyruvate 
tautomerase (EC 5.3.2.1) (for MIF) and phenylpyruvate tautomerase II (for D-DT), the two 
catalyse the conversion of keto-phenylpyruvate to enol-phenylpyruvate (a typical in vitro 
substrate is p-hydroxyphenylpyruvate (HPP)) (Lubetsky et al., 1999). 
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As protein-thiol oxidoreductase, MIF catalyses the reduction of both insulin as well as 2-
hydroxyethyldisulfide (HED) by glutathione (Kleemann et al., 1998; Nguyen et al., 2003). 
Two bacterial homologues of MIF/D-DT, 4-oxalocrotonate tautomerase and 5-
carboxymethyl-2-hydroxy-muconate isomerase retain their Pro-2-mediated eponymous 
enzymatic activities important in catabolic processes (Burks et al., 2010). Although MIF 
and D-DT retain Pro-2 and thus the tautomerase activity, this ancient feature may no 
longer be necessary in metazoans. Some authors attribute it to redox signalling regulation 
since MIF-deficient cardiac fibroblasts have fewer ROS (Koga et al., 2011). However, an 
endogenous substrate of MIF/D-DT is yet to be described, and Pro-2 appears to be critical 
for the maintenance of the secondary/tertiary structure rather than the enzymatic action 
per se (Fingerle-Rowson et al., 2009). 
2.5. MIF inhibition is clinically relevant 
Despite an incomplete understanding of the physiological role of the enzymatic activities 
of MIF, the inhibition of MIF by small-molecule agonists (Xu et al., 2013) and neutralising 
antibodies has a viable therapeutic potential. In animal models of sepsis, neutralising 
antibodies – which bind the extracellular (serum) MIF pool only – alleviated disease 
symptoms and increased survival in mice (Calandra et al., 2000). 
Neutralising MIF secreted by bone marrow-derived macrophages (BMDM) is an effective 
strategy to inhibit germ cell tumour (teratoma) formation after stem cell transplantation 
(Wang et al., 2012). A monoclonal antibody against the oxidised form of MIF was 
documented to be beneficial in tumour targeting (Thiele et al., 2015b) and alleviated 
kidney infection (Thiele et al., 2015a). Antibodies that bind to MIF epitopes aa 50-68 and 
aa 86-102 seem to be most effective in alleviating sepsis (Kerschbaumer et al., 2012). 
A new fully-humanised antibody that specifically targets the tautomerase activity was 
described, and may be used to diminish inflammatory responses (Tarasuk et al., 2014). 
Pancreatic ductal adenocarcinomas secrete MIF-rich exosomes which contribute to pre-
metastatic niche formation, that can be prevented by MIF lentiviral knockdown (Costa-
Silva et al., 2015). In tumour biology, MIF and CD74 levels correlate positively with the 
Introduction 
11 
 
severity of cancer (Grieb et al., 2014), and genetic depletion of either MIF or CD44/CD74 
reduces tumourigenic potential of ccRCCs (Du et al., 2012). 
In a phase I clinical trial on cancer patients vaccinated with lethally irradiated, autologous 
tumour cells, the patients successfully developed autoantibodies against pro-angiogenic 
factors such as angiopoietin-1 and -2, leading to prolonged survival by impairing tumour 
vascularisation (Schoenfeld et al., 2010). Remarkably, MIF autoantibodies were detected 
after combined vaccination with (a) inactivated tumour cells and (b) a neutralising 
antibody against cytotoxic T lymphocyte-associated antigen-4 in five patients, including 
one stage IV melanoma patient who survived more than 50 months, and one advanced 
ovarian carcinoma patient. Thus MIF autoantibody generation is a natural reaction to 
protect the body from tumour-induced inflammation. 
In contrast, since MIF stimulates rhabdomyosarcoma cell adhesion, recombinant MIF 
administration or MIF gene therapy rather than MIF inhibition would appear to be 
therapeutically beneficial in treating this cancer (Tarnowski et al., 2010). 
Out of the many small-molecule pharmacological inhibitors, (S,R)-3-(4-hydroxyphenyl)-4,5-
dihydro-5-isoxazole acetic acid (ISO-1) (Al-Abed et al., 2005; Al-Abed and VanPatten, 2011) 
and 4-iodo-6-phenylpyrimidine (4-IPP) (Winner et al., 2008) are most widely used. They 
are membrane-permeable, inhibit the secretion of MIF, and – in the case of 4-IPP but not 
ISO-1 – covalently bind Pro-2 in MIF and D-DT to form 6-PP-adducts (Rajasekaran et al., 
2014). 4-IPP is more potent than ISO-1 in inhibiting MIF’s tautomerase activity (Schulte, 
2011) as well as A549 adenocarcinoma cell motility and anchorage-independent growth 
(Winner et al., 2008). Moreover, 4-IPP decreases active Ras-related C3 botulinum toxin 
substrate 1 (Rac1) (section 2.7.4) in A549 cells (Winner et al., 2008). 
As much as neutralising antibodies, in vitro and in vivo inhibition of MIF´s tautomerase 
activity by ISO-1 and 4-IPP and their derivatives has been reported to diminish many MIF-
stimulated responses and alleviate sepsis. The physiological relevance of MIF’s 
tautomerase activity was studied in a knock-in mouse in which the N-terminal Pro-2-
coding codon CCT within the endogenous Mif locus was mutated into a glycine-coding 
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GGC by homologous recombination (Fingerle-Rowson et al., 2009). This model revealed: 
(a) that tautomerase-null MIF P2G binds to its receptor, the invariant chain of the major 
histocompatibility complex (MHC) class II (CD74 or Ii), but with a lower affinity than MIF 
WT, (b) that MIF P2G binds JAB1, and (c) that the phenotype of MifP2G/P2G mice in terms of 
growth control and tumour induction is intermediate between Mif+/+ and Mif–/– mice. This 
indicates that the intrinsic tautomerase activity of MIF is dispensable for its cellular 
functions in mice, suggesting Pro-2 is rather important for protein-protein interactions. 
To delineate which amino acid(s) might be involved in MIF-mediated enzymatic activity, 
an array of mutants was used in the past. 
Tautomerase-inactive MIF P2F (Pro-2-to-Phe substitution) and nearly completely 
tautomerase-inactive MIF P2S (Pro-2-to-Ser substitution) retain their capacity to inhibit 
chemotaxis and random migration of peripheral blood mononuclear cells (PBMCs) 
(Hermanowski-Vosatka et al., 1999). The P2S mutant can also override glucocorticoid-
driven TNF-α release from monocytes (Bendrat et al., 1997). Due to the different 
physicochemical properties of amino acids, the enzymatic activity of point mutants varies 
depending on which amino acid replaces P2. While MIF P2F is enzymatically fully inactive, 
P2S is active but to a lesser extent than WT (Hermanowski-Vosatka et al., 1999; Stamps et 
al., 2000). MIF C60S (Cys-60-Ser substitution) but not P2A (Pro-2-to-Ala substitution) 
tautomerises HPP (Kleemann et al., 2000b). While insulin reduction is the same for MIF 
WT, MIF P2A, and MIF Δ4, in a hydroxyethyl disulphide transhydrogenase assay (whereby 
MIF catalyses the reduction of hydroxyethyl disulphide by glutathione) MIF P2A is only 
half-active and MIF Δ4 is completely inactive. 
Beyond neutralising antibodies and tautomerase activity inhibitors, two other MIF 
inhibition strategies were described – one involving protein-protein interactions and the 
other one involving DNA vaccines. 
Heat-shock protein 90 (HSP90) protects its clients such as MIF from degradation, and 
inhibition of HSP90 ATPase activity by tanespimycin proved successful in destabilising MIF 
(Schulz et al., 2012; Schulz and Moll, 2014). Furthermore, C-terminus of gremlin-1, a bone 
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morphogenic protein antagonist, inhibits MIF-induced monocyte chemotaxis (Beck et al., 
2016). From a pre-clinical standpoint, two proteins have the potential to abrogate MIF-
induced damage: (a) secreted ribosomal protein S19 (RPS19) protects mice against renal 
dysfunction in a model of anti-glomerular basement membrane glomerulonephritis by 
inhibiting MIF-CD74 binding (Lv et al., 2013), and (b) knockdown of p115 in human 
multiple myeloma cells decreases proliferation and induces apoptosis by inhibiting MIF 
secretion (Jin and Dai, 2016). In sum, HSP90, gremlin-1, RPS19 and p115 have the 
potential to be exploited in designing alternative MIF inhibition strategies. 
Because of the limitations of anti-MIF antibodies in treating RA – high titres and repeated 
injections are necessary – a MIF cDNA-containing tetanus toxoid DNA vaccine was 
developed and tested in mice to help to resolve chronic inflammation in RA (Onodera et 
al., 2007). Such a vaccine successfully inhibited the development of spontaneous 
autoimmune arthritis. 
Overall, there exist a few distinct modes of MIF inhibition, most notably including (a) 
neutralising antibodies (block extracellular/serum MIF), (b) cell-permeable tautomerase-
activity inhibitors (block intracellular and extracellular MIF), and RPS19-based inhibition of 
secreted MIF. In the case of cancer, either MIF inhibition or MIF supplementation might 
be therapeutically useful, while under inflammatory conditions, where high MIF levels 
potentiate immune responses, only inhibition appears to have a positive outcome on 
survival. 
2.6. MIF/D-DT mediate their actions via cell receptors 
Many cell-surface molecules have been described to bind extracellular MIF and either 
facilitate its uptake (thioredoxin, CD74) or transduce an MIF signal (EGFR, CD44, CD74, 
and GPCRs – CXCR2, CXCR4 and CXCR7). D-DT is known to require CD74 for signal 
transduction. Major endocytic pathways and the essential role of CD74-mediated 
endocytosis are mentioned within section 2.6.2. 
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2.6.1. MIF binds thioredoxin and EGFR 
Surface-bound thioredoxin helps to internalise MIF in immortalised T-cell and macrophage 
lines (Son et al., 2009) but the role of this interaction in cell motility has yet to be 
identified. 
Furthermore, O-GlcNAcylated MIF inhibits epidermal growth factor (EGF)-induced invasion 
by binding and inactivating EGFR in U87 human glioblastoma cells (Zheng et al., 2015). O-
GlcNAcylation-deficient MIF does not alter ERK1/2 or AKT signalling (Zheng et al., 2015). 
As high levels of O-GlcNAcylated MIF are found in U87 but not in human monocytic 
leukaemia THP-1 cells or BV2 mouse microglia cells (Zheng et al., 2015), the production of 
O-GlcNAcylated MIF is rather cell-specific. 
2.6.2. CD74 is a primary MIF receptor and mediates MIF’s endocytosis in fibroblasts 
Based on evidence from a THP-1-derived cDNA library expressed in COS-7 cells, CD74 was 
classified a receptor for extracellular MIF (Leng et al., 2003). CD74 was originally 
considered to be incapable of propagating intracellular signalling without a co-receptor. 
Nevertheless, CD74 does undergo intramembrane proteolysis. and further signalling can 
be elicited by a CD74-intracellular domain (CD74-ICD) which translocates to the nucleus to 
activate NF-κB (Becker-Herman et al., 2005). Notably, CD74 downregulates dendritic cell 
migration to facilitate the uptake of antigens which has a physiological significance in 
terms of efficient innate immunity responses (Faure-André et al., 2008). CD74 resides in 
the endoplasmic reticulum and is involved in antigen presentation as it shields the MHC 
class II α/β heterodimers from binding autoantigens (Riberdy et al., 1992). A small 
percentage of CD74 molecules (5%) can be trafficked to the plasma membrane and acts 
independent of MHC (Pantouris et al., 2015). 
In a number of human cells – mostly fibroblasts (Figure 3A-D) but also cancer cells, 
dendritic cells, monocytes, and B cells (Figure 3A-B) – MIF binds and mediates its actions 
through plasma membrane-bound CD74. 
CD74 and CD44 – a proteoglycan and the major receptor for hyaluronic acid (HA) and 
fibronectin (Zöller, 2011) – form a complex and mediate the MIF signal via Src tyrosine 
kinase (Shi et al., 2006). Src associates with the cytoplasmic tail (last C-terminal 67 amino 
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acids) of CD44 (Figure 3C). Once MIF is bound to CD74 and has recruited the cytoplasmic 
tail-deficient CD44Δ67 molecule, the effects of MIF on ERK1/2 phosphorylation are 
abrogated (Figure 3C) (Shi et al., 2006). 
While these effects are transduced by MIF acting as a ligand that is binding to its receptors 
CD74/CD44 and eliciting downstream cytoplasmic signalling, MIF can also be taken up by 
endocytosis that is facilitated by CD74. Generally, cellular uptake of cargo involves 
endocytic entry by (a) receptor- and clathrin-mediated endocytosis (CME), (b) clathrin- 
and caveolin-independent endocytosis, or (c) caveolin- and lipid-raft-dependent 
endocytosis (non-CME) (Figure 2) (Johannes et al., 2015). In CME and non-CME a nascent 
vesicle may be cleaved off the membrane by dynamin (Wieffer et al., 2009). Caveolin-rich 
vesicles are known as caveolar vesicles and can dynamically dock and fuse with either 
caveosomes or early endosomes (Pelkmans, 2005). 
Once a vesicle enters the intracellular space, a variety of ligand-, receptor-, and context-
specific events may occur: (a) endosomal escape of the cargo into the cytoplasm; 
(b) generation of a stable vesicle that elicits endosomal signalling (Figure 3D); (c) a fusion 
of a caveolar vesicle with caveosomes or early endosomes; (d) a fusion of an endosome 
with a lysosome and subsequent cargo degradation, (e) cargo recycling from a vesicle back 
to the plasma membrane, or (e) cargo exocytosis (Figure 2) (Pelkmans, 2005).  
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Figure 2. Endocytic trafficking. While clathrin chains form pits made up of hexagonal and pentagonal 
clathrin-rings, dynamin enables the scission of a budding vesicle. Bacteria and viruses (not shown) as well as 
multiple ligands such as proteins or small molecules enter mammalian cells through clathrin-/dynamin- and 
receptor-mediated endocytosis (first from top left), tubular clathrin-independent endocytosis (CIE; second 
from top left), or caveolin-1- and dynamin- (dynamin not depicted)-mediated endocytosis (third from top 
left). Not shown is caveolin-independent but lipid raft-dependent endocytosis. The internalised cargo fuses 
with an endosome and either undergoes lysosomal degradation (bottom right) or recycling (top right). Not 
depicted is that cargo may escape the endosomal compartment into the cytosol and act cytoplasmatically. 
Chlorpromazine (clathrin-mediated endocytosis inhibitor), dynasore (dynamin inhibitor, i.e. both clathrin-
dependent and clathrin-independent endocytosis inhibitor), nystatin and filipin (caveolae/lipid raft-
mediated endocytosis inhibitors) were used in this thesis. Adapted from (Johannes et al., 2015). 
Abbreviations: CAV1, caveolin 1; CIE, clathrin-independent endocytosis; GEEC, GPI 
(glycosylphosphatidylinositol)-anchored protein-enriched early endosomal compartments. 
 
Extracellular MIF can be endocytosed in a CD74-dependent manner, remain associated 
with the CD74 molecule within an endosome and elicit endosomal signalling via the 
receptors and second messengers (Figure 3D) (Xie et al., 2011). MIF endocytosis appears 
to be dependent on clathrin, dynamin, β-arrestin (which has a Src activity) (Xie et al., 
2011), and on CD74 and CXCR4 (Schwartz et al., 2012), and to be independent of caveolin 
in HEK293 cells (Schwartz et al., 2012). 
Long-term (24 h) MIF endosomal signalling triggers a sustained activation of ERK1/2 and 
cyclin D1 (Xie et al., 2011). However, long-term stimulation with MIF does not affect cell 
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motility of WT nor MIF–/– mouse embryonic fibroblasts (MEFs) (Figure 3B) (Dewor et al., 
2007). In contrast, presumably shortly after MIF binds CD74/CD44, a rapid and transient 
activation of ERK1/2 (30 min – 2 h) occurs (Figure 3D) (Xie et al., 2011). This may result in a 
calcium influx and subsequent upregulation of motility of WT and MIF–/– MEFs (Figure 3B) 
(Dewor et al., 2007). 
 
 
Figure 3. MIF modulates the motility of fibroblasts typically through CD74/CD44. (A-D) Schematic 
representation of the modes of action of MIF. (A) Via an unknown mechanism, rhabdomyosarcoma-derived 
MIF inhibits the chemotaxis of CAFs. (B) Short-term (2 h) but not long-term (24 h) stimulation with MIF 
triggers calcium influx and accelerated wound healing of primary mouse embryonic fibroblasts (MEFs). The 
role of CD74 in this process remains unknown. (C) In CD44
+
/CD74
+
 COS-7/M6 cells MIF stimulates EKR1/2 
phosphorylation which confers resistance against apoptosis specifically through its receptors CD44/CD74 
and Src. (D) In RAW 264.7 macrophages as well as in COS-7 fibroblasts MIF is internalised in a CD74- and β-
arrestin-dependent manner (D, right) and elicits endosomal signalling which leads to sustained ERK1/2 
activation and downstream gene activation including cyclin D1 (not depicted). Whether CD44/CD74 are 
required for MIF-triggered rapid and transient ERK1/2 activation remains unknown (D, left). Abbreviations: 
CAFs, cancer-associated fibroblasts; ECM, extracellular matrix; MEF, mouse embryonic fibroblast; MEK, 
mitogen-activated protein kinase (MAPK)/ERK kinase; p, phosphorylated. 
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2.6.3. MIF acts via CXCR2, CXCR4 and CXCR4 in immunocompetent cells 
Circulating cells exhibit an amoeboid type of motility characterised by GPCR-mediated 
formation of a glycoprotein-rich uropod (Vicente-Manzanares and Sánchez-Madrid, 2004; 
Thelen and Stein, 2008; Sánchez-Madrid and Serrador, 2009). In circulating cells, MIF 
engages GPCRs – CXCR2, CXCR4 and CXCR7 – to elicit downstream signalling. Yet these 
receptors have their own cognate ligands: (a) IL-8 binds CXCR2 (also called CD182 or IL-8R 
B); (b) CXCL12/stromal cell-derived factor 1 (SDF-1), CXCL14, extracellular ubiquitin, and 
human immunodeficiency virus-1 (co-receptor with CD4) bind CXCR4 (CD184); and 
(c) CXCL11 and CXCL12 (SDF-1) bind CXCR7 (Tillmann et al., 2013). 
GPCRs are involved in signal transduction pathways for light, odours and 
neurotransmitters across species, and many of them are directly implicated in cancer 
metastasis (Roussos et al., 2011; Wu et al., 2012). The entire GPCR signalling unit consists 
of three components: a seven-transmembrane cell surface GPCR, a trimeric cytoplasmic 
αβγ G protein, and an effector. Once a GPCR is activated by an extracellular ligand, the 
Gα and Gβγ subunits dissociate, and Gα elicits further signalling via an effector such as 
adenylyl cyclase, phospholipases, phosphodiesterases, or ion channels (Wu et al., 2012). 
An excellent physiological example of how GPCRs contribute to migration was 
demonstrated in zebrafish (Danio rerio). In its development, a group of approx. 200 
epithelial cells known as the posterior lateral line primordium self-generates a gradient of 
Cxcl12/Sdf-1 to guide its migration along the embryo until it reaches the tip of its tail 
(Friedl and Gilmour, 2009). Cxcr7 is expressed at the rear end of the primordium and acts 
as a molecular sink to locally abrogate Sdf-1 signalling. At the front, Sdf-1 guides the 
migration of the primordium via Cxcr4 as there is more Cxcr4 than Cxcr7 (Donà et al., 
2013; Venkiteswaran et al., 2013). Physiologically, such an elaborate mechanism ensures 
proper direction of motility and positioning of inner organs during development of 
zebrafish. MIF is a neutrophin in zebrafish (Shen et al., 2012), but its role in cell motility of 
the developing or adult organism is unknown at present. 
In human T cells, MIF activates AKT through a heterodimer composed of CD74 and CXCR4 
(Schwartz et al., 2009). MIF acts via CXCR4 and triggers the arrest of human neutrophils 
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(which are endogenously CD74–/–) and primary human effector T cells (Figure 4A and C) 
(Bernhagen et al., 2007). Upon MIF binding to CXCR2/CD74, it elicits chemotaxis followed 
by the arrest of PBMC-derived monocytes (Figure 4B) (Bernhagen et al., 2007) as well as 
chemotaxis of natural killer T cells (Hsieh et al., 2014). 
B cell chemotaxis is triggered by MIF by two distinct ERK1/2- and 70-kDa zeta-chain 
associated protein-dependent mechanisms: via CXCR4/CD74 followed by calcium influx 
and actin polymerisation, and via CXCR7 (Figure 4D) (Klasen et al., 2014; Alampour-Rajabi 
et al., 2015). 
MIF promotes adhesion of rhabdomyosarcoma cells via CXCR4 and CXCR7. Additionally, in 
the microenvironment of a rhabdomyosarcoma, MIF inhibits the recruitment of CAFs 
through an unknown mechanism (Figure 3A) (Tarnowski et al., 2010). MIF and SDF-1 
cooperate through CXCR4 to promote migration of metastatic colon cancer cells (Shin et 
al., 2012). As a clinically-relevant illustration, hypoxia-stimulated MIF expression mediates 
chemotaxis of CD11b+/Gr-1+ myeloid cells – also known as myeloid-derived suppressor 
cells (MDSCs) – in a CD74/CXCR2/CXCR4-dependent manner (Zhu et al., 2014). MIF 
mediates MDSC migration and may contribute to lung metastasis (Simpson and Cross, 
2013; Kitamura et al., 2015). Moreover, tumour-derived MIF increases the number of 
immune-suppressive MDSCs and contributes to tumour growth and metastasis (Simpson 
et al., 2012). 
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Figure 4. MIF modulates motility of mononuclear immunocompetent cells by acting on CXCR2/4/7. (A-D) 
Schematic representation of the mode of action of MIF. (A) MIF triggers neutrophil chemotaxis via CXCR2, 
(B) monocyte chemotaxis/arrest via CXCR2/CD74, and (C) T-cell chemotaxis/arrest via CXCR4. (B-C) Under 
flow conditions in vivo, endothelium-immobilised MIF attracts monocytes and T cells (chemotaxis) and 
causes their arrest at the arterial wall. (D) MIF promotes B cell chemotaxis via CXCR4/CD74 or CXCR7, 
calcium influx, actin polymerisation, ERK1/2 phosphorylation, and ZAP-70. Abbreviations: CXCR, C-X-C motif 
chemokine receptor; ZAP-70, 70-kDa zeta-chain associated protein. 
 
2.7. MIF/D-DT influence cytoskeletal dynamics and migration 
Cell migration is essential in health and disease. It primarily relies on dynamic 
rearrangements of the cellular cytoskeleton including microtubules (MTs), actin filaments, 
septins (Mostowy and Cossart, 2012; Shindo and Wallingford, 2014), and intermediate 
filaments (IFs) (Chung et al., 2013). The following paragraphs provide an overview on MIF-
dependent regulation of MTs (section 2.7.1) and actin (section 2.7.2-2.7.4) in the context 
of cell motility since little or no experimental evidence exists for MIF-mediated regulation 
of septins or IFs. The chapter describes further the link between MIF and adhesion 
(section 2.7.5) and motility (2.7.6). 
2.7.1. MIF causes microtubule rearrangements 
Responsible for intracellular transport and chromosome partitioning during cell division, 
MTs – composed of α- and β-tubulin dimers – are known to cooperate with actin filaments 
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to drive cell migration. In fibroblasts, MT polymerisation drives Rac1 and lamellipodial 
protrusion (Waterman-Storer et al., 1999). In Chinese hamster ovary cells, MTs are 
dispensable for cell motility but govern the directionality of cell migration (Ganguly et al., 
2012). In vitro, chemotaxis of human monocytes/macrophages is typically inhibited by MIF 
(Lind et al., 1999). MIF triggers excessive MT polymerisation thereby inhibiting 
macrophage migration (McCarthy et al., 1979). 
Under flow conditions, chemokines immobilised on the endothelium trigger rapid integrin 
activation leading to the arrest of a rolling leukocyte (Laudanna and Alon, 2006). In 
atherosclerosis, MIF immobilised on the endothelium of the arterial wall is now 
recognised as a chemoattractant as well as an arrest molecule for PBMC-derived 
monocytes and T cells (Figure 4) (Bernhagen et al., 2007). In fact, syndecan-1 is one of the 
proteoglycans that bind MIF on the surface of epithelial cells to directly contribute to MIF-
mediated motility (Pasqualon et al., 2016), but the interaction between MIF and 
endothelium were not assessed there. 
However, only a few follow-up studies addressed this putative MIF-MT axis. First, MIF 
promotes MT formation in human myocardial (atrial) trabeculae but motility remained 
uncharacterised (Preau et al., 2013). In a different study human cytomegalovirus was 
shown to hijack the host immune responses of human monocyte-derived macrophages, as 
evidenced by a variety of methods including treatments with MIF-depleted supernatants. 
Upon infection, the virus triggers MIF secretion, thereby causing a loss of (a) podosomes, 
(b) ruffling lamellipodia and (c) the conical tail. Finally this leads to a complete 
rearrangement of actin, tubulin, and IF (vimentin) networks into dense and rigid 
assemblies. Ultimately, virus-induced MIF inhibits chemokine-induced but not random 
motility of macrophages (Frascaroli et al., 2009). In a third study of human monocytic U-
937 cells, MIF causes a cyclic activation and deactivation of Rho GTPases (DiCosmo-
Ponticello et al., 2014). Although this leads to migration inhibition as assessed by an 
agarose microdroplet assay, the status of the MT and actin networks remains unevaluated 
(DiCosmo-Ponticello et al., 2014). Lastly, MIF inhibition by 4-IPP disrupts microtubule 
networks in CD74+ human thyroid cancer TCP-1 cells and leads to a mitotic catastrophe 
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(Varinelli et al., 2015), suggesting that MIF inhibition overcomes the cancer’s resistance to 
apoptosis. 
Interestingly, p27Kip1 – described as an MIF-dependent fibroblasts cell-cycle inhibitor – 
associates in neurons with MTs to promote MT polymerisation in vitro and in vivo and 
hence neurite outgrowth (Godin et al., 2012). However, the relation between MIF, p27Kip1 
and microtubules in fibroblasts remains unknown. 
Taken together, recombinant MIF as well as MIF’s tautomerase inhibition by 4-IPP disrupts 
the microtubular network. Excessive recombinant MIF (a) downregulates chemotaxis of 
monocytes by perturbing their MTs and (b) causes human myocardial contractile 
dysfunction by promoting excessive MT polymerisation. Similarly, MIF’s inhibition leads to 
disrupted MTs, suggesting that (a) under normal conditions MIF levels ought to be low 
and (b) MIF’s inhibition in a disease state is beneficial. 
2.7.2. Cell migration depends on actin cytoskeleton 
Cytoplasmic actin exists in the form of globular actin (G-actin) that can dimerise into 
helical filamentous actin (F-actin; also known as axial bundles or stress fibres) in human 
and rodent cells. Only recently it became clear that also the nucleus is equipped with a 
dynamic and polymeric actin network that is modulating the serum response (Vartiainen 
et al., 2007; Baarlink et al., 2013). In the cytoplasm, actin orchestrates a myriad of 
processes including cell division (Heng and Koh, 2010), muscle contraction, and cell 
migration. Six highly homologous actin isoforms exist (αskeletal-, αcardiac-, αmuscle-, βcyto-, γcyto-, 
and γsmooth-actin) in different cell types (Perrin and Ervasti, 2010) but β-actin specifically 
drives cell motility in MEFs and T cells (Bunnell et al., 2011). 
In the lamellipodial form of cell migration, actin filaments are severed at the cell rear 
(trailing) end of a migrating cell by actin depolymerising actors such as destrin or cofilin. 
Inhibition of these factors by phosphorylation may lead to accumulation of F-actin within 
the cytoplasm. At the same time actomyosin contractions facilitate the retraction of the 
cell rear end. While at this site focal adhesions are disassembled, new focal adhesions are 
built at the cell forward end (Ridley et al., 2003). New actin filaments are assembled at the 
leading edge where the actin-related protein 2/3 (ARP2/3) complex – a 7-subunit actin-
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binding protein complex – is mediating actin branching at a fixed angle of 70° (Robinson et 
al., 2001). An existing filament is elongated by addition of new actin monomers. The 
barbed (plus) end of such a filament can be capped by capping proteins, which inhibit 
further elongation. Such a mechanism ensures that the filaments are kept short, thereby 
allowing for new filament generation which ultimately steers motility (Mejillano et al., 
2004). The verprolin, cofilin, acidic (VCA) domain of WASP (Wiskott-Aldrich syndrome 
protein)-family verprolin-homologous proteins (WAVE) activates the ARP2/3 complex 
(Rotty et al., 2013). The VCA domain is sufficient to activate actin assembly in vitro. 
Actin-rich filopodia, pseudopodia and invadopodia are specialised cell protrusions in which 
formins are responsible for actin elongation in form of parallel bundles, in contrast to the 
ARP2/3-mediated branched actin network (Faix and Grosse, 2006). Aside from the ARP2/3 
complex and formins, Ena/VASP proteins also mediate actin elongation by competitively 
antagonising capping proteins (Krause et al., 2003; Rotty et al., 2015). 
In either case the net movement forward of a cell is achieved by an actin build-up at the 
cell front and actin severing at the rear cell end. At the morphological level single-cell 
motility is defined as either amoeboidal or mesenchymal. Prominent F-actin stress fibres 
and the presence of lamellipodia and filopodia can be attributed to mesenchymal cell 
migration. Contrariwise, cells that are migrating in an amoeboid fashion are faster and 
lack F-actin stress fibres (Welch, 2015). When more than one cell is considered, collective-
cell motility, that is rather characteristic of transformed cells such as cancer-derived cells, 
is either cluster- or strand-like (Friedl and Alexander, 2011). Two cell motility assays based 
on these features were employed in this work: a chemokinesis assay, to assess random 
single-cell motility, and a wound healing (scratch) assay to assess collective-cell motility. 
2.7.3. MIF causes actin cytoskeleton rearrangements 
Although MIF/D-DT do not bind actin directly, actin cytoskeleton-associated proteins such 
as destrin, cofilin, and myosin light chain kinase (MLCK) were described experimentally in 
the context of MIF. In human umbilical vein endothelial cells for example, cholinergic 
agonists increased not only MIF but also destrin. While this is the only study which 
identifies both proteins as part of one signalling network, the authors assessed this MIF-
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destrin relationship within the non-neuronal acetylcholine system but not in the context 
of cell migration (Zhang et al., 2014). 
A link between MIF and actin polymerisation has been established based on F-actin 
rhodamine-phalloidin immunostaining and F-actin quantification by flow cytometry. While 
MIF–/– as well as CD74–/– BMDMs exhibit fewer C-C motif chemokine 2 (CCL2)/monocyte 
chemotactic protein 1 (MCP-1)-induced stress fibres (Fan et al., 2011), recombinant MIF 
induces calcium influx and F-actin accumulation in B cells (Klasen et al., 2014). Notably, 
MIF also triggers metastatic colorectal cancer cell chemotaxis by increasing the F-actin 
content through phosphorylation of cofilin at Ser-3 (Hu et al., 2015). One study from 2005 
identified the actomyosin-associated protein myosin light chain kinase (MLCK) as an 
interactor of cytoplasmic MIF in endothelial cells (Wadgaonkar et al., 2005), and co-
localised both proteins along F-actin stress fibres which was enhanced by thrombin. While 
MLCK activates the contractile machinery of endothelial cells, the precise role of MIF in 
contractility, let alone F-actin assembly, remained uncharacterised. 
In a mass spectrometry-based proteomics study of pseudopodia isolated from 
chemotaxis-stimulated cells, MIF was found predominantly in pseudopodia but not the 
cell body (Lin et al., 2004). However, another study did not corroborate that finding (Ito et 
al., 2012). In addition, MIF localises near peripheral plasma membrane – reminiscent of a 
leading edge – of HeLa cells (Kleemann et al., 2000a) as well as NIH 3T3 (Filip et al., 2009). 
Overall, MIF has been found to be associated with a few actin-associated proteins, or to 
be localized at the leading edge of migrating cells, but these relationships were never fully 
investigated in the context of cell migration. This thesis provides some experimental 
evidence for the MIF-actin cytoskeleton axis based on actin assembly assays and F-actin 
staining with phalloidin. 
2.7.4. MIF influences Rho GTPases 
Crucial for cell migration are Rho GTPases which exist in two states: an active GTP-bound 
and an inactive GDP-associated state (Figure 5A). Guanine nucleotide exchange factors 
(GEFs) activate Rho GTPases by mediating the exchange of GDP into GTP. Conversely, 
GTPase-activating proteins (GAPs) deactivate Rho GTPases by hydrolysis and release of an 
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inorganic phosphate (Pi). Within the cytoplasm, Rho GDP-dissociation inhibitors (RhoGDI) 
binds and sequesters Rho GTPases from the plasma membrane to keep them in an 
inactive cytoplasmic form. This mechanism serves two purposes: it protects Rho GTPases 
from degradation and prevents the GDP-to-GTP exchange. In other words, a Rho GTPase is 
in an inactive state when either bound to the membrane or to RhoGDI (Figure 5A) 
(Heasman and Ridley, 2008; Garcia-Mata et al., 2011). 
 
A 
 
B 
 
 
Figure 5. Rho GTPases cycle between an active and inactive state. (A) Cytoplasmic Rho proteins – most 
notably Rac1, RhoA, Cdc42 and RhoQ – cycle between an inactive, GDP-bound state, and an active, plasma 
membrane/GTP-bound state. RhoGDI prevents Rho degradation by sequestering them from the membrane. 
Adapted from (Garcia-Mata et al., 2011). (B) MIF affects Rho GTPases in a cell-type dependent manner (1-4) 
(see text for explanation). Abbreviations: IF, intermediate filaments.  
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Three main Rho GTPases were described in quiescent NIH 3T3 (Hall, 1998): (a) Rac1 is 
best-known to promote cell motility via increasing actin polymerisation in membrane 
ruffles and inducing lamellipodia (leading edges) by activating WAVE (Ridley et al., 1992; 
Eden et al., 2002); (b) Ras homolog gene family, member A (RhoA) contributes to the 
formation of actin stress fibres and focal adhesions (Ridley and Hall, 1992; Rottner and 
Stradal, 2011); and (c) cell division control protein 42 homolog (Cdc42) stimulates 
filopodia formation but also activates Rac and therefore contributes to the formation of 
lamellipodia. Although cell type-dependent, Rac1 is typically associated with pro-
migratory and RhoA with anti-migratory phenotypes (Rottner and Stradal, 2011). 
Abundant in serum, lysophosphatidic acid induces characteristic RhoA-dependent stress 
fibres. On the other hand insulin or platelet-derived growth factor (PDGF) stimulate typical 
Rac1-mediated cortical actin accumulation, lamellipodia and ruffles/filopodia (Hall, 1998). 
Starvation produces a characteristic cortical actin rim around the periphery of a cell. It 
reduces the number of stress fibres, results in fewer organised actin filaments, and 
ultimately slows down motility. The migration of starved cells can be rescued by re-
addition of either full serum or a single growth factor such as EGF. 
In collective cell motility, Rac is enriched in leader but not follower cells (Yamaguchi et al., 
2015). In single-cell motility, differential Rac levels determine the migratory capacity of 
cells. Too low and too high Rac levels immobilise cells but a moderate Rac level promotes 
motility. In fact, a moderate reduction of Rac can stimulate chemotaxis. Over-reactive Rac 
is inhibitory due to over-accumulation of actin at the cell rim (Pankov et al., 2005). 
While MIF promotes RhoA to drive cyclin D1 expression and proliferation of MEFs and 
NIH 3T3 cells (Swant et al., 2005), it decreases RhoA in monocyte-derived macrophages 
(Frascaroli et al., 2009). Similar to reduced actin polymerisation (section 2.6.3), CCL2-
induced RhoA activity was reduced in MIF–/– BMDMs as compared to WT (Fan et al., 
2011). In A549 adenocarcinoma cells, MIF stabilises Rac1 in caveolin-1-rich lipid rafts – 
cholesterol-rich plasma-membrane domains which serve as ‘signalling platforms’ – and 
upregulates motility (Figure 5B) (Rendon et al., 2007). In one report MIF was found within 
the proteome of focal adhesions of human foreskin fibroblasts, and defined as one of Rac1 
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activators leading to dendritic actin treadmilling (Kuo et al., 2011). Nonetheless, the exact 
mechanisms are yet to be elucidated (Lawson and Burridge, 2014). 
MIF promotes human bone marrow-derived mesenchymal stromal cell (fibroblast-like, 
interstitial stem cells) chemotaxis via Gαi protein-coupled receptor CXCR4 through 
upregulation of Cdc42 and then RhoQ (Figure 5B) (Lourenco et al., 2015). In contrast, MIF 
inhibits chemokinesis of iliac crest bone marrow-derived mesenchymal stem cells, but the 
mechanism remains poorly understood (Fischer-Valuck et al., 2009; Barrilleaux et al., 
2010). Only one study systematically addressed the role of MIF in Rho GTPase activation in 
human monocytic U-937 cells where it caused Rac deactivation, RhoA activation, and 
Cdc42 cyclic activation/deactivation, eventually leading to motility inhibition, finally 
providing compelling evidence for the eponymous function of MIF (DiCosmo-Ponticello et 
al., 2014). 
In summary, MIF regulates the actin cytoskeleton in a highly cell-dependent manner via 
the activation/deactivation of Rho GTPases (Figure 5B). 
2.7.5. MIF alters cell adhesion and plays a role in wound healing 
Integrins are a family of transmembrane receptors that mediate cell adhesion by either 
linking two neighbouring cells (cell-cell interaction) or the cytoskeleton with the 
extracellular matrix (ECM) (cell-ECM interaction). MIF upregulates αvβ3 integrin in human 
chondrosarcoma cells (Lee et al., 2011). Concurrently, the levels of integrins in MIF–/– 
endometrium are downregulated (Rakhila et al., 2014). The fact that the E-cadherin 
interactome contains MIF points to a role in cell adhesion by means of protein-protein 
interactions (Guo et al., 2014). Additionally, MIF stimulates rhabdomyosarcoma adhesion 
leading to a diminished tumour spreading (Tarnowski et al., 2010). Aside from the 
cytoplasmic phenomena which largely rely on protein-protein interactions, cell migration 
involves ECM degradation and rearrangements. MIF is known to promote the expression 
of matrix metalloproteinases (MMPs) and thus directly contributes to invasion of cancer 
cells (Pakozdi et al., 2006). Wound healing (multicellular migration) also involves many 
simultaneous events including dynamic ECM rearrangements. However, wound healing is 
distinct from single-cell migration as it maintains intact cell-cell junctions. In fact, MIF 
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exhibits opposing roles in wound healing; on the one hand it promotes fibroblast 
proliferation and migration thus enhancing wound healing but on the other it may impair 
healing by upregulating MMP-2 (Pakozdi et al., 2006) or MMP-9 (Li et al., 2004). 
2.7.6. Summary 
Overall, there were many attempts to elucidate the molecular pathways that MIF utilises 
to influence cell migration. The research in the field of circulating cells points to the fact 
that MIF promotes motility via GPCRs (CXCR2, CXCR4 and CXCR7). Other studies attribute 
upregulation of cell motility by MIF to steady-state Rac1 levels in A549 adenocarcinoma 
cells (Rendon et al., 2007) or inhibition of cell motility by MIF to cyclic Rac1/RhoA/Cdc42 
activation/deactivation in human monocytic U-937 cells (DiCosmo-Ponticello et al., 2014). 
In mesenchymal stromal cells, MIF upregulates Cdc42 and RhoQ (Lourenco et al., 2015). 
Calcium signalling (Dewor et al., 2007) and subsequent calcium influx and ERK1/2 
phosphorylation mediates MIF-induced motility in fibroblasts. It is well established that 
calcium, a danger signal released after wounding, drives actin polymerisation and wound 
resealing via Rho GEFs and Rho GTPases (Cordeiro and Jacinto, 2013). 
In vitro, MIF enhances U373 human glioblastoma cell chemotaxis in an ERK1/2-dependent 
and CD74-independent manner (Piette et al., 2009). In hepatocellular carcinoma cells 
(HCC), MIF drives angiogenesis and migration by promoting IL-8 (Ren et al., 2003). 
Conversely, in a human neuroblastoma cell line, MIF inhibition decreases IL-8 levels, 
reduces cell growth and chemotaxis, and inhibits metastasis to lung and liver in vivo (Ren 
et al., 2006). In A549 adenocarcinoma cells, MIF promotes invasion and anchorage-
independent growth, and the inhibition of MIF’s tautomerase activity by ISO-1 or a 
knockdown of MIF attenuates these effects (Rendon et al., 2007). 
Short-term (30 min – 2 h) but not long-term (24 h) MIF exposure accelerates MEF wound 
healing (Dewor et al., 2007). This might be attributed to a rapid and transient 
MAPK/ERK1/2 activation (Xie et al., 2011) or calcium signalling (Dewor et al., 2007). In 
vascular smooth muscle cells (VSMCs), short-term (6.5 h) MIF treatment enhanced PDGF-
BB-mediated chemotaxis; long-term (24 h) treatment reduced the stimulatory effect of 
PDGF but retained the effect of PDGF-BB (Schrans-Stassen et al., 2005).  
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The clinical relevance of fibroblast migration is best exemplified by fibroblast-guided 
collective invasion of squamous cell carcinoma cells (Gaggioli et al., 2007). Because 
carcinoma cells cannot degrade ECM, migrating fibroblasts create tracks in an integrin- 
and protease-dependent manner which supports invasion of carcinoma cells. While the 
role of MIF in fibroblast-guided invasion is yet to be elucidated, it is important to study the 
biology of MIF in migrating fibroblasts in order to complement the vast body of evidence 
that already exists for MIF in cancer and circulating cells. 
The intertwined signalling pathways show the complexity of MIF’s action on motility and 
leaves room for future experiments not only in the field of protein-protein interaction but 
also in cell-to-cell crosstalk.  
2.8. The MIF/D-DT interactome – the starting point 
The MIF/D-DT interactome in fibroblasts has been determined (Cayli et al., 2009; Filip et 
al., 2009; unpublished results). To that end four stable NIH 3T3 murine fibroblast cell lines 
had been generated: one expressing biotin protein ligase A (birA) only and three more cell 
lines co-expressing birA in combination with human MIF, human D-DT, and murine D-DT, 
all fused to a biotin linker and a tobacco etch virus (TEV) protease cleavage site. 
Following in vivo biotinylation of MIF/D-DT fusion proteins, MIF/D-DT-interacting proteins 
(MIPs) were pulled down on streptavidin-agarose beads. After a TEV protease-mediated 
release of MIPs from the biotin-streptavidin-agarose resin, proteins were separated by 
SDS-PAGE. Individual lanes were sliced, digested with trypsin, and subjected to mass 
spectrometric analysis to determine the m/z ratio of the resulting peptides. These 
peptides were mapped in silico against a MASCOT library of all theoretical proteins 
(a catalogue of all known open-reading frames) in order to create a list of candidate MIPs. 
Ultimately a repertoire of actin cytoskeleton-associated proteins was identified as 
putative interactors of MIF and D-DT (Table 2). These results sparked an interest in 
delineating the role of cytoplasmic MIF/D-DT in modulating motility of fibroblasts. Specific 
interest was placed on addressing the question whether known MIF/D-DT receptors are 
required for modulating the motility of fibroblasts. 
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Table 2. List of putative MIF/D-DT-binding partners. 
Name of putative MIF/D-DT interactors UniProt identifier 
ARPC3 (ARP2/3 complex subunit 3; or p21-ARC) human: O15145 
ARPC4 (ARP2/3 complex subunit 4; or p20-ARC) human: P59998 
CAPZA1 (F-actin-capping protein subunit α-1) human: P52907 
CAPZB (F-actin-capping protein subunit β human: P47756 
Destrin (actin-depolymerising factor or ADF) human: P60981 
Moesin (membrane-organizing extension spike protein), member of 
the ERM (ezrin-radixin-moesin) family 
human: P26038 
NDPKB (nucleoside diphosphate kinase B; also: NM23-H2 or NME2) human: P22392 
RhoGDI1 or RhoGDIα (Rho GDP-dissociation inhibitor 1 or α) human: P52565 
TPM4 (tropomyosin α-4 chain) human: P67936 
Only proteins associated with the actin cytoskeleton and motility are shown. RhoGDI was identified within 
the MIF but not D-DT interactome. Protein identification by mass spectrometry was performed in 
collaboration with Dr. Henning Urlaub and is partially published elsewhere (Filip et al., 2009). Data originate 
from affinity-tag protein purification of biotinylated MIF from stable cell lines generated by Suada Fröhlich, 
Tamara Henke and Dr. Jörg Klug. 
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3. Purpose of the study 
MIF/D-DT exhibit their biological effects extra- and intracellularly. While cytosolic MIF 
promotes cell cycle progression by interacting with JAB1, secreted MIF activates 
secondary messenger signalling by binding CD44/CD74. MIF/D-DT have emerged as crucial 
regulators of cell motility based on evidence from studies using recombinant MIF 
supplementation, genetic depletion, and overexpression. Whereas MIF inhibits cancer-
associated fibroblast chemotaxis, it promotes mouse embryonic fibroblast wound healing. 
Since prior studies on motility did not systematically evaluate the status of the 
endogenous receptors, it remains unknown whether or not the effects of MIF were 
receptor-dependent. Moreover, the extent of the contribution of D-DT was lacking. 
Mechanistically, the MIF/D-DT-actin cytoskeleton axis was never broadly addressed. 
This thesis aims to elucidate the mechanisms of action of MIF/D-DT on motility, building 
on two previous studies (Shi et al., 2006; Dewor et al., 2007). The specific questions were: 
 Are the MIF receptors CD44 and CD74 essential for the action of MIF/D-DT on cell 
migration? Here fibroblasts deficient in MIF/D-DT receptors CD44 and CD74 were 
used to establish stable cell lines expressing CD44, CD74 and their combination. 
 Are native MIF, tautomerase-null and oxidoreductase-null MIF mutants, and D-DT 
capable of influencing fibroblast chemokinesis in vitro? 
 If exogenous MIF/D-DT are capable of influencing fibroblast motility, what is the 
contribution of endogenous MIF to the observed effect? This question is addressed by 
employing siRNA-mediated MIF knockdown in WT and CD44+/CD74+ COS-7/M6 cells. 
 Are exogenous MIF/D-DT endocytosed and released from the endosomal 
compartment in order to be able to act cytoplasmically? This question is addressed by 
employing specific inhibitors of clathrin- and non-clathrin-mediated endocytosis. 
 Does MIF affect actin dynamics in cell extracts and living cells? To define the role of 
MIF/D-DT in affecting actin polymerisation, a series of actin assays was employed: 
actin assembly assays that measure the rate of actin polymerisation; and F-actin 
staining with phalloidin. 
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4. Materials and methods 
4.1. Materials 
Table 3. List of equipment. 
Name Supplier or origin 
Agarose gel electrophoresis system PerfectBlue peqlab, Erlangen 
Bacterial shaker Certomat® IS B. Braun Biotech International, Melsungen 
Benchtop centrifuges Labofuge® 400/400R Thermo Fisher Scientific, Waltham MA, USA 
Cryo freezing container Mr. Frosty™ Nalgene®, a brand of Thermo Fisher Scientific, 
Waltham MA, USA 
Electrophoresis Power Supply E143 Consort, Turnhout, Belgium 
Fluorescence microscope Axioplan 2 Imaging with 
AxioCam 
Carl Zeiss, Oberkochen 
FPLC/HPLC system: Monitor UPC-900; Pump P-900; 
Fraction collector Frac-920; columns: Sephacryl™ S-
100 HiPrep™ 16/60 High Resolution size-exclusion 
chromatography; Resource™ S and Mono S™ 5/50 
GL (cation exchangers); Mono Q™ 5/50 GL (anion 
exchanger) (ÄKTAbasic) 
GE Healthcare 
Haemocytometer Neubauer – improved LO, Laboroptik, Lancing, UK 
High-speed Centrifuge Sorvall® RC-5C with Fiberlite 
F14 and SS34 rotors 
Sorvall, a brand of Thermo Fisher Scientific, Waltham 
MA, USA 
Incubators (for bacterial and mammalian cells) Binder, Tuttlingen 
Inverted microscope CKX41 with Olympus C-7070 
camera 
Olympus Optical, Hamburg 
Inverted microscope system Eclipse Ti with CCD 
camera Clara 
Nikon, Düsseldorf and Andor Technology Ltd., 
Belfast, UK 
Laminar-flow hood class II BDK-S 1800 BDK, Sonnenbühl 
Liquid nitrogen container ARPEGE 170 Air Liquide Deutschland GmbH, Düsseldorf 
Microcentrifuge Pico 21 Heraeus®, a brand of Thermo Fisher Scientific, 
Waltham MA, USA 
Orbital shaker (3017) GFL Gesellschaft für Labortechnik, Burgwedel 
pH-meter 766 Calimatic® Knick, Berlin 
Power Supply PowerEase 500 Invitrogen 
Spectrofluorophotometer RF-5301PC Shimadzu, Kyoto, Japan 
Spectrophotometer NanoDrop™ 2000 NanoDrop, a brand of Thermo Fisher Scientific, 
Waltham MA, USA 
Spectrophotometer Ultrospec 2011 pro GE Healthcare 
Stuart tube rotator SB3 Barloworld Scientific Ltd, Stone, Staffordshire, UK 
Thermocycler PCR Primus 96 Advanced® Gradient peqlab, Erlangen 
Thermocycler PTC-200 MJ Research, now a brand of Bio-Rad, Munich 
Thermoshaker PCMT Grant Instruments, Shepreth, Cambridgeshire, UK 
Thermoshaker TS-100 peqlab, Erlangen 
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Trans-Blot® Semi-Dry Electrophoretic Transfer Cell Bio-Rad, Munich 
Ultracentrifuge Ultra Pro 80 with T-865 rotor Sorvall, a brand of Thermo Fisher Scientific, Waltham 
MA, USA 
Ultrasonic bath Sonorex Super Bandelin, Berlin 
UV transilluminator 312 nm / INTAS Gel Jet Imager Intas Science Imaging Instruments, Göttingen 
Vertical electrophoresis chamber (Slab-Gel-Kammer) von Keuz Labortechnik, Reiskirchen 
 
Table 4. List of consumables. 
Name Supplier or origin 
Centrifugation bucket (high-speed, 250 ml) Nalgene, Langenselbold 
Chemiluminescence film Amersham Hyperfilm™ GE Healthcare 
Chromatography paper Whatman™ GE Healthcare 
Cryogenic vials Nalgene, Langenselbold 
Filtropur syringe filter, 0.2-µm pore size Sarstedt, Nümbrecht 
Glass Pasteur pipettes VWR International, Darmstadt 
Glass Superfrost™ slides (to mount coverslips) R. Langenbrinck, Emmendingen 
High-speed centrifugation tubes (15, 50 ml falcons) Sarstedt, Nümbrecht 
Microcentrifuge tubes (0.5, 1.5 and 2.0 ml) Sarstedt, Nümbrecht; Eppendorf, Hamburg 
MμltiFlex Round Tips Sorenson, BioScience, Salt Lake City, UT, USA 
Nitrocellulose membrane Amersham™ Hybond™-ECL GE Healthcare 
Petri dishes (92x16 cm) for bacterial culture Sarstedt, Nümbrecht 
Pipette tips (10, 20 and 200 μl, 1 ml) Sarstedt, Nümbrecht 
Pipette tips (5 ml epT.I.P.S.) Eppendorf, Hamburg 
Polystyrene cuvettes 10x4x45 mm Sarstedt, Nümbrecht 
Round coverslips (11 mm diameter) R. Langenbrinck, Emmendingen 
Serological pipettes (5 ml, 10 ml, 25 ml) Greiner Bio-One, Frickenhausen 
Snap cap tubes (15 ml) Thermo Fisher Scientific, Waltham MA, USA 
Spectra/Por® Biotech Grade cellulose ester dialysis 
tubing with a 5-kDa molecular weight cut-off 
Spectrum Laboratories, Rancho Dominguez, CA, USA 
Syringes (1 ml, 5 ml, 10 ml, 20 ml) B. Braun, Melsungen 
Tissue-culture 75-cm
2
 flask (T75) Sarstedt, Nümbrecht 
Tissue-culture multi-well plates (12- and 24-well) BD Labware, Fanklin Lakes, NJ, USA 
Tissue-culture multi-well plates (6- and 96-well) Sarstedt, Nümbrecht 
Tissue-culture Petri dishes (Ø35 mm, 6 cm, 10 cm) Sarstedt, Nümbrecht 
μ-Slide 8-well ibiTreat ibidi, Planegg/Martinsried 
 
Table 5. List of reagents employed in cell culture and molecular biology experiments. 
Name Supplier or origin 
(S,R)-3-(4-Hydroxyphenyl)-4,5-dihydro-5-isoxazole 
acetic acid (ISO-1) 
Merck, Darmstadt 
1,4-Dithiothreitol (DTT) Roche, Mannheim 
1,4-Piperazinediethanesulfonic acid (PIPES) Sigma-Aldrich, Steinheim 
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2-(N-Morpholino)ethanesulfonic acid (MES) Serva Electrophresis, Heidelberg 
3,8-Diamino-5-ethyl-6-phenylphenanthridinium 
bromide (ethidium bromide) 
Carl-Roth, Karlsruhe 
3′,3′′,5′,5′′-Tetrabromophenolsulfophthalein sodium 
salt (bromophenol blue) 
Sigma-Aldrich, Steinheim 
4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) 
Carl-Roth, Karlsruhe 
4-Iodo-6-phenylpyrimidine (4-IPP) Sigma-Aldrich, Steinheim 
5X siRNA resuspension buffer Dharmacon/GE Healthcare 
6-Aminocaproic acid (C6H13NO2) Carl-Roth, Karlsruhe 
Acetic acid (CH3COOH) (100% or 17.5 M) Merck, Darmstadt 
Acrylamide (Rotiphorese® Gel 30 (37, 5:1)) Carl-Roth, Karlsruhe 
Adenosine triphosphate (ATP) Sigma-Aldrich, Steinheim 
Agarose (electrophoresis grade) Invitrogen 
Ammonium persulfate (APS) Sigma-Aldrich, Steinheim 
Ammonium sulphate (AS) Carl-Roth, Karlsruhe 
Ampicillin (ampicillin sodium salt) Sigma-Aldrich, Steinheim 
Bacto™ agar Becton, Dickinson and Co., Sparks, MD, USA 
Bacto™ yeast extract Becton, Dickinson and Co., Sparks, MD, USA 
BglII Promega, Mannheim 
Blue/Orange 6X loading dye Promega, Mannheim 
Bovine serum albumin (BSA, Fraction V, 60 kDa) Carl-Roth, Karlsruhe 
Bovine serum albumin (BSA, Fraction V, 67 kDa) Serva Electrophoresis, Heidelberg 
Calcium chloride (CaCl2) Merck, Darmstadt 
Chloroform (100%) Merck, Darmstadt 
Chlorpromazine (CPZ) Sigma-Aldrich, Steinheim 
Collagen type I from calf skin Sigma-Aldrich, Steinheim 
Coomassie Brilliant Blue G-250 (PageBlue™ Protein 
Staining Solution) 
Fermentas, Vilnus, Lithuania 
Creatine phosphate Sigma-Aldrich, Steinheim 
Dimethyl sulfoxide (DMSO) (≥99.5%, BioScience-
Grade) 
Carl-Roth, Karlsruhe 
Di-potassium hydrogen phosphate (K2HPO4) Merck, Darmstadt 
Disodium hydrogen phosphate (Na2HPO4) Merck, Darmstadt 
DNaseI (from bovine pancrease, grade II) Boehringer, Mannheim; Roche 
Dulbecco’s phosphate-buffered saline (DPBS), 
without calcium and magnesium 
PAA, Pasching, Austria/Cölbe, Marburg-Biedenkopf; 
Life Technologies, Darmstadt 
Dulbecco’s modiﬁed Eagle’s medium (DMEM) 
GlutaMAX™, high glucose (4.5 g/l) 
Life Technologies, Darmstadt 
Dulbecco’s modiﬁed Eagle’s medium (DMEM), high 
glucose (4.5 g/l), L-glutamine 
PAA, Pasching, Austria/Cölbe, Marburg-Biedenkopf 
Dynasore (DYN) Sigma-Aldrich, Steinheim 
Ethanol (CH3CH2OH) J.T.Baker (now VWR), Darmstadt 
Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-
tetraacetic acid (EGTA) 
Carl-Roth, Karlsruhe 
Ethylenediaminetetraacetic acid (EDTA) Carl-Roth, Karlsruhe 
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Filipin III from Streptomyces filipinensis Sigma-Aldrich, Steinheim 
Foetal calf serum (FCS) PAA, Pasching, Austria/Cölbe, Marburg-Biedenkopf; 
Life Technologies, Darmstadt 
G418 sulfate (geneticin) Calbiochem/Merck, Darmstadt 
GIBCO® Zeocin™ selection reagent Invitrogen 
Glycerol Merck, Darmstadt 
Glycine Carl-Roth, Karlsruhe 
Hexammine cobalt(III) chloride ([Co(NH3)6]Cl3) Sigma-Aldrich, Steinheim 
High-mass DNA ladder Invitrogen 
Hydrochloric acid (HCl) Merck, Darmstadt 
Hydrogen peroxide (H2O2) Merck, Darmstadt 
IGEPAL® CA-630 (previously known as NP-40) Sigma-Aldrich, Steinheim 
Immersion liquid type F (refractive index 1.518) Leica Microsystems CMS, Wetzlar 
Isopropanol ((CH3)2CHOH, 2-propanol) Sigma-Aldrich, Steinheim 
Isopropyl-β-D-thiogalactopyranoside (IPTG) Carl-Roth, Karlsruhe 
L-3,4-Dihydroxyphenylalanine methyl ester 
hydrochloride (L-dopa methyl ester) 
Sigma-Aldrich, Steinheim 
Lipofectamine™ 2000 Reagent Invitrogen 
Luminol sodium salt Sigma-Aldrich, Steinheim 
Lysozyme from chicken egg white (EC 3.2.1.17) Sigma-Aldrich, Steinheim 
Magnesium chloride (MgCl2) Sigma-Aldrich, Steinheim 
Magnesium sulphate (MgSO4) Sigma-Aldrich, Steinheim 
Manganese(II) chloride dihydrate (MnCl2 · H2O) Merck, Darmstadt 
Methanol (CH3OH) Sigma-Aldrich, Steinheim 
Milk powder, blotting grade Carl-Roth, Karlsruhe 
N,N,N′,N′-Tetramethylethylenediamine (TEMED) Carl-Roth, Karlsruhe 
Nystatin (NYS) Sigma-Aldrich, Steinheim 
Opti-MEM® GlutaMAX™ Invitrogen 
PageRuler™ pre-stained protein ladder Fermentas/Thermo Scientific, Vilnus, Lithuania 
Paraformaldehyde Fluka/Sigma-Aldrich, Steinheim 
p-coumaric acid Sigma-Aldrich, Steinheim 
Penicillin (10,000 units/ml) and streptomycin 
(10,000 µg/ml) 
Pasching, Austria/Cölbe, Marburg-Biedenkopf; 
Thermo Scientific/Life Technologies, Darmstadt 
Phenylmethyl sulfonyl fluoride (PMSF) Carl-Roth, Karlsruhe 
Ponceau S Carl-Roth, Karlsruhe 
Potassium chloride (KCl) Merck, Darmstadt 
Potassium dihydrogen phosphate (KH2PO4) Merck, Darmstadt 
ProLong® gold antifade mountant with DAPI Thermo Scientific/Life Technologies, Darmstadt 
Protease inhibitor cocktail (cat. no. P8340) Sigma-Aldrich, Steinheim 
Rabbit skeletal muscle α-actin (10% pyrene-labelled) Hypermol, Bielefeld 
Sodium chloride (NaCl) Carl-Roth, Karlsruhe 
Sodium deoxycholate Sigma-Aldrich, Steinheim 
Sodium dihydrogen phosphate monohydrate 
(NaH2PO4 · H2O) 
Merck, Darmstadt 
Sodium dodecyl sulphate (SDS) Carl-Roth, Karlsruhe 
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Sodium fluoride (NaF) Sigma-Aldrich, Steinheim 
Sodium hydroxide (NaOH) Merck, Darmstadt 
Sodium orthovandate (Na3VO4) Sigma-Aldrich, Steinheim 
Sodium periodate (NaIO4) Merck, Darmstadt 
Sulfosalicylic acid Sigma-Aldrich, Steinheim 
SuperSignal® West Pico Chemiluminescence 
Substrate (Luminol/Enhancer and Stable Peroxide) 
Thermo Scientific/Life Technologies, Darmstadt 
Texas Red®-X-conjugated phalloidin Invitrogen 
Trichloroacetic acid (TCA) Carl-Roth, Karlsruhe 
Tris-(hydroxymethyl aminomethane) (Tris) Carl-Roth, Karlsruhe 
Triton® X-100 Sigma-Aldrich, Steinheim 
Trypsin-EDTA (0.25%), phenol red GIBCO™, Life Technologies, Darmstadt 
Tween-20 Sigma-Aldrich, Steinheim; Carl-Roth, Karlsruhe 
Yeast extract Sifin, Berlin 
β-Mercaptoethanol Sigma-Aldrich, Steinheim 
 
Table 6. List of recombinant proteins. 
Name Origin 
Recombinant GST-tagged VCA (GST-VCA) (1 mg/ml) Robert Grosse lab, Marburg 
Recombinant human epidermal growth factor (EGF) Sigma-Aldrich, Steinheim 
Recombinant human insulin-like growth factor (IGF)-
I (7.6 kDa; 1 mg/ml in PBS) 
R&D Systems, Wiesbaden (Małgorzata Wygrecka 
lab) 
Recombinant human macrophage migration 
inhibitory factor (MIF): MIF WT/buffer P 
(13.08.2010), MIF C60S/20 mM phosphate buffer 
(01.11.2005), MIF P2A/PBS (01.11.2005), and MIF 
Δ4/PBS (17.11.2005) 
Laboratory stock (Ana-Maria Filip, Suada Fröhlich, 
and Jörg Klug) 
Recombinant human MIF, human and mouse D-
dopachrome tautomerase (D-DT) 
This thesis 
 
Table 7. List of bacterial strains. 
Name Origin 
E. coli BL21 (DE3) (B F
–
 dcm ompT hsdS(rB
–
 mB
–
) gal 
λ(DE3)) 
Laboratory stock 
Subcloning Efficiency™ E. coli DH5α™ competent cells 
(fhuA2 Δ(argF-lacZ)U169 phoA glnV44 Φ80 Δ(lacZ)M15 
gyrA96 recA1 relA1 endA1 thi-1 hsdR17) 
Thermo Fisher Scientific 
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Table 8. List of mammalian cell lines. 
Name Origin 
COS-7 (African green monkey kidney) fibroblasts Laboratory stock 
COS-7/M6 (COS-7 clone M6) Kindly provided by the Richard Bucala lab, Yale 
COS-7/M6 CD44
+
  This thesis, stable cell line 
COS-7/M6 CD44
+
/CD74
+
  This thesis, stable cell line 
COS-7/M6 CD44Δ67
+
  This thesis, stable cell line 
COS-7/M6 CD44Δ67
+
/CD74
+
  This thesis, stable cell line 
COS-7/M6 CD74
+
  This thesis, stable cell line 
HEK293 (human embryonic kidney) fibroblasts Laboratory stock 
 
Table 9. List of primary antibodies. 
Name Catalogue number; manufacturer 
or supplier 
Dilution; blocking solution; 
electro-transfer time 
Anti-CD74 (FL-296) (rabbit pc) sc-20082, Santa Cruz 1:500; 5% milk; 60 min 
Anti-MIF (83) (rabbit pc) Meinhardt lab, JLU Giessen 1:20,000; 5% milk; 80 min 
Anti-mouse CD44 (Hermes-3) 
(mouse mc) 
Margot Zöller, Heidelberg 1:500; 5% milk; 90 min 
Anti-β-actin antibody (AC-15) 
(ascites fluid) 
A5441, Sigma-Aldrich 1:5,000; 5% milk 
Purified mouse anti-human CD74 
(mouse mc) (IgG2a) 
555538, BD Pharmingen 1:500; 5% milk; 60 min 
Rabbit anti-phospho-p44/42 MAPK 
(ERK1/2) (Thr-202/Tyr-204 and 
Thr-185/Tyr-187) (rabbit pc) 
9101S, Cell Signaling 1:1,000; 5% BSA; 35 min 
Rabbit anti-total p44/42 MAPK 
(ERK1/2) (rabbit pc) 
9102, Cell Signaling 1:1,000; 5% BSA; 35 min 
 
Table 10. List of secondary antibodies. 
Name Catalogue number; manufacturer or 
supplier 
Dilution; blocking solution 
Goat anti-rabbit HRP-
conjugated secondary antibody 
55676, MP Cappel; and 12-348, 
Merck 
1:10,000; 5% milk or BSA 
Sheep anti-mouse HRP-
conjugated secondary antibody 
A5906, Sigma-Aldrich 1:10,000; 5% milk or BSA 
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Table 11. List of primers. 
Primer name Sequence (5’3’) Length 
[bp] 
Tm 
[° C] 
Amplicon 
size [bp] 
Features recognised by 
primers; ID 
β-actin-For ATGGTGGGTATGGGTCAGAA 20 60.0 
232 
β-actin; 
AB004047.1 β-actin-Rev GGGTCATCTTTTCACGGTTG 20 60.3 
CD74-For1 ACGCTCCACCGAAAGAGTC 19 60.4 
194 
His-tag and V5 epitope; 
NM_004355.3 CD74-Rev1 CGTAGAATCGAGACCGAGGA 20 60.3 
CD44FL-For3 CTCCAGTGAAAGGAGCAGCA 20 59.9 
146 
Exon 5-exon 6; 
NM_001001391.1 CD44FL-Rev3 TGGGGTGGAATGTGTCTTGG 20 59.8 
CD74-For2 CCATGGAGACCATAGACTGGA 21 59.9 
99 
Exon 5-exon 6; 
NM_004355.3 CD74-Rev2 CGTCAGTGGGCTTTTGCT 18 59.9 
Primer synthesis was carried out by Invitrogen. 
Table 12. List of DNA constructs and their maps. 
Name Origin Antibiotic resistance 
pTracer™-SV40-CD44H Richard Bucala lab, Yale (Shi et al., 2006) Zeocin 
pTracer™-SV40-CD44Δ67 Richard Bucala lab, Yale (Shi et al., 2006) Zeocin 
pcDNA™3.1/V5-His TOPO®-
CD74 
Richard Bucala lab, Yale (Shi et al., 2006) Ampicillin 
pET-11b-WT hMIF Jürgen Bernhagen lab, Aachen (Bernhagen et al., 1994) Ampicillin 
pET-22b(+)-WT hD-DT Richard Bucala lab, Yale (Merk et al., 2011) Ampicillin 
pET-22b(+)-WT mD-DT Richard Bucala lab, Yale (Merk et al., 2011) Ampicillin 
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1. pTracer™-SV40 (Thermo Scientific) 
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2. pcDNA™3.1/V5-His TOPO® (Thermo Scientific) 
 
3. pET-11b (Agilent) 
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4. pET-22b(+) (Novagen) 
 
 
Table 13. List of short interfering RNAs (siRNAs). 
Name Sequence (5’ to 3’) 
ON-TARGETplus MIF #1 Sense: GGGUCUACAUCAACUAUUAUU 
Antisense: P-UAAUAGUUGAUGUAGACCCUU 
ON-TARGETplus MIF #2 Sense: GCGCAGAACCGCUCCUACAUU 
Antisense: P-UGUAGGAGCGGUUCUGCGCUU 
ON-TARGETplus MIF C911 #1 Sense: GGGUCUACUAGAACUAUUAUU 
Antisense: P-UAAUAGUUCUAGUAGACCCUU 
ON-TARGETplus MIF C911 #2 Sense: GCGCAGAAGGCCUCCUACAUU 
Antisense: P-UGUAGGAGGCCUUCUGCGCUU 
All siRNAs (10 nmol each) were custom-synthesised by Dharmacon/GE Healthcare. Base pairs 9 to 11 
(complementary in C911 #1 and 2 to MIF #1 and2, respectively – are highlighted. 
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4.2. Methods 
4.2.1. Biochemistry 
4.2.1.1. Preparation of nucleic acids 
DNA midi-preps were prepared according to manufacturer’s instructions (NucleoBond® 
Xtra Midi, Macherey-Nagel, Düren) and stored at –20°C. RNA was prepared with the 
peqGOLD Total RNA Kit (peqlab, Erlangen) and stored at –80°C. 
4.2.1.2. Determination of protein and nucleic acid concentrations 
Protein concentrations were determined with the Bradford assay (Bradford, 1976) using 
the Bradford assay reagent (BioRad, Munich). Nucleic acid (DNA or RNA) concentrations 
were determined with a NanoDrop™ 2000 spectrophotometer using the NanoDrop 
software (version 1.4.2). 
4.2.1.3. RNA reverse transcription and PCR 
2 μg of RNA from WT and stable COS-7/M6 cell lines were combined with 0.5 µg oligo dT 
primer (all reagents were from Promega, Mannheim) per 1 µg RNA and heated up to 70 °C 
for 5 min. Following the Promega protocol, the total volume of this reaction was always 
smaller or equal to 15 μl (in water), because each starting RNA preparation had a different 
concentration. Next, the RNA-oligo dT primer mix was combined with 5 µl 5X reaction 
buffer, 1.25 µl each deoxynucleotide (dNTP, i.e. dATP, dCTP, dGTP and dTTP, each 
10 mM), 0.625 µl (25 units) recombinant RNasin® ribonuclease inhibitor (stock: 40 u/µl), 
1 µl (200 units) Moloney murine leukemia virus reverse transcriptase (200 u/µl), and 
water up to 25 µl. Following an incubation at 42 °C for 1 h in a PCR thermal cycler, the 
reaction was stopped at 72 °C for 15 min. 1 μl of freshly-prepared cDNA was used in the 
subsequent PCR. 
Next, a PCR mix was combined in 0.5-ml microcentrifuge tubes on ice (Table 14). 
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Table 14. Components of PCR mix. 
Component Volume Final concentration 
5X Green GoTaq® reaction buffer 
containing 7.5 mM MgCl2 
10 µl 1X buffer and 1.5 mM MgCl2 
dNTPs (each 10 mM) 1 µl 0.2 mM 
Forward primer (10 pmol) 0.5 µl 0.1 pmol 
Reverse primer (10 pmol) 0.5 µl 0.1 pmol 
cDNA generated as described above 1 µl - 
GoTaq® DNA polymerase 0.25 µl (1.25 units) - 
Water Fill up to 50 µl - 
 
The tubes were placed within a PCR thermal cycler. All steps of the PCR were performed 
with lid heating (100 °C). The template cDNA was denatured at 95 °C for 2 minutes. Then 
25 cycles of denaturation (95 °C) for 30 sec, annealing (53.7 °C for actin, 60 °C for CD74, 
and 66.3 °C for CD44FL) for 1 min, and extension (72 °C) for 1 min/kb were performed. 
The final extension was carried out at 72 °C for 5 minutes, and the PCR reactions were 
cooled down to 4 °C until retrieved for agarose electrophoresis. 
4.2.1.4. Agarose gel electrophoresis 
For a standard agarose gel, 1.2 % (w/v) agarose were dissolved in 100 ml TAE buffer 
(40 mM Tris base, 1 mM EDTA pH 8.0, 20 mM acetic acid) in an Erlenmeyer flask by boiling 
for 1-5 min at maximum power in a microwave oven. Once agarose had dissolved 
completely, the flask was cooled down under cold tap water for 2 min. Following drop-
wise addition of ethidium bromide (2-3 drops for a small 7x8 cm and 4-5 drops for a large 
15x15 cm gel), the agarose solution was poured into the gel holder mounted within the 
adjustable casting chamber, and the gelation of the agarose gel was allowed for approx. 
30 min. 5 μl of the PCR samples were loaded into the wells together with a suitable DNA 
size marker and electrophoresed for 30 min at constant 110 V. If the PCR mix or DNA size 
marker did not include already a dye, the samples were complemented with 
6X Blue/Orange loading dye (0.4% orange G, 0.03% bromophenol blue, 0.03% xylene 
cyanol FF, 15% Ficoll® 400, 10 mM Tris-HCl (pH 7.5) and 50 mM EDTA (pH 8.0), Promega) 
so that the final concentration was 1X. After electrophoresis the gel was placed on a 312 
Materials and Methods 
44 
 
nm UV transilluminator and documented with an INTAS Gel Jet Imager running INTAS GDS 
Software (version 3.2816.01.2009).  
4.2.1.5. Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Two glass plates and 1-mm spacers were assembled on a temporary holder. To cast the 
resolving gel the following components were combined (Table 15): 
Table 15. Components of the resolving gel. 
Component Gel percentage Unit 
7.5% 12.5% 15%  
Water 4.895 3.225 2.395 ml 
1.5 M Tris-HCl pH 8.8 2.5 2.5 2.5 ml 
20% (w/v) SDS 50 50 50 µl 
Acrylamide (30%) 2.5 4.17 5 ml 
10% (w/v) APS 50 50 50 µl 
TEMED 5 5 5 µl 
Total volume (2 gels) 10 ml 
 
The polymerisation of each polyacrylamide gel was catalysed by APS and TEMED. The 
solution was immediately poured into the space between the two glass plates, overlaid 
with 100% isopropanol, and set aside to polymerise for 30 min at room temperature. 
Following isopropanol removal, a stacking gel solution containing 4% acrylamide (Table 
16) was combined and poured over the resolving gel. 
Table 16. Components of the stacking gel. 
Component Gel percentage: 4% Unit 
Water 3.025 ml 
0.5 M Tris-HCl pH 6.8 1.25 ml 
20% (w/v) SDS 25 µl 
Acrylamide (30%) 0.65 ml 
10% (w/v) APS 25 µl 
TEMED 5 µl 
Total volume (2 gels) 5 ml 
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As earlier, APS and TEMED were added shortly before casting the gel. A multi-well comb 
was inserted momentarily between the spacers, and the gel was set aside to polymerise 
for 15-20 min at room temperature. 
Finally, the gels were mounted within the electrophoresis apparatus, creating an inner as 
well as outer chamber. The running buffer (25 mM Tris base, 192 mM glycine, 0.1% (w/v) 
SDS, no pH adjustment) was poured into both chambers. The comb was carefully removed 
and the wells thoroughly rinsed with running buffer. 
Protein samples (either chromatography fractions or cell culture-derived, see sections 
below) were dissolved in an SDS-PAGE sample loading dye (50 mM Tris-HCl pH 6.8, 
2% (w/v) SDS, 10% (v/v) glycerol, 0.002% (w/v) bromophenol blue, 200 mM DTT), boiled 
for 5 min, and immediately applied to the wells.  
During electrophoresis through the stacking gel, the conditions were 80-90 V until the 
proteins reached the resolving gel. Within the resolving gel, the voltage was increased to 
120-140 V, and the electrophoresis continued until the bromophenol blue dye migrated 
out of the gel. 
4.2.1.6. Immunoblotting 
Following SDS-PAGE, proteins were transferred in transfer buffer (25 mM Tris-HCl pH 8.3, 
192 mM glycine, 20% (v/v) methanol) from the polyacrylamide gel onto nitrocellulose 
membranes using a semi-dry electroblotter (Trans-Blot® Semi-Dry Electrophoretic 
Transfer Cell). Briefly, four sheets of chromatography paper (Whatman™) were immersed 
in the transfer buffer and placed on the anode, followed by the buffer-soaked membrane, 
the SDS-acrylamide gel, and additional four sheets of chromatography paper. The cathode 
was placed back on the stack, and proteins were transferred at 1 mA/cm2. To validate 
protein transfer, the membranes were stained in Ponceau S solution (0.2% (w/v) Ponceau 
S, 3% (v/v) trichloroacetic acid (TCA), 3% (w/v) sulfosalicylic acid) for 5 min, scanned, and 
destained with TBST (15 mM Tris-HCl pH 7.6, 137 mM NaCl, 1% (v/v) Tween-20). 
Membranes were blocked with freshly-made 5% (w/v) non-fat dry milk or BSA in TBST for 
1 h on an orbital shaker. The blocking solution was discarded and a new primary antibody-
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containing milk solution was added to the membranes and kept overnight at 4 °C with 
shaking (for dilutions see Table 9). Following washing with TBST for 3 x 5 min, the 
membranes were incubated for 1 h at room temperature with shaking in either 5% (w/v) 
non-fat dry milk or BSA supplemented with secondary antibodies (Table 10). Secondary 
antibodies were conjugated to horseradish peroxidase which catalyses the oxidation of 
luminol to chemiluminescent 3-aminophthalate. 
Following the incubation with secondary antibodies, the membranes were washed with 
TBST for 3 x 10 min, placed within the Fusion development chamber (Vilber Lourmat, 
Eberhardzell), and covered entirely with the ECL substrate. To create an ECL substrate 
(Haan and Behrmann, 2007), 1 ml solution A (0.1 M Tris-HCl pH 8.6, 0.25 mg/ml luminol), 
0.3 μl 30% (v/v) H2O2, and 100 μl solution B (1.1 mg/ml p-coumaric acid ((E)-3-(4-
hydroxyphenyl)-2-propenoic acid) in DMSO) were combined 1 min before image 
recording. The ECL signal was detected using the FusionCapt Advance software (Vilber 
Lourmat, Eberhardzell). 
Immunoblots against phosphorylated proteins were performed in essentially the same 
manner with the following exceptions. The blocking solution (5% BSA instead of 5% (w/v) 
non-fat dry milk in TBST) contained 50 mM NaF and Na3VO4, and the primary and 
secondary antibodies were dissolved in 5% BSA/TBST/50 mM NaF to inhibit phosphatases. 
To re-probe with new antibodies, the membranes were incubated in stripping buffer 
(62 mM Tris-HCl pH 6.8, 0.5% (w/v) SDS, 0.8% (v/v) β-mercaptoethanol) for 5 min in a 
water bath at 65 °C, and then washed with TBST in order to quantitatively remove β-
mercaptoethanol (approx. 1 h). The stripping procedure – time, temperature, and 
stripping buffer composition – has been standardised in our laboratory (Zhang, 2015) such 
that an ECL exposure after stripping does not yield a detectable signal. 
4.2.2. Bacterial cell culture 
Bacterial media were prepared as follows: LB (10 g/l tryptone, 5 g/l yeast extract (the 
supplier were switched from Sifin to Becton, Dickinson and Co.), 10 g/l NaCl); 2YT (16 g/l 
tryptone, 10 g/l yeast extract, 5 g/l NaCl); SOB (20 g/l tryptone, 5 g/l yeast extract, 0.5 g/l 
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NaCl; 833 µl of 3 M KCl to a final of 2.5 mM; 10 mM MgCl2 and 10 mM MgSO4); and SOC 
(SOB supplemented 20 mM glucose). All media – without prior pH adjustment – were 
autoclaved and stored at 4 °C. Glucose (SOC) was added after autoclaving. For LB/agar 
plates, 15 g/l agar was added to LB, sterilised by autoclaving, and allowed to cool down to 
approx. 50 °C before the addition of antibiotics. The LB-agar mixture was poured into Petri 
dishes and allowed to harden at room temperature. LB/agar plates were dried at 37 °C 
overnight and stored at 4 °C until use. 
4.2.2.1. Inoculation from a glycerol stock, propagation from a single-colony 
Bacterial cells were stored in microcentrifuge tubes at – 80 °C and were retrieved from a 
glycerol stock and kept on ice when necessary. A sterile inoculation loop was submerged 
into the tube with partially-thawed cells and the bacteria were streaked out on an LB/agar 
plate. For overnight cultures a single colony was picked with a sterile pipette tip, and the 
tip was put into a 13 ml snap cap tube containing 3-5 ml LB and incubated in an orbital 
shaker at 37°C overnight.  
4.2.2.2. Preparation of competent bacterial cells and transformation 
Chemically-competent Escherichia coli (E. coli) cells were prepared according to a 
simplified Hanahan protocol (Hanahan, 1983) and transformed with plasmid DNA 
encoding the gene/protein of interest – human MIF, mouse D-DT (mD-DT) or human D-DT 
(hD-DT). For overnight cultures a colony of E. coli DH5α (for plasmid DNA mini-preps) or E. 
coli BL21 (DE3) (for protein overexpression) was picked and inoculated into 3 ml SOB 
medium and grown overnight at 37 °C.  
100 μl of the overnight culture were transferred into 30 ml SOB in a 500 ml Erlenmeyer 
flask. The optical density at 600 nm (OD600) was checked regularly. At OD600 = 0.45-0.55, 
the culture was transferred into a 50 ml conical tube and put on ice for 10-15 min. The 
cells were pelleted by centrifugation at 2,500 rpm for 12 min at 4 °C. The supernatant was 
discarded, and the pellet resuspended in 10 ml transformation buffer (TFB) (10 mM K-MES 
pH 6.2, 100 mM KCl, 45 mM MnCl2, 10 mM CaCl2, 3 mM [Co(NH3)6]Cl3, filter-sterilised and 
stored at 4 °C). After 10-15 min on ice, the cells were centrifuged again at 2,500 rpm for 
12 min at 4 °C, the supernatant was discarded, and the pellet resuspended in 2.4 ml TFB. 
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The following compounds were added to the bacteria sequentially, the suspension was 
mixed, and the tubes were incubated on ice for the indicated time: DMSO (84 µl, 5 min); 1 
M DTT (84 µl, 10 min); DMSO (84 µl, 5 min). The competent cell suspension was split into 
200 µl aliquots in 1.5 ml microcentrifuge tubes and either used directly or snap-frozen in 
liquid nitrogen and stored at – 80 °C. 
For transformation 1-5 µl plasmid DNA (100-300 ng) was added to 200 µl competent cell 
suspension. After incubation on ice for 30 min, the cells were heat-shocked for 45 sec at 
42 °C and immediately transferred onto ice for 1-2 min. 800 µl SOC medium was added, 
and the microcentrifuge tubes were securely mounted in a bacterial shaker and incubated 
for 1 h at 37 °C with shaking for establishing antibiotic resistance. 200 µl bacterial 
suspension were streaked out on an ampicillin-containing agar plate. The plate was dried 
for 30 min at room temperature and incubated at 37 °C overnight.  
4.2.2.3. Glycerol stocks 
As needed, 1 ml overnight culture of wild type as well as transformed bacteria were 
combined with glycerol to a final concentration of 25% (v/v) and stored at – 80 °C. 
4.2.3. Purification of recombinant MIF/D-DT from E. coli 
4.2.3.1. Cell lysis 
In order to produce wild-type recombinant proteins, fresh competent E. coli BL21 (DE3) 
were transformed (section 4.2.2.2) with an expression plasmid encoding either human 
MIF, human D-DT (hD-DT) or mouse D-DT (mD-DT) (Table 12), and plated on LB/ampicillin 
plates. 200 ml 2YT/ampicillin was inoculated with 200 µl of an overnight culture and 
incubated with shaking at 37°C. 1 ml of the bacterial culture was periodically transferred 
from the flask into a cuvette, and the OD600 was measured. At OD600 = 0.5, protein 
expression was induced by adding 40 µl 0.25 M IPTG (0.5 mM final). After shaking for 
another 3 h at 37°C the flask was put on ice for 5 min. The culture was centrifuged at 
4,500 rpm for 15 min in a Fiberlite F14 rotor at 4 °C, the supernatant discarded and the 
pellet weighed (a 200-ml culture should yield a pellet of approx. 1 g). The pellet was 
resuspended in 3 ml of freshly-made resuspension buffer I (50 mM Tris-HCl pH 8.0, 1 mM 
EDTA, 100 mM NaCl) per gram of pellet. The suspension was transferred into a 50 ml high-
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speed centrifugation tube (www.laborgeraete-beranek.de) for the Sorvall SS34 rotor. Per 
gram pellet 4 µl 100 mM PMSF and 80 µl lysozyme (10 mg/ml) were added. After 
incubation on a rotating platform at room temperature for 20 min, 4 mg Na-deoxycholate 
were added per gram pellet. The bacterial lysate was then placed at 37°C with occasional 
careful mixing until the solution became viscous (approx. 30 min). Next, 20 µl DNase I 
(1 mg/ml) was added per gram pellet, and the lysate was incubated at room temperature 
for 30 min until it was no longer viscous. The lysate was cleared by centrifugation at 
11,000 rpm in a SS34 rotor at 4°C for 15-30 min. 
The lysate was dialysed at room temperature using a 16 mm flat width Spectra/Por CE 
membrane with a MWCO of 5,000 (from www.spectrumlabs.com) against PBS (87.6 g 
NaCl, 22.8 g K2HPO4, 6.8 g KH2PO4, pH 7.4, water up to 1 l) supplemented with 1 mM DTT. 
In 2 hour intervals the dialysis buffer was replaced with fresh buffer twice, and the last 
dialysis step continued overnight. The next morning the dialysate was centrifuged in a 
SS34 rotor at 11,000 rpm and 4°C for 30 min. At this point, the purification protocols for 
MIF and D-DT diverged. 
4.2.3.2. Purification of human MIF 
The MIF-containing dialysate was recovered and proteins were precipitated by adding 
drop-wise 3.33 ml saturated ammonium sulphate (AS) solution per 5 ml dialysate (40% AS 
saturation) for 30 min on ice. A saturated AS solution is obtained by dissolving 80 g AS in 
100 ml deionised water (approx. 4.1 M) with gentle heating (60 °C). The solution is cooled 
down to room temperature, adjusted to pH 7.0 with concentrated NH4OH, 0.45 µm 
filtered and stored at 4°C. The precipitate was collected by centrifugation at 11,000 rpm in 
a Sorvall SS34 rotor at 4°C for 30 min. The pellet was set aside and remaining proteins 
were precipitated from the supernatant by increasing AS saturation to 60%. If start 
volume was 5 ml, 2.5 ml saturated AS solution was added to the 8.33 ml of the 40% 
solution. After 30 min on ice the precipitate was again collected by centrifugation at 
11,000 rpm in a Sorvall SS34 rotor at 4°C for 30 min. The supernatant was set aside for 
analysis by SDS-PAGE, and the 60% AS pellet (if starting with a 200-ml bacterial culture) 
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was dissolved in 1 ml buffer P (20 mM HEPES pH 7.9, 5 mM EDTA, 200 mM NaCl, 1 mM 
DTT) and transferred to an Eppendorf tube. 
The dissolved protein solution was cleared by centrifugation for 10 min at maximum 
speed in a microcentrifuge at 4 °C.  
The protein concentration was determined (section 4.2.1.2), and 1 ml (up to 25 mg) was 
applied to a 16/60 HiPrep S-100 gel filtration column operated manually by an ÄKTA Basic 
HPLC system (GE Healthcare) using buffer P without PMSF as solvent (flow 0,4 ml/min, 
fraction size 2 ml). The major protein peak representing the recombinant protein eluted at 
approx. 58 ml. 
The peak fractions (2-3 fractions) were combined, and the protein concentration was 
measured again. Using a 10-ml superloop and buffer P as solvent the combined peak 
fractions (approx. 4-6 ml) were passed over a 1-ml Resource™ S column screwed on top of 
a 1-ml Mono Q™ column operated again manually by an ÄKTA Basic HPLC system. The 
flow-through, containing MIF, was collected in one tube by manual fractionation and 
stored at 4 °C.  
All samples that were set aside at critical preparation steps during the whole procedure 
were analysed by SDS-PAGE followed by Coomassie staining with either commercially-
available Coomassie Brilliant Blue G-250 staining solution (Fermentas) or a staining 
solution made according to Sedmak and Grossberg (2% H3PO4, 10% (NH4)SO4, 20% 
methanol, 0.1% Coomassie Brilliant Blue G-250) (Sedmak and Grossberg, 1977). 
4.2.3.3. Endotoxin removal 
The next day the protein concentration of the flow-through was determined. The NaCl 
concentration was adjusted to 0.5 M and the protein sample was applied to a Detoxi-Gel™ 
AffinityPak Prepacked Column (Thermo Scientific, Pierce Biotechnology, Rockford, IL, USA) 
according to the manufacturer’s instructions. Briefly, the column was conditioned with 
1% (w/v) sodium deoxycholate, MilliQ water, and Ampuwa water. Then, the protein 
solution was applied, and the flow-through was collected in Eppendorf tubes for protein 
concentration measurement and long-term storage. 
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4.2.3.4. Purification of D-DTs 
The purification of mD-DT and hD-DT was similar to the purification of hMIF (section 
4.2.3.2) with the following exceptions. In the AS precipitation step mD-DT precipitated 
already at 40% AS saturation whereas hD-DT precipitated at 60% AS saturation like MIF. 
Following size-exclusion chromatography combined fractions were passed over Mono 
S™/Mono Q™ instead of Resource™ S™/Mono Q™, and 20 mM phosphate buffer pH 7.0 
(12.2 ml of 1 M Na2HPO4, 7.8 ml 1 M NaH2PO4 in a total of 1 l) was used as solvent. Both 
D-DTs, identical to MIF, did not bind to the combined anion/cation exchangers, and eluted 
in the flow-through that was collected manually, aliquoted, and snap-frozen in liquid 
nitrogen for long-term storage at – 80 °C. 
4.2.3.5. Confirmation of MIF and D-DT protein identity – mass spectrometry 
The identity of all purified proteins was verified by matrix-assisted laser 
desorption/ionisation time-of-flight (MALDI-TOF) mass spectrometry (Protein Analytics, 
Institute for Biochemistry, JLU, Günter Lochnit lab). Briefly, recombinant proteins were 
separated on a polyacrylamide gel, bands were cut out, digested with trypsin and LysC 
(MIF only), and subjected to MS (see results below, points 1-3). In each result there is a 
box containing the expected amino acid sequence, and each peptide identified by MS is 
represented by one or more black boxes (e.g. for hMIF the box spans IGGAQNRSYSK), 
revealing the identity of each recombinant protein sequence verified over large parts of 
the primary amino acid sequence. Taken together, the multiple sequence alignments 
(below, point 4) show that the species identity could be confirmed for all proteins. 
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1. Human MIF 
 
2. Human D-DT 
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3. Murine D-DT 
 
4. CLUSTAL O(1.2.1) multiple sequence alignments 
Selected peptides found by MS that were not identical between human and murine are 
highlighted: 
 Human MIF 
sp|P14174|MIF_HUMAN      MPMFIVNTNVPRASVPDGFLSELTQQLAQATGKPPQYIAVHVVPDQLMAFGGSSEPCALC 
sp|P34884|MIF_MOUSE      MPMFIVNTNVPRASVPEGFLSELTQQLAQATGKPAQYIAVHVVPDQLMTFSGTNDPCALC 
                         ****************:***************** *************:*.*:.:***** 
 
sp|P14174|MIF_HUMAN      SLHSIGKIGGAQNRSYSKLLCGLLAERLRISPDRVYINYYDMNAANVGWNNSTFA 
sp|P34884|MIF_MOUSE      SLHSIGKIGGAQNRNYSKLLCGLLSDRLHISPDRVYINYYDMNAANVGWNGSTFA 
                         **************.*********::**:********************* **** 
 
 Human D-DT 
sp|P30046|DOPD_HUMAN      MPFLELDTNLPANRVPAGLEKRLCAAAASILGKPADRVNVTVRPGLAMALSGSTEPCAQL 
sp|O35215|DOPD_MOUSE      MPFVELETNLPASRIPAGLENRLCAATATILDKPEDRVSVTIRPGMTLLMNKSTEPCAHL 
                          ***:**:*****.*:*****:*****:*:** ** ***.**:***::: :. ******:* 
 
sp|P30046|DOPD_HUMAN      SISSIGVVGTAEDNRSHSAHFFEFLTKELALGQDRILIRFFPLESWQIGKIGTVMTFL 
sp|O35215|DOPD_MOUSE      LVSSIGVVGTAEQNRTHSASFFKFLTEELSLDQDRIVIRFFPLEAWQIGKKGTVMTFL 
                           :**********:**:*** **:***:**:* ****:*******:***** ******* 
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 Murine D-DT 
sp|P30046|DOPD_HUMAN      MPFLELDTNLPANRVPAGLEKRLCAAAASILGKPADRVNVTVRPGLAMALSGSTEPCAQL 
sp|O35215|DOPD_MOUSE      MPFVELETNLPASRIPAGLENRLCAATATILDKPEDRVSVTIRPGMTLLMNKSTEPCAHL 
                          ***:**:*****.*:*****:*****:*:** ** ***.**:***::: :. ******:* 
 
sp|P30046|DOPD_HUMAN      SISSIGVVGTAEDNRSHSAHFFEFLTKELALGQDRILIRFFPLESWQIGKIGTVMTFL 
sp|O35215|DOPD_MOUSE      LVSSIGVVGTAEQNRTHSASFFKFLTEELSLDQDRIVIRFFPLEAWQIGKKGTVMTFL 
                           :**********:**:*** **:***:**:* ****:*******:***** ******* 
 
4.2.3.6. Crystal structures of MIF and D-DT in PyMOL 
Based on X-ray-derived atom coordinates, three-dimensional structures of MIF (1MIF) 
(Sun et al., 1996) and D-DT (1DPT) (Sugimoto et al., 1999) were visualised by the PyMOL 
Molecular Graphics System (Version 1.7.4 Schrödinger, LLC.) on a transparent background. 
False colour-coding was employed to show residues responsible for distinct biological 
functions. Select amino acids were shown as sticks (i.e. the side chains were visible in full) 
whereas most of the structure is shown as a ribbon presentation (i.e. α-helices and β-
sheets). 
4.2.4. Mammalian cell culture 
4.2.4.1. Passaging, freezing, and thawing of mammalian cells 
WT and stable COS-7/M6 cell lines were cultured in GlutaMAX™ high-glucose DMEM 
supplemented with 10% (v/v) FCS (heat-inactivated at 56 °C for 30 min) and 100 units/ml 
penicillin and 100 µg/ml streptomycin (1:100 dilution of stock). COS-7/M6 single-
transfectant stable cell lines were cultured in DMEM supplemented with antibiotics at 
500 µg/ml: for CD44+, zeocin (diluted from the ready-to-use stock solution of 100 mg/ml); 
for CD44Δ67+, zeocin; for CD74+, geneticin (diluted from the stock of 100 mg/ml in 
100 mM HEPES pH 7.3). COS-7/M6 double-transfectant stable cell lines were cultured in 
DMEM with both zeocin and geneticin (250 µg/ml each): CD44+-CD74+ or CD44Δ67+-
CD74+-double-expressing cells. 
Cell passaging was performed according to the American Type Culture Collection 
guidelines for all cell types under investigation. Having inspected a flask or dish under a 
phase-contrast microscope, cells were washed once with PBS and 1 ml of the releasing 
solution (0.1 mM trypsin, 0.9 mM EDTA, Invitrogen) per a T75 flask/10-cm dish was used 
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to dislodge adherent cells from the substrate. To facilitate the detachment, the tissue 
culture vessel was kept in the incubator at 37 °C for 1-2 min. To stop the reaction, serum-
containing DMEM was added to a total of 10 ml. In a new vessel, 11 ml of fresh medium 
was combined with a fraction of the trypsin-DMEM cell suspension such that the surface 
of a T75 flask was entirely covered. This fraction determined by cell counting with a 
haemocytometer. The cells were returned to an incubator with a humidified atmosphere 
consisting of 5% carbon dioxide (CO2) at a constant temperature of 37 °C. Routine 
maintenance of cells involved passaging for up to 20-30 passages, after which the cells 
were discarded and cells with a lower-passage number were retrieved from the liquid 
nitrogen storage. 
Cryopreservation of mammalian cells was carried out in liquid phase nitrogen. Cells grown 
to 80% confluency in T75 flasks were washed with PBS, trypsinised and centrifuged for 6 
min at 600g. Following resuspension in 0.5 ml DMEM/10% (v/v) FCS without antibiotics, 
cells were transferred to a cryogenic vial and 0.5 ml of pre-chilled DMSO-containing 
freezing medium (DMEM/10% (v/v) FCS/20% (v/v) DMSO) was added. Tubes were gently 
inverted several times and kept in a Nalgene® Mr. Frosty™ Cryo 1 °C freezing container 
overnight at – 80 °C. The next day the tubes were placed in a designated area within the 
liquid nitrogen container. 
In order to retrieve cells from liquid nitrogen, cells were warmed up in a water bath at 
37 °C, transferred immediately to 10 ml pre-warmed medium, centrifuged for 6 min at 
600g to remove DMSO, and transferred to a T75 flask. This way cells quickly reached 
confluency, so that passaging was required the next day. It was only after the second 
passage that functional assays were performed. 
4.2.4.2. Generation of stable cell lines 
To create stable COS-7/M6 cell lines, the following steps were undertaken. WT cells were 
grown in 6-cm dishes to 50% confluency. To determine the concentration of antibiotics for 
selection of clones, DMEM was supplemented with either zeocin, geneticin or both at a 
final concentration of 0, 100, 250, 500, 750 and 1000 μg/ml. For single antibiotics 500 
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μg/ml and for a combination of the two 250 μg/ml of each were eventually chosen as the 
lowest and yet 100% cytotoxic concentrations. 
For transfection, WT COS-7/M6 were seeded at 50% confluency on 6-cm dishes. 
Lipofectamine 2000 (6.25 μl) and Opti-MEM (500 μl) were combined and incubated at 
room temperature for 5 min. Next 2 μg of BglII-linearised plasmid DNA was mixed with 
Opti-MEM (500 μl), added to the Lipofectamine-Opti-MEM mixture and incubated for 
15 min at room temperature. The culture medium was aspirated and replaced by the new 
Lipofectamine-DNA-Opti-MEM-containing medium. After 6 h, the medium was replaced 
by FCS-free DMEM. After 2 days, cells were grown in new medium with FCS, and 
zeocin/geneticin were introduced to begin selection. The targeted linearisation step prior 
to transfection ensured that a full-length coding sequence was introduced into the 
genome of COS-7/M6 cells. 
4.2.4.3. Cell lysis 
To isolate cytoplasmic proteins, cells were grown to 80% confluency, washed with pre-
warmed PBS, and lysed in a standard lysis buffer containing 1% (v/v) IGEPAL® CA-630, 
150 mM NaCl, 50 mM Tris-HCl pH 8.0, protease inhibitor cocktail (1:100), and 1 mM PMSF. 
After centrifugation at 13,000g for 10 min at 4 °C, the supernatant was carefully removed 
and protein concentration determined. 
4.2.4.4. Wound healing (scratch) assay in multi-well plates and μ-Slides: phase-contrast 
microscopy 
Wound healing assays were performed as described previously (Liang et al., 2007). The 
desired tissue culture vessels were coated with collagen type I (stock: 0.1% w/v in 0.1 M 
acetic acid, sterilised in chloroform according to manufacturer’s instructions) at 8 μg/cm2 
for several hours at 37 °C. 
The cells were seeded at 100% confluency in either (a) 1-cm2 μ-Slides or (b) multi-well 
plates. A gap was created in the monolayer with a p10 (μ-Slide) or p200 (multi-well plate) 
pipette tip. 
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Serving as a positive control, epidermal growth factor (EGF) was supplied as a 100 μg/ml 
stock in water (Sigma). 
The establishment of a wound healing assay in a μ-Slide was challenging due to its small 
size and a high risk of cell detachment, but eventually a seeding density of 50,000 cells per 
well in a total volume of 300 μl with collagen type I coating were chosen as most optimal 
conditions. Because these experiments yielded ambiguous results, wound healing assays 
were next performed in multi-well plates based on the same set of principles established 
for wound healing in μ-Slides. Cells were cultured in DMEM/10% (v/v) FCS. When being 
90%-100% confluent, cells were trypsinised, centrifuged, resuspended in DMEM/1% (v/v) 
FCS and seeded so as to reach confluency within 6 h in a well of a 24-well plate. Following 
a wound with a p200 pipette tip, cells were allowed to migrate for 1-2 days. Images were 
acquired manually under a phase-contrast microscope (at a 4X magnification) 3, 6, 9, 24 
and 48 h post wounding. Surface area was measured with ImageJ (version 1.49i, US 
National Institutes of Health, Bethesda, MD, USA, http://imagej.nih.gov/ij/, 1997-2014). 
For data analysis, only cell velocity was reported. 
4.2.4.5. Chemokinesis (random single-cell motility) assay in μ-Slides: phase-contrast 
microscopy 
Chemokinesis (random single-cell motility) assays allowed for single-cell tracking. Cells 
were seeded at 20% confluency (13,000 cells/well/cm2) and allowed to adhere for 6 h in 
order to measure cell velocity (calculated as velocity = accumulated distance/time) 
(μm/min). 
To set up a time-lapse chemokinesis experiment with COS-7/M6 cells at the Nikon Eclipse 
Ti microscope, the live-cell imaging chamber was mounted onto the motorised stage. To 
maintain a humidified atmosphere, water was poured into the outer basin of the chamber 
and maintained at 37 °C. The NIS-Elements software was initiated and 10 fields of view 
per one treatment were chosen under the 20X objective (200X final magnification; 1 px = 
0.46 μm). A μ-Slide was carefully mounted in the chamber and data was acquired for at 
least 3.5 h with 30-min intervals. Following acquisition, data were saved as an “.nd” file, 
and each image stack (i.e. video) was then exported in the NIS-Elements software as an 
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“.avi” file. Using the Manual Tracking plug-in of ImageJ, approx. 100 cells were selected 
and their trajectories were tracked and saved. Using the Chemotaxis Tool plug-in, the 
velocity was calculated based on cell trajectories. 
For chemokinesis assays, a boxplot representing all measured velocities was shown. 
Boxplots were composed of: (a) a box extending from the 25th to 75th percentile (i.e. half 
of all data points); (b) a line in the middle of the box representing the median and a plus 
sign representing the mean; (c) whiskers encompassing the 10th-90th percentiles (i.e. 80% 
of all data points); and (d) outliers depicted as individual dots (i.e. 10% of all data points 
form the 0th-10th percentile and 10% of all data points from the 90th-100th percentile). 
In the case of individual data points, the mean ± interquartile range (25%-75% percentiles) 
was shown. 
In total, approx. 100 cells were chosen per condition (one well in one μ-Slide). Final figures 
represent therefore approx. 300 cells from three unique wells in three separate μ-Slides, 
each representing a different cell passage (n = 3). A similar approach was employed 
elsewhere (Kuriyama et al., 2014). 
Following data analysis from all the experiments, figures were generated and statistical 
analyses were performed in GraphPad Prism (version 5.04 for Windows, GraphPad Prism 
software, San Diego, CA, USA, www.graphpad.com). 
4.2.4.6. siRNA-mediated knockdown of endogenous MIF in COS-7/M6 cells 
Dharmacon (GE Healthcare) offers a SMART pool composed of four human MIF-specific 
siRNAs (L-HUMAN-XX-0005) that have been selected by a proprietary SMART–selection™ 
design algorithm and guarantees high efficiency silencing. However, the knockdown was 
performed in COS-7/M6 cells that had been derived from the African green monkey 
(Chlorocebus) which is closely related to man (Gluzman, 1981). 
The MIF protein sequences from both species are identical, and both mRNAs differ in only 
eight nucleotides within the open reading frame. Dharmacon confidentially provided the 
human siRNA nucleotide sequences so that they could be tested for identity with the 
Chlorocebus sequence. Based on this comparison two sequences from the human MIF 
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SMART pool were selected for knockdown of the Chlorocebus MIF mRNA (Table 13). The 
specificity of these siRNAs was enhanced by a patented modification pattern to reduce 
off-target effects called ON-TARGET plus. 
In the past control siRNAs with a scrambled, i.e. randomly shuffled, sequence of the gene-
specific siRNA had been routinely used for identifying potential off-target effects. 
Although it has been pointed out that scrambled siRNAs are not optimal controls, a 
validated alternative was introduced only in 2012 (Buehler et al., 2012). They introduced 
the C911 controls that eliminate on-target effects while retaining the same off-target 
effects of the gene-specific siRNA by maintaining its guide and passenger strand seed 
sequences (bases 2-8 and bases 12-17 respectively). C911 controls have the same 
sequence as the gene-specific siRNA except that bases 9 through 11 are the complement 
of the original siRNA (Table 13). Therefore C911 controls allow effective experimental 
discrimination between true and false positive knockdown effects (Chung et al., 2014). 
Both siRNA preparation and siRNA-mediated knockdown were carried out according to 
the manufacturer’s instructions. Briefly, 10 nmol of each lyophilised siRNA (Table 13) were 
resuspended in 0.5 ml to a final concentration of 20 μM in 1X resuspension buffer (60 mM 
KCl, 6 mM HEPES pH 7.5, 0.2 mM MgCl2) diluted from a 5X stock (Dharmacon) 
resuspension buffer using RNase-free DEPC-treated water. siRNAs were further diluted 1:4 
in 1X resuspension buffer before setting up the transfection reactions (final concentration 
5 μM). The day before transfection, COS-7/M6 cells were seeded in four wells of a 6-well 
plate at 50,000 cells/well: 
 Well no. 1: non-treated cells. 
 Well no. 2: cells transfected with MIF siRNA #1 + #2. 
 Well no. 3: cells transfected with MIF siRNA C911 #1 + #2. 
 Well no. 4: mock-transfected cells (OptiMEM + Lipofectamine, no siRNA). 
The next day, medium was exchanged for the transfection medium that was set up in the 
following manner.  
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In one tube 2.5 μl of each siRNA #1 and #2 (5 μM, either specific or C911 control) were 
combined with 15 μl of 1X resuspension buffer and 180 μl OptiMEM to a final volume of 
200 μl. For the mock transfection, 200 μl OptiMEM were used. Overall there were three 
individual microcentrifuge tubes at this stage, one for experimental siRNA, one for the 
C911 control, and the last one for the mock reaction. 
In a separate tube 4 μl Lipofectamine 2000 were combined with 196 μl OptiMEM to a final 
volume of 200 μl per individual transfection. This reaction was assembled in one 
microcentrifuge tube and was scaled up according to the total number of reactions 
intended. 
After a 5-min incubation at room temperature, 200 µl of diluted Lipofectamine were 
added to the tube containing the siRNAs, and incubated for additional 20 min at room 
temperature. Complete medium (1.6 ml, DMEM/10% (v/v) FCS) was added at last to each 
transfection reaction yielding a total volume of 2 ml (final concentration of both siRNAs 
together 12.5 nM). 
Cell culture medium in a well was exchanged for the transfection medium for 6 h. 
Subsequently the transfection medium was aspirated, and replaced by DMEM/10% (v/v) 
FCS cell culture medium without washing. 
In test experiments to establish transfection conditions, after 3 days cells were lysed and 
cytoplasmic proteins were extracted to perform an immunoblot against MIF (section 
4.2.1.6). 
On the morning of a live-cell imaging experiment (66 h after transfection), cells were 
trypsinised, counted, seeded in μ-Slides (section 4.2.4.5), and incubated for another 6 h. 
As one μ-Slide has eight wells, each cell line (i.e. WT and CD44+/CD74+ COS-7/M6) was 
assayed individually on a single μ-Slide in the following manner. Commencing with four 
transfection conditions in four wells of each 6-well plate – (a) non-siRNA-treated, (b) MIF 
siRNA #1 + #2, (c) MIF siRNA C911 #1 + #2, and (d) mock-transfected – cells were seeded 
in such a way that two wells in an 8-well μ-Slide contained cells from (a), two from (b), 
two from (c), and finally two from (d). This allowed for a simultaneous comparison of cell 
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motility under non-MIF and MIF-stimulated conditions. To that end three days (72 h) after 
transfection, medium was exchanged for medium containing 0.5% (v/v) FCS with or 
without MIF, and time-lapse data acquisition followed as described before (section 
4.2.4.5). 
4.2.4.7. Actin staining with phalloidin: static distribution of actin 
WT COS-7/M6 cells were seeded at 20,000 cells/cm2 on round coverslips in a 12-well 
plate, allowed to adhere overnight, and treated with the compounds of interest. All the 
subsequent steps were performed at room temperature. The cells were fixed with 4% 
paraformaldehyde in PBS for 10 min, washed twice with PBS, permeabilised with 0.1% 
(v/v) Triton™ X-100 in PBS for 3-5 min, washed again twice in PBS, blocked with 1% (w/v) 
BSA for 30 min, and stained with Texas Red®-X-conjugated phalloidin (1:500 in PBS/1% 
(w/v) BSA) in the dark for 30 min. Following washing, the coverslips were removed from 
the 12-well plate, air-dried, overlaid with 4’,6-diamidino-2-phenylindole (DAPI)-containing 
mounting medium, placed on a glass slide sample side-down, and dried overnight in the 
dark. This procedure is based on the ‘Actin Staining Protocol’ provided by the 
manufacturer of Texas Red®-X phalloidin (Invitrogen). 
To visualise and document Texas Red®-X-conjugated phalloidin-stained actin in COS-7/M6 
cells, the Axioplan 2 imaging microscope with AxioVisio 4.8.2 SP2 software were used. 
First the microscope and then the mercury light source were initiated. A glass slide with 
coverslips was mounted onto the microscope stage. Each coverslip was brushed with 
mineral oil and the 63X objective was initiated (630X final magnification). To take an 
overlay photograph of the nucleus and actin, two channels were activated within the 
Mehrdimensionale Bildaufnahme (multidimensional acquisition) panel: “3” for DAPI and 
“6” for Texas Red®-X. The illumination time was approx. 70-100 ms for the latter and 100-
300 ms for the former. Images were saved as a TIFF file (1300 px x 1030 px/138,84 μm x 
110 μm). The excitation/emission wavelengths of 596 nm/615 nm (for Texas Red®-X 
phalloidin) and 358 nm/461 nm (for DAPI) were used. For data analysis, ImageJ was used 
to enhance the contrast in order to better visualise all cytoplasmic actin structures. The 
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cells were categorised based on the unique characteristics of their actin cytoskeleton. 
More than 100 cells were quantified for each MIF and boiled MIF samples. 
4.2.5. Cell-free assays/Spectrophotometric assays 
4.2.5.1. Tautomerase activity assay 
The tautomerase activity of recombinant and endogenous MIF was determined using L-
dopachrome methyl ester as substrate in a spectrophotometric assay in a 
spectrophotometer (Filip et al, 2009). 
Freshly-made 200 µl solution of 4 mM L-3,4-dihydroxyphenylalanine methyl ester was 
combined with 200 µl freshly-made solution of 8 mM sodium periodate and incubated for 
3 min at room temperature in a microcentrifuge tube protected from light. Next, the 
substrate solution was combined with either 400 µl PBS to determine the background 
substrate decay or with 1 µM MIF or D-DT in 400 µl PBS to determine intrinsic MIF/D-DT 
tautomerase activities. 
The SWIFT II programme was initiated to measure the kinetics of each reaction. The 
settings were adjusted in Open View > Parameters. To monitor the reaction kinetics at 475 
nm, the options were adjusted to: (a) time units: mm:ss or sec; (b) duration: 10 min; (c) 
period: 0:00:02 (i.e. 2 sec); (d) number of assays: 1; (e) serial mode; (f) wavelength: 
475.0 nm. Next, Run > Method was selected. After a short calibration step, two windows 
appeared: one (‘load cell changer’) with a list of all available cuvette positions (‘cell 1 to 
cell 8’) and another one with the real-time values of the absorbance, slope (A/min), 
duration, next reading, and sample name. Before commencing the measurement with OK, 
an empty cuvette filled with air was inserted in the Ultrospec 2011 pro UV/visible 
spectrophotometer in position 1 (or cell 1). When the 3-min incubation was over, the 
substrate (400 µl) was transferred from the microcentrifuge tube to the cuvette, and a 
plastic inoculating loop was placed into the cuvette. The remaining 400 µl PBS with or 
without protein was transferred to the cuvette and mixed as quickly as possible. The loop 
was taken out of the cuvette and the lid of the spectrophotometer was closed. As soon as 
possible, OK was pressed to begin measurement. The data were saved by exporting to an 
Excel file via File > Export. 
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4.2.5.2. Pyrene-actin assembly assay 
Human embryonic kidney 293 (HEK293) cells were washed twice with ice-cold PBS and 
harvested in a lysis buffer (section 4.2.4.3) in the minimal possible volume (approx. 600 μl 
per T75, with several used at a given time) in order to maximise the end protein 
concentration. After 15 min on ice in a microcentrifuge tube, the lysates were centrifuged 
at 13,000g at 4 °C for 20 min, and immediately dialysed against XB buffer (10 mM HEPES 
pH 7.7, 100 mM KCl, 2 mM MgCl2, 0.1 mM CaCl2, 5 mM EGTA, 1 mM DTT) at 4 °C (two 
buffer exchanges during the day, then the third buffer exchange for an overnight dialysis). 
Combined always in the following order, the final reaction volume of 100 μl consisted of: 
(1) XB buffer, up to 100 μl (see composition above); (2) 10 μl energy regenerating mix (150 
mM creatine phosphate, 20 mM ATP, 2 mM EGTA, 20 mM MgCl2); (3) 700 μg total HEK293 
cell extract as source of the ARP2/3 (63 μl when a stock of 11 mg/ml HEK293 extract was 
used); (4) 10 μg (2.6 μM) GST-VCA to activate the ARP2/3 complex (10 μl when a stock of 1 
mg/ml GST-VCA was used); (5) 1 μM MIF/D-DT or the same volume of the corresponding 
buffer (MIF or buffer P – 3.1 μl; D-DT or 20 mM sodium phosphate buffer pH 7.0 – 7.4 μl); 
and (6) 10 μl pyrene-labelled G-actin (final concentration 2 μM, 10% labelled). 
Immediately after the addition of pyrene-actin the reaction was mixed by pipetting up and 
down, and transferred into a black-walled quartz cuvette. Pyrene-actin fluorescence was 
measured at 10-second intervals for 10 minutes at 407 nm with excitation at 365 nm using 
a RF-5301PC spectrofluorophotometer (Shimadzu, Kyoto, Japan). Data were saved using 
the Panorama Fluorescence (version 2.1.16.0) software (Shimadzu, Kyoto, 
Japan/LabCognition Analytical Software, Cologne) and exported as a text file. To 
normalise, fluorescence at time zero (the first out of 60 measurements is defined as ‘10 
sec’ and the last one is defined as ‘600 sec’) was set to zero by subtracting the initial value 
(in arbitrary units) from all measurements.  
The rate of actin assembly was calculated by determining the slope of each curve at 50% 
polymerisation using the linear regression-based function =slope() in Excel 2010 
(Microsoft Corporation, Redmond, WA, USA). The slope was measured for all data points 
within the log phase by performing a linear regression on seven data points – three data 
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points below and three data points above the point of interest. The maximal value was 
regarded as the slope at 50% polymerisation. 
4.2.6. Statistical analysis 
R (R Project, Vienna, Austria) and GraphPad Prism version 5.04 for Windows, GraphPad 
Prism software (San Diego, CA, USA, www.graphpad.com) were used to: (a) assess 
normality of data by generating q-q plots; and (b) calculate statistical significance using 
the following tests: Student’s t-test for two samples of normal distribution (for 
experiments where triplicates were performed); Mann-Whitney U-test for two samples of 
non-normal distribution (for experiments where triplicates were performed); and Kruskal-
Wallis one-way ANOVA with Dunn’s multiple comparison test as a post test (significance 
level set to α = 0.05) for a group of more than 3 samples with non-Gaussian distribution 
(i.e. non-parametric) (for chemokinesis experiments). 
4.2.6.1. Assessment of normality of chemokinesis data 
To determine if chemokinesis datasets came from a Gaussian (normal) distribution, q-q 
plots were generated in R. Data input in R was performed using the concatenate option: 
(FCS10 <- c( 0.51, 0.09, 0.08, 0.09)) 
where FCS10 was the name of a dataset corresponding to 10% (v/v) FCS-containing 
control, <-c was the concatenate function, and the numerical values (0.51 and so forth) 
were velocities in μm/min). 
Normal q-q plots with reference lines were generated using the qqnorm and qqline 
functions (below). In a typical q-q plot, sample quantiles fall on the Y axis and theoretical 
quantiles fall on the X axis. If the reference line (below) crosses all or almost all data 
points, the data are considered to be normally distributed. If this is the case it would be 
justified to use statistical tests which assume normality in order to calculate statistical 
significance. Otherwise, if a q-q plot does not reveal normality, it indicates that data do 
not originate from an ideal Gaussian distribution. In such a case tests which do not assume 
normality would rather be employed. 
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Often present in motility assays, outlier points skew the distribution and thus the overall 
dataset is not of a Gaussian distribution. As shown by the q-q plot analysis (below), none 
of the chemokinesis datasets were normally distributed. Therefore a Kruskal-Wallis 
ANOVA was used to determine statistical significance. 
 
 
4.2.7. Genetic safety 
Documentation on genetically modified bacterial or mammalian cells – i.e. date of 
generation, storage location, and date of disposal by autoclaving – was maintained 
according to university regulations. Sterilisation of material derived from or contaminated 
with transformed bacteria or transfected mammalian cells was performed by autoclaving 
(Betriebsanweisung UGI 67). 
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5. Results 
5.1. Bacterial expression and purification of recombinant MIF and D-DT 
To study MIF/D-DT in cell and cell-free assays, recombinant proteins were generated. 
Overexpression of human MIF and human D-DT (hD-DT) and mouse D-DT (mD-DT) was 
carried out in protease-deficient BL21 (DE3) E. coli. Bacteria were grown in 2YT medium 
overnight and a fraction of the overnight culture was used to inoculate a large-volume of 
2YT for the preparative small-scale protein production. The levels of overexpressed 
proteins were monitored on Coomassie-stained SDS-polyacrylamide gels (Figure 6). Before 
induction of protein expression, there was no appreciable band at 12.5 kDa indicative of 
human recombinant MIF (Figure 6A, lane 1 vs 4). Upon induction of protein expression at 
OD600 = 0.5 with 0.5 mM IPTG (Figure 6A, lane 2-4), cells were allowed to grow for 3 h and 
then lysed (Figure 6A, lane 3-5). 
Prior to the chromatographic purification, cell lysates were dialysed against PBS/1 mM 
DTT (Figure 6A, lane 6), and precipitated with 40% (Figure 6A, lane 7) and 60% ammonium 
sulphate (AS) (Figure 6A, lane 8-9; Figure 6B, lane 1). AS-precipitated proteins were first 
passed onto a size-exclusion column (Figure 6B, lane 2), and then anion and cation 
exchangers (Figure 6B, lane 3). While MIF was captured by these exchangers and then 
eluted in a high-salt gradient (Figure 6, lane 3), D-DTs were found in the flow-through of 
the exchangers (data not shown). The purity of the endotoxin-free proteins was 
monitored through a Coomassie-stained polyacrylamide gel (Figure 6B, lane 5; Figure 7). 
The identity of the protein sequences was determined by mass spectrometry (section 
4.2.3.5), and the yield was 7.5 mg total protein from 200 ml of E. coli culture, similar to the 
first MIF purification report (1 mg/50 ml of E. coli culture) (Bernhagen et al., 1994).  
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Figure 6. Purification of human MIF from bacteria. (A and B) Coomassie-stained polyacrylamide gels (top) 
with protein samples collected after each purification step (schematics below). Each fraction (a pellet 
resuspended in SDS loading dye, a supernatant, or a post-chromatography sample/pooled samples) is 
abbreviated as such for clarity. Sample in lane 9 in A is the same as in lane 2 in B. Recombinant hMIF served 
as a size control (A, lane 11; B, lane 8). (A) Plasmid DNA encoding hMIF was overexpressed in E. coli BL21 
(DE3) and protein expression was induced with IPTG (lane 2-3). Following cell lysis (lane 4-6), the lysate was 
dialysed against PBS/1 mM DTT (lane 7) and the proteins were precipitated with AS (lane 8-10). (B) 
Precipitated proteins were subjected to size-exclusion chromatography (lane 3) and anion- and cation-
exchange chromatography (lane 4) using an FPLC/HPLC system. Endotoxin was removed by passing the 
purified protein over columns with immobilised polymyxin B which has affinity towards endotoxin (lane 5-7). 
Abbreviations: AS, ammonium sulfate; DTT, dithiothreitol; FPLC/HPLC, fast protein/high-performance liquid 
chromatography; IPTG, isopropyl-β-D-thiogalactopyranoside. 
 
 
Figure 7. Analysis of purified recombinant MIF and D-DTs. Purified proteins (MIF, 12. 5kDa; mD-DT, 13.1 
kDa; and hD-DT, 12.7 kDa) were resolved on a 15% polyacrylamide gel and stained with Coomassie.   
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5.2. MIF but not D-DTs has a high tautomerase activity  
MIF and D-DT catalyse the tautomerisation of non-naturally occurring L-dopachrome 
(Rosengren et al., 1996; Filip et al., 2009). While a genuine, endogenous substrate for 
MIF/D-DT in metazoans is yet to be identified, the inhibition of MIF’s tautomerase activity 
has been shown to be therapeutically beneficial in murine models of sepsis (Al-Abed et al., 
2005) and human cell-culture models of gallbladder cancer invasion (Subbannayya et al., 
2015). Hence tautomerase assays were employed to verify whether recombinant MIF/D-
DT used in cell-culture experiments were biologically active. A robust enzymatic activity of 
MIF/D-DT in solution would suggest they are properly folded. 
To verify that MIF remains stable and active in cell-culture medium, and to exclude the 
possibility that an FCS- or cell-derived component binds and inactivates it, WT COS-7/M6 
cells were seeded in multi-well plates in DMEM supplemented with 10 nM, 100 nM, and 
1 μM MIF, with or without MIF’s tautomerase inhibitors (S,R)-3-(4-hydroxyphenyl)-4,5-
dihydro-5-isoxazole acetic acid (ISO-1) and 4-iodo-6-phenylpyrimidine (4-IPP) and their 
solvent, DMSO. The next day, 1 ml of MIF-containing supernatant was used in a 
tautomerase activity assay in which L-dopachrome methyl ester is tautomerised into 5,6-
dihydroxy-1-H-indole-2-carboxylic acid methyl ester over the course of 600 sec at room 
temperature. Noteworthily, the tautomerase activity of MIF-containing supernatants may 
be lower than if MIF was dissolved in DMEM/10% (v/v) FCS only, due to the fact that some 
MIF molecules might have been endocytosed by the cells or stay immobilised on their 
surface. 
The substrate and the MIF-containing supernatant were mixed in a cuvette placed directly 
within the spectrophotometer. The reaction started immediately and a kinetics recording 
was initiated as soon as the lid of the spectrophotometer was closed (Figure 8). 
  
Results 
69 
 
A       B 
 
C       D 
 
Figure 8. MIF but not D-DT tautomerises L-dopachrome methyl ester in a dose-dependent manner. 
Original kinetics traces of absorbance are shown over the course of (C) 600 sec (full-time experiment), (A-B) 
300 sec and (D) 180 sec (shorter scale for better data visualisation). (A-B) Supernatants of COS-7/M6 cells 
were supplemented with increasing concentrations of MIF. The next day, 1 ml of supernatant was used for a 
spectrophotometric measurement of absorbance at 475 nm. MIF tautomerised L-dopachrome methyl ester 
into 5,6-dihydroxy-1-H-indole-2-carboxylic acid methyl ester. The graphs represent one (single) replicate (in 
order to avoid the use of too much recombinant protein in cell culture medium). (A) MIF tautomerises L-
dopachrome methyl ester in a dose-dependent manner. (B) The tautomerisation reaction is sensitive to the 
inhibition of MIF’s tautomerase activity by ISO-1 and 4-IPP. (C) Recombinant MIF, mD-DT and hD-DT were 
assayed for their tautomerase activity. The graph represents triplicate values of absorbance ± standard 
deviation. (D) Two samples of MIF, one stored at 4 °C and the other at – 80 °C, were assayed side-by-side for 
their tautomerase activity. The graph represents duplicate values of absorbance ± standard deviation. 
Abbreviations: 4-IPP, 4-iodo-6-phenylpyrimidine; ISO-1, (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole 
acetic acid.  
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Within the initial few seconds, 1 μM MIF tautomerised 50% of the substrate (Figure 8A). 
Moreover, 100 nM and 10 nM MIF tautomerise 50% of the substrate within 100 sec and 
250 sec, respectively (based on raw absorbance data) (Figure 8A). While DMSO (solvent 
for ISO-1 and 4-IPP) did not affect the reaction, a combination of 50 μM ISO-1 and 50 μM 
4-IPP abrogated the MIF-mediated tautomerase activity (Figure 8B). 
Recombinant mD-DT exhibited a modest tautomerase activity since it tautomerised only 
50% of the substrate at the end of the 600-sec experiment (Figure 8C). On the other hand, 
hD-DT had no measurable tautomerase activity (Figure 8C). 
To complement results obtained with MIF incubated in cell-culture medium for 24 h 
(Figure 8A), purified MIF – stored either at 4 °C for a few months or directly retrieved from 
storage at – 80 °C – was used in PBS in the same tautomerase assay. One μM and 100 nM 
MIF tautomerised 50% of the substrate in a few seconds and approx. 40 sec, respectively 
(Figure 8D). Importantly, freezing did not negatively affect MIF’s tautomerase activity. On 
the contrary, the tautomerase activity of the frozen protein was slightly higher (Figure 
8D). For the following experiments (sections 5.3-5.4) MIF was stored at 4 °C. 
Taken together, MIF is a stable protein as it exhibits its tautomerase activity in an ISO-1/4-
IPP-sensitive manner both in cell-culture medium and in PBS, virtually irrespective of 
storage conditions. mD-DT has a modest whereas hD-DT has no tautomerase activity 
towards L-dopachrome methyl ester. In the subsequent experiments on cell migration, 
biologically active MIF was used for 3.5 h in DMEM since no detrimental effect on its 
activity could be expected. 
5.3. The role of MIF receptors in cell motility 
5.3.1. Generation of stable COS-7/M6 cell lines expressing CD44 and CD74 
To address the questions if (a) MIF receptors are required for MIF-mediated motility and if 
(b) endocytosis of MIF mediates this effect, MIF receptor-negative WT COS-7/M6 cells (Shi 
et al., 2006) were chosen to generate stable cell lines expressing the receptors. WT COS-7 
cells are parental to WT COS-7/M6 cells but express CD44 i.e. they are CD44+/CD74– (Shi 
et al., 2006). WT COS-7/M6 cells do not express CD44/CD74 as shown in this thesis and 
elsewhere (Shi et al., 2006). 
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The pTracer-CD44, pTracer-CD44Δ67, and pcDNA-CD74 receptor-expression constructs also 
contained antibiotic-resistance genes – zeocin, zeocin, and geneticin, respectively. 
Moreover, CD74 protein was fused to a V5 epitope and His-tag. CD44 and CD44Δ67 were 
not tagged but the zeocin-resistance gene within the backbone of each plasmid was fused 
with enhanced green fluorescence protein (EGFP) (section 4.1: Table 12 and maps). 
Cells were seeded on 6-cm dishes, transfected with BglII-linearised pTracer or pcDNA 
constructs, and allowed to grow for a few weeks with decreasing antibiotic 
concentrations. Well-defined foci (5-6) were picked with trypsin-soaked paper filter disks 
and allowed to grow further in 6-well plates. The levels of CD44 and CD74 gene expression 
and protein production were assessed by PCR (Figure 9) and immunoblotting (Figure 10), 
respectively. 
Using PCR primers (Table 11) amplifying non-tagged CD74 mRNA, CD74 mRNA was 
detected in one CD74+, CD44+/CD74+ and CD44Δ67+/CD74+ clone, respectively, and in 
RAW264.7 macrophages (positive control) (Figure 9A). mRNA fragment specifically 
encoding V5 and His-tag was detected in two out of three CD74+ foci and in both 
CD44+/CD74+ and CD44Δ67+/CD74+ clones but not in the other ones (Figure 9B). While the 
presence of the V5 epitope and His-tag mRNA was useful in a PCR validation of CD74+ 
clones, the tags were not used in later experiments. Primers amplifying the V5 epitope 
and His-tag mRNA of CD74 show four positive clones (Figure 9B) but when compared to 
the non-tagged regions of CD74 amplicons, CD74+ F1 has a lower CD74 expression, 
reflecting differential primer efficiency. CD44 mRNA was detected in all CD44+ stable lines 
and in HeLa cells (positive control) (Figure 9C-D). Lowly-expressed CD44 mRNA was also 
found in parental, CD44-negative cells (Figure 9C-D). β-actin mRNA was detected in all 
mRNA preparations (loading control) (Figure 9E).  
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Figure 9. PCR analyses of stable COS-7/M6 cell lines expressing MIF receptors. RNA from indicated cells 
was isolated, reverse-transcribed, and specific gene fragments were amplified. Specific mRNA regions were 
amplified under conditions described in Materials and Methods with cognate primers, and resolved on 1.2% 
agarose gels. DNA was stained with ethidium bromide. (A-D) HeLa mRNA was used as a positive control for 
CD44 and RAW264.7 mRNA for CD74. (A) A 99-bp amplicon of exon 5 and 6 of the non-tagged CD74 mRNA. 
(B) A 194-bp non-intron-spanning amplicon of V5- and His-tag-encoding CD74 mRNA. (C) A 146-bp amplicon 
between exon 5 and 6 of the CD44 mRNA (encoding all variable v1-v10 splice variants). (D) An inversed and 
contrast-enhanced gel image of (C) is shown to better visualise low-intensity endogenous CD44 mRNA 
bands. (E) A 232-bp amplicon of β-actin mRNA.  
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CD74 was found in one out of three CD74+ foci and in both CD44+/CD74+ and 
CD44Δ67+/CD74+ clones (Figure 10B). β-actin was used as loading control (Figure 10C). 
Multiple antibodies were tested in CD44 immunoblots: (a) monoclonal antibody 23-32 
(Margot Zöller); (b) Hermes-1 (Margot Zöller); (c) Hermes-3 (Margot Zöller), and (d) Santa 
Cruz sc-7297 (Shi et al., 2006). Only Hermes-3 recognised CD44 (Figure 10A). CD44 protein 
was found in all CD44+ lines. Faint, non-specific CD44 protein bands were also detected in 
CD44-negative cells upon closer inspection of the blots (Figure 10A). As CD44Δ67+ has a 
lower molecular weight than full-length CD44, a corresponding shift in size was observed 
for the single-transfectant (Figure 10A, lane CD44Δ67+) but not the double-transfectant 
(Figure 10A, lane CD44Δ67+/CD74+), possibly due to differential protein processing. 
 
 
Figure 10. Immunoblot analysis of stable COS-7/M6 cell lines expressing MIF receptors. Protein lysates 
were resolved on two polyacrylamide gels, and transferred onto nitrocellulose membranes. The membranes 
were probed with antibodies against (A) CD44 (full-length as well as truncated CD44
Δ67
) (Hermes-3), (B) 
CD74 (FL-296), and (C) β-actin, then washed, and probed with HRP-conjugated secondary antibodies. After 
washing, the HRP signal was detected using ECL. HeLa and RAW264.7 whole protein extracts were used as 
positive controls for CD44 and CD74, respectively. COS-7 is COS-7/M6’s parental cell line. Insert in A depicts 
the chemiluminescence signal with increased contrast to better visualise low levels of CD44. 
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To summarise, Table 17 lists all generated cell lines and the patterns of CD44 and CD74 
gene and protein expression. 
Table 17. Levels of mRNA expression and protein production in WT and stable COS-7/M6 
cells. 
COS-7/M6 cell 
line 
CD44 CD74 
mRNA Protein mRNA Protein 
WT –/+ –/+ – – 
CD44+ F0 +++ + – – 
CD44+ F1 +++ – – – 
CD44+ F2 +++ – – – 
CD44+ F3 +++ ++ – – 
CD44Δ67+ –/+ + – – 
CD74+ F0 –/+ – ++ – 
CD74+ F1 –/+ – + ++ 
CD74+ F2 –/+ – – – 
CD44+/CD74+ +++ + +++ + 
CD44 Δ67+/CD74+ +++ + +++ +++ 
Abbreviations and signs: F, focus; – lack of mRNA/protein; –/+ background; +, ++ and +++ slight to strong 
mRNA/protein.  
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The pTracer construct encoding CD44 protein contained EGFP protein-coding DNA fused 
to the zeocin-resistance DNA (section 4.1: Table 12 and maps). Because EGFP was not 
fused to the insert (CD44), the EGFP signal marks the stability of transfection and not the 
cellular localisation of CD44 (Figure 11). The levels of EGFP were visualised by fluorescence 
microscopy in WT and CD44+/CD74+ COS-7/M6 cells. Whereas there was no measurable 
EGFP signal in WT cells (Figure 11C), almost every cell was EGFP-positive in CD44+/CD74+ 
COS-7/M6 cells (Figure 11D). For the duration of image acquisition, the phenol red-
containing DMEM was exchanged for PBS to avoid phenol red-derived autofluorescence. 
 
 
Figure 11. EGFP levels in WT and CD44
+
/CD74
+
 COS-7/M6 cells visualised by fluorescence microscopy. (A 
and C) WT and (B and D) CD44
+
/CD74
+
 COS-7/M6 cells were seeded in tissue-culture flasks and grown to 
50% confluency. Medium was exchanged for PBS to avoid autofluorescence, and the cells were observed 
under phase-contrast (A and B) and with the EGFP channel (C and D) for 50 sec. The bar is 100 μm.  
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Considering that MIF triggers extracellular signal-regulated kinase 1/2 (ERK1/2) 
phosphorylation via CD74 and CD44/CD74, the functionality of the introduced receptors 
was evaluated. Therefore the levels of total as well as phosphorylated ERK1/2 were 
evaluated by immunoblotting with antibodies recognising (a) total ERK1/2 (Figure 12B, D, 
F) and (b) Thr-202/Tyr-204- and Thr-185/Tyr-187phosphorylated ERK1/2 (Figure 12A, C, E) 
in MIF-treated cell lysates. MIF upregulated ERK1/2 phosphorylation in MIF receptor-
positive CD74+ COS-7/M6 and CD44+/CD74+ COS-7/M6 cells after a 30-minute stimulation 
but not in MIF receptor-negative WT COS-7/M6 cells (Figure 12, MIF 30 min vs. boiled 
MIF). This result validates the observations from the original investigation on COS-7/M6 
cells (Shi et al., 2006). In sum, MIF stimulation enhances the ratio of phosphorylated-to-
total ERK1/2 when compared to heat-inactivated MIF treatment, showing the 
functionality of the receptors (CD74+ and CD44+/CD74+) (Figure 12G). 
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Figure 12. Analysis of MIF-mediated ERK1/2 phosphorylation in COS-7/M6 cells. Immunoblot analyses of 
(A, C, E) phosphorylated and (B, D, F) total ERK1/2 in lysates from MIF-treated WT, CD74
+
, and CD44
+
/CD74
+
 
COS-7/M6 cells. Proteins (15 μg) were resolved on one large-scale polyacrylamide gel and transferred onto a 
nitrocellulose membrane. The membrane was blocked in 5% BSA, probed with antibodies against 
phosphorylated ERK1/2, washed, and probed with HRP-conjugated secondary antibodies. After washing, the 
HRP signal was detected using ECL. The membrane was stripped (section 4.2.1.6) and re-probed against total 
ERK1/2. All ECL images were slightly contrast-enhanced using the FusionCapt Advance software to better 
visualise lowly-expressed protein bands. For clarity the ECL images were cropped to show ERK1/2 bands 
only. (G) Quantification of pERK1/2-to-totalERK1/2. Pixel values (area under peak in ImageJ) for each lower 
band were normalised towards NT (100%). Error bars are derived from duplicates (NT, MIF 10 min, MIF 30 
min).  
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5.3.2. Wound healing (scratch) assays are not suitable to study COS-7/M6 cell motility 
Wound healing (scratch) assays were initially chosen to address the role of MIF receptors 
in cell motility. In each assay, cells are seeded on a collagen-coated surface and allowed to 
attach such that they form a confluent monolayer. Cells are seeded in μ-Slides (ibidi), a 
microscopy-compatible chamber allowing to study cell behaviour under eight distinct 
conditions at a time. Next, a wound (scratch) is created with a pipette tip, and cell 
migration is monitored over time either in an automated time-lapse fashion (live-cell 
imaging in a humidified chamber) or by taking individual photographs (cells are manually 
taken out of the incubator, observed, and returned to the incubator) at a known position 
within the wound (section 4.2.4.4). 
First, experiments were performed on monolayers of cells seeded in 35-mm dishes. To 
measure the expected wound width and wound closure time, three different pipette tips 
were used to create a wound (width ± SEM; time to close): p10 (187 ± 32 μm; 2.9 h); p200 
(312 ± 38 μm; 15.3 h); and p1000 (430 ± 39 μm; only 90% closed overnight). Because a 
300-μm wide wound can be easily observed under a 200X magnification, and the 
acquisition time of 15-20 h (overnight) is best to identify differences between 
stimulations, the p200 tip was chosen as optimal to create a wound in a monolayer grown 
in a μ-Slide. 
However, within μ-Slides all pipette tips (p10, p200) removed many more cells than the 
width of the tip. Unlike in 35-mm dishes, the two cell fronts were not fully visible on μ-
Slides in the field of view (20X objective; 200X total magnification). Visibility of the two cell 
fronts was required to determine cell motility as well as wound closure (Figure 13 depicts 
a rare example of two cell fronts visible within one field of view). Taken together, the 
wound width could not be controlled in a reproducible manner. 
Furthermore, because of the confluency of the monolayers, the cells were frequently 
washed off at the edges of each well, causing stress to the remaining cells and leaving 
behind not enough cells for analysis. Cells which did remain attached to the well often 
rounded up – a phenomenon indicative of cell death upon stress. As data acquisition was 
limited to the duration of the overnight time-lapse experiment, it was challenging to 
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measure when the wound closed up entirely. Because the width of each wound always 
differed considerably, some gaps never closed. To be more precise, the two cell fronts 
more than 500-700 μm apart would never meet even after 2-3 days of observation 
whereas the two cell fronts 200-300 μm apart would close the gap in a few hours (Figure 
14C). 
As the two cell fronts approach one another, a cellular bridge would be formed between 
two fronts by some fast-moving cells (Figure 13) (Green et al., 2004). Only then the 
remaining cells would close up the wound. A similar phenomenon was observed with COS-
7/M6 cells, making it difficult to unambiguously measure cell velocity across the wound 
edge. 
Even though wound healing assays provide easy imaging and relatively simple analysis, the 
abovementioned challenges prevented proper data analysis. A major disadvantage was 
that collagen appeared to be removed mechanically from the surface once a wound was 
made. Sometimes only one cell front migrated to close the wound while the other would 
not, possibly due to the removal of the substrate. Overall, data analysis was considerably 
hindered by these problems. 
A             0 h   B             16 h 
 
Figure 13. The pattern of WT COS-7/M6 cell migration in wound healing (scratch) assays. Cells were 
seeded at 100% confluency (A) and imaged under a phase-contrast microscope for 16 h (B). Some cells did 
not migrate over the course of the experiment (white arrows, A vs. B) possibly because they were too 
confluent or undergoing cell death (B, round cells). Motile cells were tracked (dots in A representing the 
initial coordinates of unique cells) over time (trajectories in colour, B). However, the migration was often 
halted at a certain stage, possibly because of the removal of the substrate. 
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For these reasons, wound healing assays were next performed in multi-well plates over 
the course of 9 h. One advantage over μ-Slides was that the cells were no longer washed 
out, probably due to a larger surface area (9.62 cm2 vs. 1 cm2). Still the wound was never 
of the same width even when the lid of a multi-well plate was used as a ruler to help to 
move the tip across a monolayer of cells in a straight way. Because larger wounds failed to 
close up, a normalisation step to the narrowest wound was included in the final 
assessment of wound closure (Figure 14). Instead of calculating cell velocity, total wound 
surface area was measured in pixels and then converted to μm2 and normalised to the 
smallest wound. This normalisation step involved calculating the difference between the 
narrowest wound and all the other ones, and that difference was subtracted from all 
wound surface areas. The final data are reported as % of control (Figure 14A-B). 
Similar to experiments with μ-Slides, a great variability of wound widths was noted within 
multi-well plates even when using a single tip for all wounds. For example, four wounds 
created with a p10 tip had the following widths (in thousand pixels): 662; 864; 639; and 
754 such that the difference between the narrowest and widest wound was approx. 30%. 
As a result, cells encompassing a narrow gap closed it up in a matter of few hours whereas 
wide wounds did not close within 9 h (Figure 14C). Recombinant epidermal growth factor 
(EGF) and insulin-like growth factor (IGF)-I (100 ng/ml each, Figure 14) were tested as 
positive controls, but none of them consistently showed upregulation of cell motility. 
Recombinant MIF/D-DT (100 ng/ml) failed to alter cell motility regardless of MIF receptor 
status (Figure 14). The two graphs in Figure 14 represent one out of three replicates; each 
replicate greatly differed from one another in the response to the growth factors – once 
non-treated (NT) cells were the fastest in closing the wound in a matter of 6-9 h, another 
time NT cells were the slowest. 
Double-transfected CD44+/CD74+ COS-7/M6 cells were much slower than WT COS-/M6 
cells, possibly due to the fact that CD44 mediates strong cell-cell adhesion, particularly 
important during multi-cellular mode of migration (Figure 14A-B).  
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Figure 14. Analysis of COS-7/M6 wound healing in multi-well plates. (A) WT and (B) CD44
+
/CD74
+
 COS-
7/M6 cells were seeded at 100% confluency and allowed to adhere. Upon medium exchange from 10% to 
0.5% (v/v) FCS supplemented with indicated recombinant proteins, the first photograph was taken (time 0 
h). A photograph of the wound was taken at indicated times (0,3, 6, 9, and 24 h). Wound area was 
normalised to the narrowest wound due to the varying wound widths (C). Experiments were repeated three 
times for each cell line (n = 3). (C) An example of a 9-h time point (40X magnification): a narrow wound (left) 
closed entirely; an intermediate-size wound closed by half (middle); cells within a wide wound (right) did not 
migrate. The line across each photograph (left-right) was made with a scalpel on the bottom of each plate to 
be able to take the photograph always at the same position. 
 
Taken together, the wound healing assays were inconclusive. First, the positive controls – 
recombinant growth factors – failed to induce cell motility to an extent that has been 
published before (Knapek et al., 2010). Second, subsequent chemokinesis experiments 
showed that EGF is indeed a robust and reproducible inducer of fibroblast motility. Only 
C 
A B 
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one wound-healing result was reproducible: WT COS-7/M6 cells exhibited much faster 
migration than CD44+/CD74+ COS-7/M6 cells. 
5.3.3. COS-7/M6 chemokinesis (random single-cell motility) 
5.3.3.1. Chemokinesis assays are suitable to study motility of COS-7/M6 cells 
In search for a reproducible motility assay, chemokinesis (random single-cell motility) 
assays were tested. Briefly, cells were seeded at a low confluency in μ-Slides, allowed to 
attach for a few hours, and stimulated with recombinant MIF/D-DT/EGF with or without 
endocytosis inhibitors or MIF’s tautomerase inhibitors. Images were taken at 30-min 
intervals over 3.5 h and data of cell trajectories were expressed as velocities (section 
4.2.4.5). 
Preliminary chemokinesis experiments were performed in order to estimate the effects of 
recombinant proteins on fibroblast motility, and to verify the normality of velocity data, 
using a variety of cell lines: 
 WT COS-7 cells, 
 WT COS-7/M6 cells, 
 stable CD44+ COS-7/M6 cells, and 
 stable CD44+/CD74+ COS-7/M6 cells. 
Recombinant proteins were added in serum-reduced medium to diminish the amount of 
endogenous growth factors influencing motility. 
All above-mentioned cell lines significantly responded to 100 ng/ml EGF as a stimulator of 
motility. All but CD44+ COS-7/M6 cells were observed to respond to 100 ng/ml MIF. Ten 
percent (v/v) FCS was used (a) to examine cell morphology and (b) to estimate what 
maximal cell velocity can be expected under standard conditions. Under DMEM/10% (v/v) 
FCS, no abnormalities in cell morphology were found using phase-contrast microscopy, 
suggesting that the cells stayed healthy throughout the experiment. Furthermore, it was 
established that endocytosis and tautomerase inhibitors were to be used 1 h before the 
addition of the recombinant proteins instead of simultaneously with them (data not 
shown). 
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At the same time, the normality of chemokinesis data was assessed. The visual 
distribution of velocity data resembled a non-Gaussian distribution. This was further 
confirmed by q-q plots (R Project) (section 4.2.6.1). 
All chemokinesis experiments that follow were performed in triplicate such that cells from 
three subsequent passages were seeded in three distinct μ-Slides on different days. All 
data were analysed by Kruskal-Walllis one-way analysis of variance (ANOVA) with Dunn’s 
multiple comparison test as a post test (significance level set to α = 0.05). 
In these assays, recombinant proteins (EGF, MIF, MIF mutants, D-DT) and an array of 
pharmacological inhibitors (endocytosis and tautomerase activity inhibitors) were tested 
for their capacity to alter basal and MIF-induced cell migration (Figures 15-22). Following 
cell attachment, the medium was exchanged from DMEM/10% (v/v) FCS to DMEM/0.5% 
(v/v) FCS, and supplemented with recombinant proteins. In line with the preliminary 
experiments, pharmacological inhibitors of endocytosis and MIF’s tautomerase activity 
were added 1 h prior to the supplementation with recombinant proteins, and the cells 
were live-imaged for 3.5 h (section 4.2.4.5). 
5.3.3.2. MIF but not D-DT upregulates chemokinesis independent of CD44/CD74 
Previous experiments established to what extent MIF and EGF stimulate motility in a 
reproducible manner. Therefore recombinant MIF, D-DT, a combination of MIF and D-DT, 
and their heat-inactivated counterparts were used at 200 ng/ml in three independent 
experiments to verify how both members of the MIF family alter chemokinesis (Alampour-
Rajabi et al., 2015) (Figure 15). Such a side-by-side comparison of MIF/D-DT receptor-
negative and -positive COS-7/M6 cells allowed to address the question if MIF/D-DT 
receptors CD44/CD74 are required for MIF-mediated upregulation of fibroblast 
chemokinesis. 
The data distribution in Figure 15 is depicted as a boxplot (25th-75th percentile) with 
whiskers (10th-90th percentile), the arithmetic mean (a plus sign), and the median (a line 
in the middle of the box). Such a representation allows to appreciate the fact that some 
cells are virtually non-motile (outliers shown as dots below the boxplots within the 0.00-
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0.05 μm/min range) whereas another population is highly motile (outliers shown as dots 
above the boxplots, from 0.50 μm/min) (Figure 15). 
Recombinant EGF (200 ng/ml, same as MIF/D-DT) served as a bona fide stimulator of cell 
motility (Figure 15). In CD44+/CD74+ COS-7/M6 cells, MIF and EGF stimulated motility to 
the same extent (Figure 15B and Appendix 1), whereas in WT COS-7/M6 cells MIF 
stimulated motility to a lesser extent than EGF (Figure 15A and Appendix 1). 
MIF enhanced WT COS-7/M6 chemokinesis in a significant way (Figure 15A) when 
compared to the non-treated control as well as when compared to its heat-inactivated 
control (Figure 15A). The combination of MIF/D-DT upregulated motility of both cell lines 
as compared to the non-treated cells (Figure 15A-B); as compared to heat-inactivated 
MIF/D-DT, it was only significant in CD44+/CD74+ COS-7/M6 cells. 
While recombinant human MIF promoted COS-7/M6 cell motility independent of the MIF 
receptor status (Figure 15A), recombinant human D-DT promoted only CD44+/CD74+ COS-
7/M6 cell motility (Figure 15B). Heat-inactivated proteins (MIF, D-DT, and MIF/D-DT) did 
not induce motility in either cell line (Figure 15). While there was a non-significant trend 
towards D-DT induced chemokinesis in WT COS-7/M6 cells as compared to non-treated 
cells (Figure 15A), heat-inactivated D-DT vs. D-DT was insignificant (Figure 15A).  
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Figure 15. MIF upregulates chemokinesis independent of MIF receptors whereas D-DT requires the 
presence of receptors. MIF and D-DT were added at 200 ng/ml hereafter. EGF (100 ng/ml) was used as a 
positive control. (A) WT and (B) CD44
+
/CD74
+
 COS-7/M6 cells were seeded at 13,000 cell/cm
2
 in eight-well μ-
Slides and allowed to attach in 10% (v/v) FCS-containing DMEM. Subsequently medium was exchanged for 
0.5% (v/v) FCS/DMEM with or without the compounds of interest. The μ-Slide was mounted in a live-cell 
imaging chamber (humidified atmosphere, 37 °C, 5% CO2) at a Nikon Ti microscope stage and time-lapse 
phase-contrast microscopy was performed over the course of 3.5 h with 30-min intervals. Velocity data from 
three independent wells (replicates) (approx. 300 cells from 30 fields of view) were pooled from each 
experimental round, and a Kruskal-Walllis one-way analysis of variance (ANOVA) was performed. Data are 
shown as boxplots composed of a box (25th-75th percentile), a plus sign (arithmetic mean), a line in the 
middle of the box (median), whiskers (10th-90th percentile), and dots (outliers). Significance levels: ns, non-
significant (p > 0.05); *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001.  
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5.3.3.3. ISO-1 and 4-IPP abrogate MIF-triggered chemokinesis of WT COS-7/M6 cells 
Knowing that the inhibition of MIF’s enzymatic activity may interfere with MIF-mediated 
migration and invasion, specific inhibitors of MIF’s tautomerase activity, ISO-1 and 4-IPP, 
were used at maximal non-toxic concentrations established elsewhere (Winner et al., 
2008). But ISO-1 and 4-IPP inhibited MIF-induced cell motility only to a minimal extent 
(Figure 16A-B, MIF + DMSO vs. MIF + ISO-1 and MIF + DMSO vs. MIF + 4-IPP) because their 
solvent, DMSO, had a strong inhibitory effect on its own (Figure 16 and Appendix 1). 
However, ISO-1 appeared to inhibit MIF-driven chemokinesis in WT COS-7/M6 cells (Figure 
16A) and 4-IPP – in CD44+/CD74+ COS-7/M6 cells (Figure 16B). 
 
 
Figure 16. ISO-1 and 4-IPP dissolved in DMSO moderately inhibit MIF-triggered chemokinesis due to the 
inhibitory effect of DMSO. ISO-1 and 4-IPP were added at 100 μM. DMSO was at 0.5% (v/v) not only in 
DMSO-only but also ISO-1- and 4-IPP-containing wells. (A) WT and (B) CD44
+
/CD74
+
 COS-7/M6 cells were 
seeded in μ-Slides and imaged as described in Figure 15, with one exception: the data represents only one 
replicate. Abbreviations: 4-IPP, 4-iodo-6-phenylpyrimidine; ISO-1, (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-
isoxazole acetic acid (ISO-1). Significance levels: ns, non-significant (p > 0.05); *, p ≤ 0.05; **, p ≤ 0.01; ***, p 
≤ 0.001.  
B 
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Prompted by the fact that DMSO exhibited an inhibitory effect on chemokinesis on its 
own, ethanol was tested as an alternative solvent for MIF’s tautomerase inhibitors ISO-1 
and 4-IPP. Because D-DT did not exhibit a measurable tautomerase activity (Figure 8C), 
only one cell line – WT COS-7/M6 – that was MIF-responsive but not D-DT-responsive was 
used here. Since ethanol altered neither basal nor MIF-induced chemokinesis, it was 
considered an appropriate solvent (Figure 17 and Appendix 1). Ultimately both ethanol-
dissolved ISO-1 and 4-IPP abrogated MIF-stimulated motility of WT COS-7/M6 cells, 
leading to non-stimulated levels (Figure 17). 
 
 
Figure 17. ISO-1 and 4-IPP dissolved in ethanol abrogate MIF-triggered chemokinesis of WT COS-7/M6 
cells. ISO-1 and 4-IPP were added at 100 or 50 μM, respectively. Ethanol concentration was 0.1% (v/v) in 
treatments no. 3-5 (from left to right). The cells were seeded in μ-Slides, imaged, and analysed as described 
in Figure 15. Velocity data from three independent wells (replicates) (approx. 300 cells from 30 fields of 
view) were pooled from each experimental round, and a Kruskal-Walllis one-way analysis of variance 
(ANOVA) was performed. Abbreviations: 4-IPP, 4-iodo-6-phenylpyrimidine; EtOH, ethanol; ISO-1, (S,R)-3-(4-
hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic acid (ISO-1). Significance levels: ns, non-significant (p > 0.05); 
*, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001. 
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5.3.3.4. Full-length WT but not tautomerase-null MIF upregulates chemokinesis 
To complement the result obtained with pharmacological MIF’s tautomerase inhibitors, 
recombinant tautomerase-null MIF mutants – MIF P2A (Pro-2-to-Ala substitution) and Δ4 
(deletion of the first four amino acids of the N-terminus) were employed. They both acted 
as dominant-negative proteins as they did not alter the motility of WT COS-7/M6 cells 
(Figure 18 and Appendix 1). 
Taken together, the use of MIF’s tautomerase inhibitors as well as tautomerase-null MIF 
mutants show that tautomerase activity is required for chemokinesis. 
 
 
Figure 18. Full-length WT but not tautomerase-null MIF upregulates chemokinesis. WT COS-7/M6 cells 
were seeded in μ-Slides, imaged, and analysed as described in Figure 15. Velocity data from three 
independent wells (replicates) (approx. 300 cells from 30 fields of view) were pooled from each 
experimental round, and a Kruskal-Walllis one-way analysis of variance (ANOVA) was performed. 
Abbreviations: P2A, Pro-2-to-Ala substitution; Δ4, deletion of the first four amino acids of the N-terminus. 
Significance levels: ns, non-significant (p > 0.05); *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001. 
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5.3.3.5. Oxidoreductase-null MIF C60S is defective in upregulation of WT COS-7/M6 
chemokinesis 
To find out if MIF’s oxidoreductase activity is also required to alter WT COS-7/M6 cell 
chemokinesis, oxidoreductase-null MIF C60S (Cys-60-to-Ser substitution) was used. Here, 
a few changes were incorporated into the protocol as compared to other experiments. 
Recombinant MIF C60S is known to localise to inclusion bodies during bacterial expression 
(Kleemann et al., 1998). Likewise, MIF C60S – particularly a highly concentrated stock 
thereof – tends to precipitate after thawing. Therefore MIF C60S – believed to have a 
concentration of 350 ng/μl following protein purification – was first centrifuged at the 
highest speed, the supernatant was transferred to a new microcentrifuge tube, and kept 
at room temperature. The protein concentration was measured on a semi-quantitative 
basis with an immunoblot using MIF WT as standard and estimated to be 23 ng/μl. 
Ultimately this approach ensured that the motility assays were performed with a fully 
reconstituted protein in solution. To that end, WT COS-7/M6 cells were seeded in one μ-
Slide instead of three consecutive μ-Slides as in all other experiments. Three wells 
contained non-treated cells, three wells contained MIF C60S-treated cells, and two wells 
contained MIF WT-treated cells. Such an approach ensured that the appropriate protein 
amount (200 ng/ml) of soluble MIF C60S (Figure 19A) was added to all wells. 
MIF C60S only slightly increased chemokinesis (Figure 19A and Appendix 1) but the 
significance level is merely below the threshold of 0.05. This result is corroborated by 
other experiments (Figure 19B) in which a stock of MIF C60S with a lower concentration 
(nominal protein concentration of 45 ng/μl following protein purification, and 11.7-17.8 
ng/μl when measured on two spectrophotometers after thawing) did not alter 
chemokinesis at a final concentration of 200 ng/ml in a significant way (Figure 19B, low), 
and neither did MIF C60S re-solubilised at 37 °C (the protein was kept in a cell-culture 
incubator until it was fully re-solubilised) or on ice (the protein was kept on ice until it was 
fully re-solubilised) (Figure 19B, 37 °C and ice). Overall, oxidoreductase-null MIF C60S is 
defective in upregulation of WT COS-7/M6 chemokinesis. 
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Figure 19. Oxidoreductase-null MIF C60S is defective in upregulating WT COS-7/M6 chemokinesis. (A-B) 
The cells were seeded in μ-Slides, treated with 200 ng/ml MIF WT or C60S, imaged, and analysed as 
described in Figure 15. (A) The concentration of MIF C60S was estimated by immunoblot, with MIF WT as 
reference. (B) The concentration of MIF C60S was determined (section 4.2.1.2) after re-solubilisation at 
given conditions (see text for details of re-solubilisation). Here one experimental round was performed – in 
one μ-Slide there were two (for NT) and three wells (for recombinant proteins) to ensure that the 
appropriate protein amount was added to the cells. Significance levels: ns, non-significant (p > 0.05); *, p ≤ 
0.05; **, p ≤ 0.01; ***, p ≤ 0.001.  
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5.3.3.6. MIF-triggered chemokinesis appears to rely on lipid raft/caveolae- and not 
clathrin-mediated endocytosis 
Extracellular cargo – including growth factors and cytokines – is known to be internalised 
by a plethora of mechanisms (Figure 2 and Wieffer et al., 2009): 
 receptor-independent endocytosis, 
 receptor-dependent endocytosis (Figure 3D for MIF), 
 clathrin-mediated endocytosis (CME), 
 non-clathrin-mediated endocytosis (non-CME, or caveloae-dependent), 
 non-clathrin-mediated (non-CME) and caveloae-independent but lipid raft-dependent 
endocytosis. 
MIF has been hitherto described to be endocytosed in MEFs (Schwartz et al., 2012) as well 
as in RAW264.7 macrophages (Xie et al., 2011) in a clathrin- and CD74-dependent but 
caveolae-independent manner, although no data exist on MIF internalisation in 
fibroblasts. 
Given that MIF does not require its receptors to stimulate motility of MIF receptor-
negative COS-7/M6 cells (Figure 15), the hypothesis was tested that MIF endocytosis – 
specifically non-CME endocytosis – contributes to the observed effects. Once released 
from a vesicle via the so-called endosomal escape mechanism, internalised MIF could 
potentially act within the cytoplasm in order to alter motility. 
Prior to the assessment of the effect of endocytosis inhibition on MIF-mediated 
chemokinesis, titration of four pharmacological inhibitors was performed. COS-7/M6 cells 
were grown to 50% confluency and treated with inhibitors at a wide range of 
concentrations (Table 18). The toxic dose was defined as the concentration that led to the 
detachment of all cells upon stimulation with each inhibitor, and was assessed under a 
phase-contrast microscope for up to 3.5 h (Table 18). In fact, 100% cell detachment was 
observed within the first 10-30 minutes. Concentrations chosen for the assays closely 
resemble the concentrations used in earlier studies (Table 18).  
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Table 18. Evaluation endocytosis inhibitor cell toxicity.  
 Chlorpromazine 
(CPZ) 
Dynasore (DYN) Nystatin (NYS) Filipin (FIL) 
Stock 50 mM in water 10 mM in DMSO 5.4 mM in DMSO 7.6 mM in DMSO 
Inhibitor 
target 
CME CME and non-CME Non-CME Non-CME 
Tested 
doses 
100 pM; 1; 10; 100 
nM; 1; 10; 50 μM 
0.1; 1; 10; 15; 50 μM 0.108; 1.08; 10.8; 27; 
54 and 108 μM 
0.03; 0.06; 0.15; 0.3; 
0.75; 1.5; 3; 7.5 μM 
Toxic 
dose(s) 
50 μM No detachment 
observed 
54 and 108 μM  3 and 7.5 μM 
Dose used 10 μM 50 μM 27 μM 1.5 μM 
Previously 
used doses 
(reference) 
14 μM for MIF in 
RAW294.7 cells (Xie et 
al., 2011); 
50 μM (Schwartz et al., 
2012) 
80 μM (IC50 = 15 μM) 
for transferrin in COS-7 
cells (Kirchhausen et 
al., 2008); 
80 μM for MIF in 
HEK293 cells (Schwartz 
et al., 2012) 
54 μM for MIF in 
HEK293 cells (Schwartz 
et al., 2012) 
5 μM for MIF in 
RAW294.7 cells (Xie et 
al., 2011); 
7.7 μM for MIF in 
HEK293 cells (Schwartz 
et al., 2012) 
At toxic dose(s) all WT COS-7/M6 cells detached in 10-30 minutes. Abbreviations: CME, clathrin-mediated 
endocytosis. 
 
The mechanism of action varies between the four drugs (Macia et al., 2006; Ivanov, 2008). 
Chlorpromazine is known to inhibit clathrin-mediated endocytosis (CME) by lowering 
clathrin and adaptor protein complex 2 (AP2) levels at the cell surface. Dynasore (DYN) 
binds dynamin and therefore inhibits both clathrin-mediated endocytosis (CME) and non-
CME (caveolae-mediated endocytosis). Nystatin (NYS) and filipin (FIL) are believed to 
inhibit non-CME by sequestering cholesterol from lipid rafts (Macia et al., 2006; Ivanov, 
2008). 
For chemokinesis experiments with endocytosis inhibitors, WT and CD44+/CD74+ COS-
7/M6 cells were prepared as earlier (Figure 15), with the following exception. Medium 
was changed from DMEM/10% (v/v) FCS to DMEM/0.5% (v/v) FCS supplemented with 
endocytosis inhibitors, and the cells were returned to the incubator for 1 h. Without a 
second medium exchange, MIF was added to appropriate wells to a final concentration of 
200 ng/ml, and the cells were imaged for 3.5 h (Figure 15). 
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While chlorpromazine and dynasore did not alter MIF-mediated motility of WT COS-7/M6 
cells (Figure 20A), MIF-triggered chemokinesis was abrogated upon inhibition of lipid 
raft/caveolae-dependent endocytosis by nystatin (Figure 20A). In contrast, dynasore and 
nystatin but not chlorpromazine inhibited MIF-mediated motility of CD44+/CD74+ COS-
7/M6 cells (Figure 20B), implicating the receptor- and dynamin-mediated internalisation in 
transducing MIF’s actions on motility in receptor-positive cells. Dynamin in WT COS-7/M6 
cells was not required for MIF-mediated upregulation of chemokinesis (Figure 20A). Taken 
together, MIF appears to exploit non-CME in upregulating chemokinesis in receptor-
negative cells, and non-CME and dynamin in receptor-positive cells. 
On the other hand, D-DT upregulates chemokinesis of CD44+/CD74+ COS-7/M6 cells under 
basal conditions (Figure 20C) but never under endocytosis inhibition. Because D-DT does 
not promote WT COS-7/M6 cell migration (Figure 15A), this implies that at least one 
receptor-dependent endocytic pathway is essential for mediating D-DT’s effect. 
Unlike the relatively well-established endocytosis inhibitors chlorpromazine and dynasore 
(section 6.3.2 of the Discussion provides a critical analysis), nystatin is known to not only 
perturb cellular uptake but also permeabilise cell membranes, making it an attractive 
compound to study ion transport across a variety of cell barriers such as lung epithelium 
or vascular endothelium. As shown in Figure 20, nystatin (a) somewhat diminishes the 
basal motility of all cells under starvation and (b) seems to abrogate MIF-driven increase in 
chemokinesis. Because it is likely that nystatin simply permeabilised the COS-7/M6 
fibroblasts under investigation, an alternative inhibitor of endocytosis, filipin, was tested 
(Figure 20C, for D-DT, and Figure 21 for MIF).  
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Figure 20. MIF-triggered chemokinesis appears to rely on lipid raft/caveolae- and not clathrin-mediated 
endocytosis. Functional dynamin in CD44
+
/CD74
+
 COS-7/M6 cells is required for MIF-mediated upregulation 
of chemokinesis, whereas D-DT only upregulates chemokinesis when at least one endocytic pathway is 
active. CPZ was added at 10 μM, DYN at 50 μM, FIL at 1.5 μM, and NYS at 27 μM, 1 h before the addition of 
MIF/D-DT. (A) WT and (B-C) CD44
+
/CD74
+
 COS-7/M6 cells were seeded in μ-Slides and imaged as described 
in Figure 15. Velocity data from three independent wells (replicates) (approx. 300 cells from 30 fields of 
view) were pooled from each experimental round, and a Kruskal-Walllis one-way analysis of variance 
(ANOVA) was performed. Abbreviations: CPZ, chlorpromazine; DYN, dynasore; FIL, filipin; NYS, nystatin. 
Significance levels: ns, non-significant (p > 0.05); *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001.  
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Finally, filipin – known to sequester cholesterol from lipid rafts and inhibit endocytosis 
similar to nystatin without its inhibitory effect on migration – abrogated MIF-induced 
chemokinesis of WT and CD44+/CD74+ COS-7/M6 cells (Figure 21A and B), providing 
additional evidence in support that MIF-induced fibroblast chemokinesis depends on lipid 
raft/caveolae assembly rather than CME. 
A                 B 
          
Figure 21. MIF-triggered WT and CD44
+
/CD74
+
 COS-7/M6 chemokinesis appears to rely on lipid 
raft/caveolae-dependent endocytosis. Filipin was added at 1.5 μM; DMSO was present in all DMSO- and 
FIL-containing wells at 0.02% (v/v). (A) WT and (B) CD44
+
/CD74
+
 COS-7/M6 cells were seeded in μ-Slides and 
imaged as described in Figure 15 with the same exception as in Figure 20 (i.e. 1-h pre-treatment with 
DMSO/FIL). Velocity data from three independent wells (replicates) (approx. 300 cells from 30 fields of view) 
were pooled from each experimental round (two for NT and MIF), and a Kruskal-Walllis one-way analysis of 
variance (ANOVA) was performed. Abbreviations: FIL, filipin. Significance levels: ns, non-significant (p > 
0.05); *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001. 
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5.3.3.7. Endogenous MIF contributes to upregulation of chemokinesis by exogenous MIF in 
CD44+/CD74+ but not WT COS-7/M6 cells 
As WT and CD44+/CD74+ COS-7/M6 cells express appreciable amounts of endogenous MIF 
(Figure 22A, lane 10), its contribution to chemokinesis induced by exogenous MIF is 
unclear. Therefore endogenous MIF was ablated using a knockdown strategy. Two 
individual MIF gene-specific short interfering RNAs (siRNAs) (Table 13) efficiently blocked 
MIF production in both cell lines three days after transfection (Figure 22A, lanes 2-3 and 5-
6). The cognate C911 controls (Buehler et al., 2012) did not affect expression levels (Figure 
22A, lanes 4, 7 and 9). When both specific siRNAs were combined MIF production was 
abrogated to background levels (Figure 22, lane 8, upper panel). Interestingly, the levels of 
endogenous MIF in CD44+/CD74+ COS-7/M6 cells was lower than in WT cells. Hence, the 
knockdown led to undetectable MIF levels (Figure 22A, lane 8, lower panel). 
Having proven that ablation of endogenous MIF is efficient, chemokinesis was again 
induced with exogenous MIF three days after transfection (Figure 22B-C, Appendix 1). The 
velocity was not significantly affected by the transfection procedure in CD44+/CD74+ cells, 
but was indeed affected in WT COS-7/M6 cells (Figure 22B, NT vs. C911 siRNA). The 
velocity was not significantly affected by the knockdown of MIF in COS-7/M6 cells but was 
indeed affected in CD44+/CD74+ COS-7/M6 cells (Figure 22C, NT vs. MIF siRNA and NT vs. 
C911 siRNA). The addition of exogenous MIF to untreated cells (WT and CD44+/CD74+ 
COS-7/M6) induced chemokinesis as shown before (Figure 16 and 22B-C). Because there 
was no significant change in upregulation of chemokinesis neither after knockdown of MIF 
nor after transfection of the C911 control siRNAs, it appears that endogenous MIF does 
not contribute to chemokinesis induced by exogenous MIF, at least not in WT COS-7/M6 
cells (for a more detailed interpretation, see Discussion, section 6.3.2.2). 
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Figure 22. Endogenous MIF contributes to upregulation of chemokinesis by exogenous MIF in 
CD44+/CD74+ but not WT COS-7/M6 cells. (A) MIF Immunoblot proves MIF knockdown in WT COS-7/M6 
cells (top panel) and CD44
+
/CD74
+
 COS-7/M6 cells (bottom panel). β-actin was used as loading control. (B) 
WT and (C) CD44
+
/CD74
+
 COS-7/M6 cells were seeded in μ-Slides and imaged as described in Figure 15, with 
the following exception. Cells were transfected in 6-well plates with MIF siRNA #1 and #2 and allowed to 
grow for 2.5 days. On the morning of the third transfection day (66 h after transfection), cells were split and 
seeded in μ-Slides for the remaining time (6 h) to a total of 72 h post-transfection. Velocity data (B-C) from 
three independent wells (replicates) (approx. 300 cells from 30 fields of view) were pooled from each 
experimental round, and a Kruskal-Walllis one-way analysis of variance (ANOVA) was performed. 
Significance levels: ns, non-significant (p > 0.05); *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001. 
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5.4. MIF/D-DT and actin cytoskeleton 
5.4.1. The MIF/D-DT interactomes include many actin cytoskeleton-associated 
proteins 
Fibroblasts play a key role in ECM maintenance, wound healing, and cancer-associated 
angiogenesis (Kalluri and Zeisberg, 2006). As fibroblasts secrete ECM components in order 
to facilitate healing, cells ensure proper spatiotemporal regulation of migration and 
proliferation of fibroblasts upon wounding and inflammation. MIF has been implicated in 
this process as it promotes wound closure of MEFs (Dewor et al., 2007). Clinically, stromal 
fibroblasts steer the collective invasion of carcinoma cells in an integrin- and protease-
dependent fashion (Gaggioli et al., 2007), suggesting that fibroblasts are attractive therapy 
targets. 
The abovementioned characterisation of COS-7/M6 fibroblasts and the effect of MIF and 
D-DT on their motility expand our knowledge of the biology of fibroblasts with a focus on 
their receptors. NIH 3T3 fibroblasts, which do not express CD74 but do express CD44, 
serve as a useful tool to study fibroblast behaviour, and specifically the cytoplasmic roles 
for MIF and D-DT. 
The MIF/D-DT interactome defined in NIH 3T3 fibroblasts helps to delineate the 
mechanism of action of cytoplasmic MIF in cell motility (Table 2). We aimed to focus on 
the MIF-ARP2/3 axis by subsequently performing actin stainings as well as ARP2/3-driven 
in vitro actin assembly assays. 
The actin-related protein 2/3 (ARP2/3) complex binds to existing actin filaments and 
initiates actin branching at a fixed angle of 70° (Robinson et al., 2001). Two out of seven of 
ARP2/3 subunits putatively interact with both MIF and D-DT. As actin filaments extend 
towards the direction of cell movement, their elongation can be inhibited by capping 
proteins of which two – CAPZA1 and CAPZB – were also found to interact with MIF/D-DT. 
Destrin (actin-depolymerising factor or ADF), a protein involved in the eponymous actin 
depolymerisation and another MIF/D-DT interactor, mediates the fast turnover of actin 
filaments. Tropomyosin, implicated in muscle contraction and actin stabilisation, 
antagonises ADFs and slows down the turnover of actin (Bugyi et al., 2010). This suggests 
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that MIF/D-DT may fine tune cytoplasmic actin dynamics in terms of actin filament 
elongation and/or depolymerisation and therefore contribute to cell migration. 
Furthermore, MIF but not D-DT interacts with Rho GDP-dissociation inhibitor (RhoGDI) 
which binds and sequesters Rho GTPases such as Rac1/RhoA/Cdc42 from the plasma 
membrane to keep them in an inactive cytoplasmic form. Since MIF is known to interfere 
with Rho GTPase activation (Figure 5, Table 19), its interaction with RhoGDI would provide 
a novel explanation to the observed effects of MIF on Rac1/RhoA/Cdc42. 
On the other hand, MIF/D-DT interact with (a) nucleoside diphosphate kinase proteins 
(NDPKs) which in turn interact with many cytoskeletal proteins and the cell adhesion 
machinery (Snider et al., 2015), and (b) moesin, a protein bridging the cytoskeleton and 
plasma membrane. As such, the MIF/D-DT-NDPK/moesin axis could be explored on the 
basis of not only cell migration but also cell adhesion and membrane dynamics. 
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5.4.2. MIF induces F-actin stress fibre formation in WT COS-7/M6 cells 
Intrigued by the two observations that MIF upregulates the migration of MIF receptor-
negative COS-7/M6 cells, and that the receptor-negative NIH 3T3-derived MIF interactome 
contains various actin cytoskeleton-related proteins, actin staining was performed to 
assess the status of the actin cytoskeleton before and after stimulation with recombinant 
MIF. 
WT COS-7/M6 cells were seeded on coverslips in multi-well plates and allowed to adhere 
overnight (section 4.2.4.7). Next, medium containing 10% (v/v) FCS was exchanged for 
medium with 0.5% (v/v) FCS supplemented with MIF or heat-inactivated MIF. Following 
fixation and permeabilisation, cells were stained with Texas Red®-conjugated phalloidin, a 
fungal toxin that binds filamentous actin, and imaged under a fluorescence microscope 
(Figure 23A-C). Under starvation, MIF but not heat-inactivated MIF promoted actin stress 
fibre formation (Figure 23D). Three times more cells were stress fibre-positive under MIF 
stimulation as compared to non-treated as well as heat-inactivated controls (Figure 23D). 
Concomitantly, the number of cells with a prominent cortical rim decreased under MIF 
treatment, while the abundance of dividing or multinucleated cells remained virtually 
unchanged (Figure 23D).  
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Figure 23. MIF induces F-actin stress fibre formation in WT COS-7/M6 cells. Cells were seeded at 40,000 
cell/cm
2
 on coverslips in a 12-well plate, allowed to adhere overnight, and treated with native or heat-
inactivated MIF for 3.5 h. The cells were fixed in 4% paraformaldehyde, permeabilised in 0.1% Triton™ X-
100, blocked in 1% BSA, and stained with Texas Red®-conjugated phalloidin (1:500) in the darkness for 
30 min. Following washing, the coverslips were overlaid with DAPI-containing mounting medium, and put 
upside down on a glass slide. The next day the cells were visualised using a fluorescence microscope under 
630X magnification (oil objective). The excitation/emission wavelengths were 596 nm/615 nm (for Texas 
Red®-phalloidin) and 358 nm/461 nm (for DAPI). (A-C) Representative images of phalloidin-stained actin. (A) 
A cell positive for both actin stress fibres and a cortical rim. (B) A cell with a prominent cortical rim but with 
no or few stress fibres. (C) A cell with prominent actin stress fibres but no cortical rim. (D) More than 
360 cells were categorised based on the unique characteristics of their actin cytoskeleton. The number of 
unique cells used for each treatment assessment is shown in parenthesis (right). The data in graph D is 
representative of one out of three experiments. Abbreviations: BSA, bovine serum albumin; DAPI, 4’,6-
diamidino-2-phenylindole; FCS, foetal calf serum; NT, non-treated. 
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5.4.3. MIF but not D-DT slows down the rate of actin assembly in actin assembly assays 
In order to test if MIF can directly affect the actin assembly, in vitro pyrene-actin assembly 
assays were performed. Actin polymerisation from globular to filamentous actin requires a 
number of factors. A branched actin network is built in vitro as well as in vivo through a 
seven-subunit actin-related protein 2/3 (ARP2/3) complex. ARP2/3 is activated by VCA 
domain present within WASP (Wiskott-Aldrich syndrome protein)-family verprolin-
homologous protein (WAVE). In in vitro reconstituted assays, total cell extracts from HeLa, 
NIH 3T3 or HEK2393 can be used as sources of ARP2/3 (Baarlink et al., 2013). Typically the 
first stage of actin assembly is the so-called lag phase when nucleation takes place (Figure 
24A-D) (Harris and Higgs, 2006). Actin elongation occurs during the second stage – known 
as the log phase. Purified GST-tagged VCA is sufficient to induce actin assembly which 
results in a prominent change in the fluorescence curve from a linear to a sigmoidal shape 
(Figure 24A, actin+ARP2/3 vs. actin+ARP2/3+VCA). 
While MIF, mD-DT and hD-DT did not modify the rate of VCA-triggered actin assembly in a 
fully reconstituted system with the seven-subunit ARP2/3 complex (Jan Faix lab, 
Hannover) (Figure 24A-C), MIF reduced the rate of VCA-induced actin assembly by 60% 
when a total HEK293 cell extract was used as a source of the ARP2/3 complex (Robert 
Grosse lab, Marburg) (not shown, pilot experiment performed by Haicui Wang PhD). 
An additional set of experiments involving HEK293 total cell extracts was performed later 
with appropriate buffer controls. MIF but not D-DT decreased the rate of cell extract-
driven actin assembly as compared to respective buffer controls (buffer P for MIF and 
20 mM phosphate buffer pH 7.0 for D-DT), likely due to protein-protein interactions 
between MIF and unknown components of the cell extract (Figure 24D). 
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Figure 24. The differential influence of MIF on the rate of actin assembly in vitro. To measure the rate of 
actin assembly, non-fluorescent pyrene-labelled G-actin was combined with either (A-C) purified ARP2/3 or 
(D) the ARP2/3-containing total HEK293 cell extract, with or without recombinant proteins. In both assays, 
the formation of filamentous actin was induced with recombinant VCA domain. Fluorescence of filamentous 
pyrene-actin was monitored at 407 nm with excitation at 365 nm in a (A-C) 200-μl or (D) 100-μl reaction 
volume, using a spectrofluorophotometer. Original fluorescence traces over time are shown (A-C, 20 min; D, 
10 min). Each experiment in A-C was performed once (Jan Faix lab, Hannover). Experiments in D are 
representative of one experiment and were consistently reproduced overall three or more times. 
Abbreviations: ARP2/3, actin-related protein 2/3 complex; A.U., arbitrary units; VCA, verprolin, cofilin, 
acidic domain. 
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6. Discussion 
Initially described as a factor inhibiting monocyte/macrophage random migration, MIF has 
emerged as a pleiotropic cytokine, chemokine and hormone. It is implicated in migration 
and invasion of cancer and non-cancer cells and orchestrates cell migration of a variety of 
immortalised and primary cells (Table 19). Much research is dedicated to MIF-mediated 
cell arrest of circulatory T cells, monocytes/macrophages, and neutrophils. Such cell arrest 
under flow conditions is primarily mediated by endothelium-immobilised MIF that is 
binding to C-X-C motif chemokine receptor type 2/4/7 (CXCR2, 4 and 7) on mononuclear 
immunocompetent cells (see Introduction, Figure 4), and plays a role in inflammation. 
Aside from circulating cells, resident cells such as fibroblasts (stromal mesenchymal cells) 
serve an equally important role in resolving inflammation, wound healing and scarring. 
Nevertheless, the mode of action of MIF on fibroblasts received much less attention 
(Table 19). First, although migration was assessed in cancer-associated fibroblasts and 
mouse embryonic fibroblasts (MEFs), the presence of MIF receptors – CD44, CD74 and 
others – was not (see Introduction, Figure 3A-B). Second, when MIF receptors CD44 and 
CD74 were identified and studied in other cellular models – COS-7/M6 and RAW264.7 
cells – the migration remained unassessed (see Introduction, Figure 3C-D). 
Aside from the actions of extracellular MIF on its receptors, many intertwined cytoplasmic 
signalling pathways are modulated by MIF. MIF acts in a pro-migratory manner on cancer 
and B cells via Rho GTPase Rac1, calcium influx, and actin polymerisation, and anti-
migratory on monocytes via a cyclic activation/deactivation of Rho GTPases (Table 19). 
However, how secreted or cytosolic MIF mechanistically influences Rho GTPases is 
unknown.  
D-DT, a structural and functional homologue of MIF, was initially characterised in the 
context of apoptosis and anchorage-independent growth (Brock et al., 2014). Despite the 
fact that MIF/D-DT increased cell migration of clear cell renal cell carcinoma (ccRCC) 
(Pasupuleti et al., 2014), the role of D-DT in migration remains poorly understood. 
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Table 19. MIF affects migration via the cytoskeleton and Rho GTPases – summary. 
Cell phenomenon Actions of MIF Cell type Reference 
Actin polymerisation Upregulates B cell (Klasen et al., 2014) 
Actin polymerisation Downregulates (because of MIF 
knockout) 
MIF
–/–
 
monocyte/macrophage 
(Fan et al., 2011) 
Actin polymerisation Upregulates (via phospho-
cofilin) 
Colorectal cancer (Hu et al., 2015) 
Actin, microtubule, and 
IF network / Rho 
activation 
Perturbs / downregulates 
(hence downregulates 
chemotaxis) 
Monocyte (Frascaroli et al., 2009) 
Chemokinesis Downregulates Mesenchymal stem cell (Fischer-Valuck et al., 2009; 
Barrilleaux et al., 2010) 
Chemokinesis Upregulates COS-7/M6 This thesis 
Chemotaxis Upregulates (via CXCRs and 
CD74) 
Monocyte/macrophage, 
neutrophil, T cell 
(Bernhagen et al., 2007) 
Chemotaxis Downregulates CAF (Tarnowski et al., 2010) 
Chemotaxis Upregulates Glioblastoma (Piette et al., 2009) 
Chemotaxis Upregulates MDSC (Simpson et al., 2012) 
Chemotaxis Upregulates (only PDGF-BB-
induced chemotaxis) 
VSMC (Schrans-Stassen et al., 
2005) 
Co-localisation with 
stress fibres 
MIF and MLCK co-localise 
(motility was not assessed) 
Endothelium (Wadgaonkar et al., 2005) 
IL-8 production Upregulates HCC (Ren et al., 2003) 
Integrin expression Upregulates Chondrosarcoma (Lee et al., 2011) 
Integrin expression Downregulates (because of MIF 
knockout) 
MIF
–/– 
endometrium (Rakhila et al., 2014) 
Microtubule 
polymerisation 
Upregulates Monocyte/macrophage, 
myocardial trabeculae 
(McCarthy et al., 1979; 
Preau et al., 2013) 
Rac1 stabilisation in 
lipid rafts 
Upregulates A549 (Rendon et al., 2007) 
Rac1/RhoA/Cdc42 
(de)activation 
Activates/deactivates (hence 
downregulates chemotaxis) 
Monocyte/macrophage (DiCosmo-Ponticello et al., 
2014) 
RhoA activation Upregulates (increases growth 
but does not affect motility) 
MEF, NIH 3T3 (Swant et al., 2005) 
RhoQ and Cdc42 Upregulates (hence upregulates 
chemotaxis) 
Mesenchymal stem cell (Lourenco et al., 2015) 
Wound healing Upregulates MEF (Dewor et al., 2007) 
Wound healing Downregulates (because of MIF 
knockout) 
Skin of MIF
–/–
 mice (Ashcroft et al., 2003) 
Abbreviations: BMDM, bone marrow-derived macrophage; CAF, cancer-associated fibroblast; Cdc42, cell 
division control protein 42 homolog; CXCR, C-X-C motif chemokine receptor; HCC, hepatocellular carcinoma; 
IF, intermediate filament; IL-8, interleukin-8; MEF, mouse embryonic fibroblast; MDSC, myeloid-derived 
suppressor cell; MLCK, myosin light chain kinase; PDGF-BB, platelet-derived growth factor chain BB; Rac1, 
Ras-related C3 botulinum toxin substrate 1; RhoA, Ras homolog gene family, member A; VSMC, vascular 
smooth muscle cell. 
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6.1. Protein purification 
Recombinant non-tagged MIF and D-DT were purified from E. coli BL21 (DE3). One caveat 
in the field of MIF research is the use of bacterially-produced MIF that is tagged (Chen et 
al., 2015). The interpretation of data could be hindered if a tag causes polypeptide 
misfolding or a steric hindrance, potentially leading to perturbed biological functions. 
Since a non-tagged MIF molecule was used throughout here, no biological interference 
can be attributed to a tag. 
Because E. coli-produced proteins lack post-translational modifications which may be 
essential for certain biological functions, MIF was tested for its biological activity. MIF 
appears to exert its effects as a trimer based on an elegant study involving a locked MIF 
trimer N110C (Fan et al., 2013), and its tautomerase catalytic site resides in a cleft 
between two MIF monomers. Therefore the tautomerase assay allowed for determination 
that the recombinant protein was: (a) biologically active with respect to its enzymatic 
(tautomerase) activity and (b) it formed a trimer in solution. MIF was active not only in 
PBS but also in cell-culture medium after the addition to cultured cells for 24 h. 
Furthermore MIF storage at 4 °C (for a few months) or – 80 °C (also for a few months, 
snap-frozen immediately after its production) did not significantly change its tautomerase 
activity, showing its stability under different conditions. 
6.2. MIF/D-DT interactome and random cell motility assays 
Fibroblasts play a pivotal role in health and disease. During wound healing, fibroblasts 
become reversibly activated and secrete ECM components such as collagen (Kalluri and 
Zeisberg, 2006). In cancer, cancer-associated fibroblasts (CAFs) secret matrix 
metalloproteinases (MMPs), monocyte chemotactic protein 1 (MCP-1) and a variety of 
oncogenic factors (Kalluri and Zeisberg, 2006). Hence fibroblast-like NIH 3T3 and COS-
7/M6 cells were chosen as convenient model cells in order to study the relationship 
between MIF, MIF receptors, actin cytoskeleton, and cell motility. 
As fibroblast-like NIH 3T3 and COS-7/M6 cells do not express the entire repertoire of MIF 
receptors, they were deemed appropriate to study the physiology of MIF and its novel 
homologue D-DT in this thesis. Importantly, both do not produce the principal MIF/D-DT 
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receptor CD74 (Fernandez-Cuesta et al., 2014). On the other hand, CD44 and CXCR4 may 
be found in minute amounts in NIH 3T3 (Okabe et al., 2005; Tzircotis et al., 2006; Yamada 
et al., 2015) and COS-7/M6 cells (section 5.3.1). 
The rationale of this study is based on two questions. First, since MIF is both an extra- and 
intracellular protein, are the receptors essential for MIF-mediated motility? Knowing that 
(a) MIF classically affects cell motility via its receptors but also that (b) MIF has multiple 
intracellular binding protein partners, attention was directed at a model of receptor-
negative COS-7/M6 cells. Second, a mass spectrometry-based proteomics screen in NIH 
3T3 cells for interactors of cytosolic MIF and D-DTs (Cayli et al., 2009; Filip et al., 2009; and 
unpublished data) revealed many actin-associated molecules including ARP2/3 and 
RhoGDI to be putative MIF/D-DT interactors. This raised the question if intracellular MIF 
mediates cell motility? 
To examine whether MIF requires its receptors for mediating motility, COS-7/M6 cells 
were chosen as a model of MIF receptor-deficient cells (Shi et al., 2006). Stable cell lines 
expressing CD44 and CD74 were generated to define the contribution of these two MIF 
receptors to MIF-mediated motility. 
6.2.1. Wound healing (scratch) assays 
A wound healing (scratch) assay is a cost-effective method that provides insight into 
collective cell motility characteristic of e.g. cancer cells. Collective migration in such a two-
dimensional setup is reminiscent of the capacity of a cancer cell to explore the 
environment within the metastatic cascade.  
Such collective-cell motility assays were performed in collagen-coated μ-Slides and multi-
well plates. The use of ECM was recommended by the original publication describing the 
method (Liang et al., 2007), based on the observation that the ECM components promote 
integrin-dependent cell motility hence would promote the overall motility of cells on 
tissue-culture vessels (Friedl, 2004). However, those assays proved challenging because 
prototypical inducers of motility such as insulin-like growth factor (IGF)-I and epidermal 
growth factor (EGF) did not upregulate motility of the investigated cells. 
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Similar to cancer cells, wound healing assays measure polarised, microtubule (MT)-
dependent cell motility (Goulimari et al., 2005). Velocity (or distance) of single cells might 
be measured but because of the formation of cellular bridges (Green et al., 2004), some 
cells are always much faster than others. In time-lapse microscopy images were acquired 
overnight but a typical wound would close only in 1-2 days. Often one cell front did not 
migrate or migrated slowly and appeared to be stuck after approximately one hour, which 
was indicative of a disrupted ECM substrate. One approach to circumvent the observed 
problem of varying wound widths would be to use cell-culture inserts of a defined 500-μm 
width (ibidi) or circular cell seeding stoppers (Oris™ Cell Migration Assays, Platypus 
Technologies) in order to ensure consistency in wound creation. It would also provide an 
environment without a physical damage inflicted by the wounding. 
In search for an alternative and more reliable technique to test migration, chemokinesis 
(random single-cell motility) assays were employed. 
6.2.2. Chemokinesis (random cell motility) assays 
6.2.2.1. Chemokinesis assays are suitable to study motility of COS-7/M6 cells 
Another convenient method to study motility is a chemokinesis (random motility) assay as 
it allows for single-cell investigations without the need for physical wounding of a 
monolayer. During preliminary chemokinesis data collection, 10% (v/v) FCS-containing 
DMEM was used as a reference to monitor the cells over the time of the experiment. Cell 
death or lack of proper cell morphology would have been indicative of non-physiological 
conditions such as altered osmolality, pH, temperature or CO2 concentration within the μ-
Slide (Cole, 2014). None of these phenomena were observed under 10% or 0.5% (v/v) FCS 
in chemokinesis assays. In contrast, aberrant cell morphology was often noted during 
wound healing assays that likely arose due to physical wounding with a pipette tip. 
Although MIF-mediated chemotaxis was studied in many reports, one caveat of 
chemotaxis assays is the maintenance of a stable gradient over the course of an 
experiment. The approach employed in this thesis creates an extracellular milieu with a 
uniform distribution of MIF/D-DT. As such, their direct effect on random motility of single 
cells was measured. Adherent fibroblasts – such as COS-7/M6 cells – have an intrinsic 
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capacity to migrate during healing in vivo. In contrast, MIF-driven chemotaxis of 
mononuclear immunocompetent cells such as monocytes/macrophages, neutrophils and 
T cells were often tested in Transwell® chambers where cells are seeded on inserts and 
allowed to migrate through 3- or 5-μm pores (Bernhagen et al., 2007). Such a strategy 
mimics the ECM/endothelium environment through which these circulating cells normally 
migrate (see Introduction, Figure 4). 
Moreover, chemotaxis assays measure the bulk motility of a heterogeneous population of 
cells. Contrary to that, an assay measuring single-cell chemokinesis permits a real-time 
observation of how individual cells behave under stimulation with MIF or D-DT. In sum, 
one can observe that some cells remain immotile throughout the experiment while some 
are strong responders, indicating the heterogeneity of cells and highlighting the 
importance of single-cell experimentation. It would be tempting to hypothesise that 
strong MIF-responders are positive for a yet-unknown MIF receptor or can better 
internalise MIF. 
MIF-mediated chemokinesis assays used in this thesis were performed with fibroblasts 
seeded at low confluency on cell-culture slides. The duration of each fibroblast 
chemokinesis assay (3.5 h) used here was similar to that in chemotaxis assays with 
circulating cells (3-6 h) and sufficient to monitor short-term (up to an hour) as well as 
long-term effects of a treatment (3.5 h) but was not exceedingly long (12-24 h). The first 
study on MIF and migration by Dewor et al. also concluded that short-term but not long-
term stimulation with MIF was necessary for MIF-mediated upregulation of motility in 
wound healing assays with WT MEFs and MIF–/– MEFs (Dewor et al., 2007). PDGF-BB 
stimulated – bot not basal – chemotaxis of vascular smooth muscle cells (VSMCs) was also 
more pronounced upon short-term (6.5 h) stimulation with MIF (Schrans-Stassen et al., 
2005). 
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6.2.2.2. Endogenous MIF contributes to upregulation of chemokinesis by exogenous MIF in 
CD44+/CD74+ but not WT COS-7/M6 cells 
In order to validate chemokinesis assays with COS-7/M6 cells, EGF was successfully used 
as a positive control for cell motility. Next, MIF was shown to be a similar potent inducer 
of motility of both WT and CD44+/CD74+ COS-7/M6 cells. 
In a set of following experiments with WT and CD44+/CD74+ COS-7/M6 cells, siRNA-
mediated MIF knockdown was employed to test the hypotheses that (a) MIF knockdown 
diminishes cell motility and (b) both endogenous and exogenous MIF additively upregulate 
cell motility. Because velocity values measured under a combination of starvation and 
transient siRNA/mock transection oscillate within a narrow range of 0.10 and 0.12 μm/min 
(Figure 22), the following interpretation is presented cautiously. 
In theory, endogenous MIF could influence the actin machinery to drive motility via (a) an 
intracrine effect (intracellular MIF produced by the same cell acts cytoplasmically), (b) a 
paracrine effect (MIF secreted by a neighbouring cell is taken up by a different cell), or (c) 
an autocrine effect (MIF is secreted and taken up by the same cell). In a scenario outlined 
in (a), cytoplasmic MIF only would drive cell motility. In scenarios (b) and (c), MIF-driven 
motility can be either receptor-mediated (likely accompanied by subsequent calcium 
influx and ERK1/2 activation) or endocytosis-mediated with subsequent cytoplasmic 
action (likely via actin cytoskeleton). In either case, knockdown of endogenous MIF with 
specific siRNAs ought to diminish motility when compared to a non-specific siRNA control. 
In CD44+/CD74+ COS-7/M6 cells, knockdown of MIF indeed resulted in a significant 
downregulation of motility as compared to basal motility of non-treated cells. However, it 
is non-significant as compared to the C911 siRNA controls, implying that the observed 
effect in receptor-positive cells is related to an effect exerted by the siRNA transfection. In 
WT COS-7 cells, MIF knockdown does not downregulate motility in a significant way as 
compared to non-treated cells. Additionally, the velocity of WT COS-7 cells under MIF 
knockdown is the same as that of cells treated with C911 siRNA control (with or without 
exogenous MIF). Overall, if only the velocities of siRNA-treated cells were to be compared, 
there is no observable effect of endogenous MIF on migration in either cell line. 
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However, a comparison between velocity values of siRNA-treated and mock-transfected 
cells could shed light on whether Lipoectamine-mediated transfection affects basal cell 
migration. Again, it is worth mentioning that the values measured in chemokinesis assays 
oscillate within a relatively narrow range. The velocities of WT COS-7/M6 cells (a) under 
MIF depletion versus the velocity of mock-transfected cells and (b) the velocity of control 
siRNA-transfected cells versus mock-transfected cells are non-significant, suggesting that 
the transfection does not affect basal velocity of receptor-negative cells. Surprisingly, in 
receptor-positive COS-7/M6 cells, the velocity of MIF-depleted cells is significantly lower 
than that of mock-transfected cells; the velocity of control siRNA-treated cells and that of 
mock-transfected cells is non-significant. As mentioned above, this phenomenon is not 
related to the presence of siRNAs because there is no significant difference between the 
velocity of control siRNA-transfected cells versus that of mock-transfected cells. This 
suggests that it is not the transfection procedure, but the specific downregulation of MIF 
that diminishes motility of receptor-positive cells. Overall, given that the differences in 
velocity values are so small, it is concluded that endogenous MIF knockdown does not 
diminish cell motility of either cell line. MIF knockdown has been reported to significantly 
impair wound healing of ccRCCs (7% wound surface area open with control GFP siRNA 
versus 33% wound surface area open upon MIF knockdown, overnight) (Pasupuleti et al., 
2014) and somewhat reduce wound healing of MIF–/– MEFs (15 arbitrary units for WT 
MEFs versus 10 arbitrary units for MIF–/– MEFs, after 24 h) (Dewor et al., 2007). While 
those experiments were performed over longer periods of time, the chemokinesis assays 
employed here lasted 3.5 h. 
Next it was asked whether the contributions of endogenous and exogenous MIF are 
additive and tested by comparing the velocities of cells with or without MIF knockdown 
but stimulated with recombinant MIF. MIF-stimulated migration of MIF-depleted WT COS-
7/M6 cells was the same as that of MIF-stimulated MIF-positive cells, implying that there 
is no underlying positive effect of endogenous MIF on migration of receptor-negative 
cells. Remarkably, in receptor-positive cells, only within the siRNA-background, a 
comparison between velocity values draws a different conclusion. The velocity of cells 
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transfected with control C911 siRNA and stimulated with MIF (i.e. positive for both 
endogenous and exogenous MIF) is significantly higher than that of MIF-depleted cells 
stimulated with exogenous MIF (i.e. positive for exogenous MIF only). This implies that the 
effect of both MIF populations is additive in receptor-positive cells, but not in receptor-
negative cells. 
Taken together, (a) MIF knockdown does not significantly lower cell velocity in either cell 
line tested over the course of 3.5 h but (b) cell velocity of receptor-positive/MIF-depleted 
cells is significantly increased by exogenous MIF and reaches the velocity observed in MIF-
stimulated MIF-positive cells, likely due to the fact that CD44/CD74 are present and 
trigger classical MIF responses via Src kinase and ERK1/2. This suggests that the 
CD44/CD74-dependent mechanism is somewhat stronger than the other, unknown one, 
which triggers motility of WT COS-7/M6 cells. 
6.2.2.3. COS-7/M6 fibroblasts respond differentially to native and enzyme-null MIF 
mutants as well as D-DT 
At a molecular level, MIF’s tautomerase activity has been implicated in mediating MIF’s 
actions including cell motility, and is a druggable target in a variety of disorders (Al-Abed 
and VanPatten, 2011; O’Reilly et al., 2016). In experimental disease management, the use 
of tautomerase-null recombinant proteins as well as specific tautomerase inhibitors ISO-1 
and 4-IPP has been proven successful, suggesting that the enzymatic activity of MIF is 
essential (Al-Abed and VanPatten, 2011; Varinelli et al., 2015). Although a genuine 
physiological substrate for MIF/D-DT is yet to be defined, the active site of MIF has been 
well characterised. In a trimer, there are three active sites composed of hydrophobic 
amino acids. Specifically, the nucleophilic N-terminal proline (the first amino acid after 
methionine cleavage) acts as a catalytic base, and its deletion renders MIF enzymatically-
inactive, impairs the MIF-CD74 interaction, and intracellular MIF protein-protein 
interactions (O’Reilly et al., 2016). A recent study developed a range of amino acid 
insertions within the active site to further delineate the role of the N-terminus in MIF-
mediated accumulation of neutrophils in the lung (Pantouris et al., 2015). A proline-to-
methionine (P2M) MIF mutant exhibited the same neutrophil accumulation activity as MIF 
WT, ΔP2, and M3A. However, it was not the catalytic pocket of MIF but rather the 
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residues surrounding it that were involved in the MIF-CD74 interaction (Pantouris et al., 
2015). Here tautomerase-null mutants (MIF P2A and Δ4) did not enhance motility of WT 
COS-7/M6 cells, hence the tautomerase activity of MIF is required for MIF-mediated 
upregulation of random two-dimensional motility of fibroblasts. Furthermore, due to the 
fact that D-DT exhibits a much lower tautomerase activity than MIF, the impact of D-DT’s 
tautomerase activity on migration was not assessed here. 
One interpretation is that the stimulatory effect of MIF on migration is dependent on its 
intrinsic tautomerase activity, conserved across species including man and rodents (Merk 
et al., 2011), bacteria (Burks et al., 2010) and parasites (Qu et al., 2014). As an alternative 
explanation, the lack of four initial amino acids or a Pro-2 substitution may perturb the 
MIF-protein interaction network or MIF trimer formation (Fingerle-Rowson et al., 2009), 
resulting in a dominant-negative effect. Similar questions were partially investigated in a 
study using N-terminal MIF truncations (P2A, Δ4, Δ5, Δ6, Δ7, Δ8, Δ10, where Δn indicates 
how many amino acids (n) were deleted from the N-terminus of MIF) (Kleemann et al., 
2000b). Based on far-ultraviolet circular dichroism spectroscopy, the secondary structure 
of MIF and its mutants was assessed. While the conformation of all MIF mutants closely 
resembled that of native MIF (WT), the structure of Δ4 MIF was characterised by more 
random coil structure (Kleemann et al., 2000b). Moreover, MIF P2F (Pro-2-to-Phe 
substitution) and MIF P2S (Pro-2-to-Ser substitution) with no or very low tautomerase 
activity, respectively, inhibit (a) MCP-1-induced chemotaxis and (b) non-induced, random 
migration of peripheral blood mononuclear cells (PBMCs) similarly to MIF WT 
(Hermanowski-Vosatka et al., 1999). Interestingly, PBMCs investigated by Hermanowski-
Vosatka et al. were composed of 70-90% monocytes and 10-30% B lymphocytes, but the 
status of MIF receptors such as CD74 remained uncharacterised. Hence, it appears that 
tautomerase activity is not required for MCP-1-induced chemotaxis and random migration 
of PBMCs. In contrast to MIF WT, MIF P2A – a mutant slightly different than the 
abovementioned 2PF and P2S – did not induce motility of WT COS-7/M6 fibroblasts 
investigated here. While monocytes and fibroblasts may differentially respond to the 
same stimulus, this result also suggests that each MIF mutant protein may exhibit a 
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different tertiary and quaternary structure and hence distinct modes of action. Next to 
tautomerase-null mutant proteins, specific pharmacological inhibitors of MIF’s 
tautomerase activity, ISO-1 and 4-IPP were used. Both ISO-1 and 4-IPP inhibited MIF-
induced motility of WT COS-7/M6 cells. In summary, as tautomerase-null MIF mutants as 
well as pharmacological tautomerase inhibitors abolish MIF’s stimulatory effect on 
chemokinesis of WT COS-7/M6 fibroblasts, the tautomerase activity itself seems to be 
required for the observed effects. 
Because the oxidoreductase-null MIF mutant C60S increased motility to a much lesser 
extent than MIF WT, the oxidoreductase activity might be partially required for MIF-
triggered upregulation of motility. Interestingly, nucleoside diphosphate kinase A (NDPKA, 
also known as NM23-H1 or NME1) interacts with MIF and this interaction is mediated by 
Cys-60 of MIF (Jung et al., 2008). Consequently, NDPKA-MIF interaction abrogates MIF-
induced proliferation of quiescent NIH 3T3 cells and MIF-induced ERK1/2 activation (Jung 
et al., 2008). The facts that (a) NDPKB is a negative regulator of MIF via a redox reaction 
mediated by Cys-60 (Jung et al., 2008), (b) its closely related paralogue NDPKB (NM23-H2 
or NME2) was found within the MIF/D-DT interactome (see Introduction, Table 2), and (c) 
MIF C60S does not upregulate chemokinesis of WT COS-7/M6 cells to the same extent as 
MIF WT, suggest that MIF-induced upregulation of chemokinesis might be mediated by an 
interaction with a member of the NDPK family. 
The C60S substitution results in poor solubility as compared to native MIF (Kleemann et 
al., 1998; Ouertatani-Sakouhi et al., 2010) but does not affect the tertiary structure 
(Kleemann et al., 1999). To unambiguously show that the CALC (Cys-Ala-Leu-Cys)-based 
oxidoreductase activity is required for MIF’s upregulation of chemokinesis, a substitution 
of both cysteines (resulting in a double mutant C57S/C60S) would be advantageous. 
Nonetheless, MIF C57S/C60S could not be tested in enzymatic assays due to solubility 
problems (Kleemann et al., 1998). Alternatively, a pharmacological inhibitor of MIF’s 
oxidoreductase activity would be valuable to complement the tautomerase-activity 
inhibitors ISO-1 and 4-IPP. 
Discussion 
115 
 
In an attempt to better characterise the MIF family of proteins, D-DT was tested for its 
effect on random motility of WT and CD44+/CD74+ COS-7/M6 cells. Only MIF but not D-DT 
enhanced random motility of WT COS-7/M6 cells. Moreover, MIF alone, D-DT alone, and 
both together enhanced motility of CD44+/CD74+ COS-7/M6 cells. These results provide 
here first experimental evidence that MIF receptors CD44/CD74 are essential for D-DT-
mediated chemokinesis but dispensable for MIF. It is remarkable since MIF and D-DT have 
hitherto been described as acting synergistically in a variety of disease models and 
signalling pathways. Both MIF and D-DT (a) are upregulated in human sepsis and ovarian 
cancer patients (Merk et al., 2011), (b) inhibit p53 in human lung cancer cell lines (Brock et 
al., 2014), (c) are hypoxia-inducible and (d) regulate human clear cell renal cell carcinoma 
(ccRCC) migration (Pasupuleti et al., 2014). In the last study, D-DT showed a more 
pronounced pro-tumourigenic effect than MIF (Pasupuleti et al., 2014). Here, conversely, 
only MIF but not D-DT affected random migration of fibroblasts, adding a novel piece of 
evidence that MIF and D-DT may act differentially depending on their cellular context. This 
would be important when considering organ-specific or organism-wide MIF/D-DT 
inhibition. For instance, Rajesakeran et al. suggest that ISO-1 inhibits MIF but not D-DT 
and 4-IPP inhibits both MIF and D-DT (Rajasekaran et al., 2014). Taken together, it is key to 
consider the cellular targets of MIF/D-DT and adjust accordingly relevant MIF-alone, D-DT-
alone or combined MIF/D-DT inhibition. 
6.2.2.4. Endocytosis of MIF via lipid rafts/caveolae may contribute to its action on COS-
7/M6 fibroblast motility 
In view of the fact that native MIF upregulated motility of MIF receptor-negative COS-
7/M6 cells, the question arose whether and how MIF is endocytosed. Most likely, MIF 
would then either elicit endosomal signalling or undergo endosomal escape. If it 
undergoes endosomal escape, it could act intracellularly and enhance migration via 
directly acting on the actin cytoskeleton. Endosomal escape is poorly understood and 
typically studied in terms of efficient antibody, siRNA, or engineered protein delivery (Li et 
al., 2015), rather than for endogenous proteins. To that end specific endocytosis inhibitors 
were used to address this question. 
Discussion 
116 
 
Inhibitors included: (a) chlorpromazine which inhibits clathrin-mediated endocytosis 
(CME) likely due to the loss of clathrin and adaptor protein complex 2 (AP2) from the cell 
surface; (b) dynasore (DYN) which inhibits both clathrin- (CME) and caveolae-mediated 
endocytosis by inhibiting dynamin GTPase activity; (c) nystatin (NYS) which inhibits 
caveolae-mediated endocytosis by sequestering cholesterol from lipid rafts and 
redistributing it across the membrane; and (d) filipin which also inhibits caveolae-
mediated endocytosis by sequestering cholesterol akin to nystatin (Macia et al., 2006; 
Ivanov, 2008). 
All four endocytosis inhibitors were used at non-toxic concentrations of the same order of 
magnitude as reported elsewhere (Kirchhausen et al., 2008; Xie et al., 2011; Schwartz et 
al., 2012). However, most previous studies only used a single inhibitor and investigated 
MEFs, RAW264.7, HeLa and HEK293 cells, but not COS-7/M6 cells, which makes it difficult 
to compare earlier results with the results shown here. 
Even though MIF is known to be endocytosed by MEFs (Schwartz et al., 2012) as well as 
RAW264.7 macrophages (Xie et al., 2011) via CME, migration was not studied by neither 
Schwartz et al. nor Xie et al. Furthermore, Schwartz et al. assessed the colocalisation of 
MIF and Rab7 (late endosome marker) with and without monodansylcadaverine and 
chlorpromazine in a Rab7GFP overexpression system, potentially inducing overexpression 
artefacts. Here the inhibition of CME by chlorpromazine did not affect MIF-triggered 
motility of MIF receptor-negative WT COS-7/M6 cells suggesting a different internalisation 
pathway. Furthermore, the extent of monodansylcadaverine/chlorpromazine-mediated 
inhibition of MIF endocytosis was within 20-50%, suggesting non-CME endocytosis might 
have occurred in parallel (Schwartz et al., 2012). 
To interfere with the putative endocytosis of MIF beyond CME, dynasore was used as an 
inhibitor of dynamin GTPase activity. Interestingly, dynamin is responsible for cargo 
endocytosis in both CME and non-CME pathways, since both require vesicle scission (von 
Kleist and Haucke, 2012). In epithelial HeLa cells, MIF endocytosis indeed depends on 
functional dynamin, as judged by experiments using dynasore (Schwartz et al., 2012). That 
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result is in line with the observation that CD44+/CD74+ COS-7/M6 cells rely on functional 
dynamin to mediate MIF-driven migration. In such a scenario, MIF binds CD44/CD74 on 
the cell surface, a clathrin-coated pit is formed around the nascent vesicle, the vesicle is 
ultimately cleaved by dynamin, and MIF can either exert endosomal signalling or undergo 
endosomal escape (see Introduction, Figure 2 and 3). Admittedly, as Schwartz et al. noted, 
HeLa cells are negative for CD74 but positive for CXCR4, implicating CXCR4-mediated MIF 
endocytosis as a putative cell entry mechanism. In contrast, MIF upregulates WT COS-
7/M6 cell motility upon dynamin inhibition, suggesting MIF is internalised in a non-clathrin 
and non-dynamin-dependent manner. However, dynasore inhibits fluid-phase endocytosis 
of dextran – a prototypical endocytic cargo – in dynamin 1, 2 and 3 triple-negative as well 
as control, dynamin 1, 2 and 3-positive cells (Park et al., 2013). Because of such off-target 
effects of dynasore, results must be considered with caution. It may be thus concluded 
that (a) dynamin-mediated endocytosis of MIF appears to facilitate MIF-induced 
upregulation of motility in receptor-positive cells, and (b) MIF-mediated motility likely 
depends on lipid rafts/caveolae and not clathrin and dynamin in receptor-negative cells. 
Nystatin – known to sequester cholesterol from lipid rafts and redistribute it uniformly 
within the plasma membrane – was employed as a model inhibitor of non-CME. In both 
cell types tested (MIF receptor-positive and -negative), nystatin abrogated the induction 
of chemokinesis by MIF. Although the status of the MIF receptors was not determined in 
MEFs obtained for the 2012 endocytosis study (Schwartz et al., 2012), MEFs are 
presumably positive for both CD44 and CD74 (Shi et al., 2006). However, nystatin – and 
closely related filipin – did not inhibit endocytosis of MIF by MEFs, despite a trend towards 
inhibition at time point 60 min (Supplementary Figure 2B in Schwartz et al., 2012). Yet it is 
noteworthy that nystatin – here used at 25 μg/ml – Is known to permeabilise cell plasma 
membranes at concentrations four times higher – 100 μg/ml (Schultheiss et al., 2008). 
Thus it hinders the cells from performing their basic physiological functions such as 
maintaining ion homeostasis, growth, or migration, hampering a proper analysis of data 
derived from the MIF/nystatin data. Furthermore, nystatin-mediated inhibition of 
internalisation of endostatin – an inhibitor of angiogenesis – switches endostatin’s uptake 
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route from lipid raft/caveolae- to clathrin-dependent pathway, suggesting that a much 
more complex cross-talk between endocytic pathways exists (Chen et al., 2011). 
Aware of the limitations of the use of nystatin, additional experiments with filipin – 
another inhibitor of caveolin- but not clathrin-dependent endocytosis – were performed 
in WT and CD44+/CD74+ COS-7/M6 cells. Filipin-mediated inhibitory effect on MIF-
stimulated chemokinesis strongly suggests that cholesterol sequestration is indeed 
responsible for MIF’s action, strengthening the conclusion drawn from the MIF/nystatin 
data. In fact, filipin-treated cells were exposed to a relatively low DMSO concentration of 
0.02% (v/v) (Figure 21), twenty-five times less than elsewhere – 0.5% (v/v) (Figure 20). 
Overall, results obtained with endocytosis inhibitors indicate that MIF-mediated increase 
in random cell migration is lipid raft/caveolae-dependent. To address the cytoplasmic 
route(s) of MIF trafficking, further studies need to be performed. How MIF is endocytosed 
can be revealed by a double-immunostaining for MIF and endogenous early endosome 
antigen 1 (EEA1, early endosome marker), Rab5 (early endosome marker), Rab7 (late 
endosome marker), or caveolin-1 (Wieffer et al., 2009). Localisation of gold nanoparticle-
conjugated MIF by using transmission electron microscopy might be useful to confirm the 
MIF internalisation route. 
6.2.2.5. MIF-caveolin/lipid raft axis plays a role in inflammation and migration 
Interestingly, MIF was shown to support the assembly of ‘signalling platforms’ of caveolin-
1-rich lipid rafts in less than an hour (Reidy et al., 2013) by enriching caveolin, 
upregulating extracellular signal-regulated kinase 1/2 (ERK1/2) and interleukin-8 (IL-8), 
and intensifying inflammation. In a model of epithelial infection, P. aeruginosa – known to 
enter the epithelium in a caveolin-1-dependent fashion – upregulated trimeric MIF in lipid 
rafts to facilitate its cellular up-take (Reidy et al., 2013). Data derived from this thesis 
show that lipid raft/caveolae-dependent endocytosis of MIF might mediate MIF’s 
upregulation of WT and CD44+/CD74+ COS-7/M6 cell chemokinesis. While Reidy et al. base 
their conclusions largely on siRNA-mediated silencing of MIF and caveolin, they do provide 
evidence that recombinant MIF N101C (almost exclusively a locked trimer) more than MIF 
WT (more monomeric than trimeric) increases IL-8 synthesis in primary human corneal 
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epithelial cells. Neither recombinant MIF N101C nor MIF WT were tested for their ability 
to upregulate caveolin in lipid rafts. Therefore, it is not unlikely that exogenous MIF causes 
enrichment of caveolin-1 platforms in COS-7/M6 cells and upregulates ERK1/2. If this 
alternative explanation were correct, MIF could upregulate motility of COS-7/M6 cells 
without being internalised. 
In fact, the study of Shi et al. (2006) reported that MIF stimulation of COS-7/M6 cells does 
not lead to ERK1/2 phosphorylation within 30 min. This result was confirmed in this thesis 
but MIF still upregulated the chemokinesis of COS-7/M6 cells in assays that lasted 3.5 h. 
Thus one can speculate that an axis involving MIF and caveolin-1 leads to enhanced 
motility via signalling cascades other than ERK1/2. 
More intriguingly, MIF was shown to stabilise Rac1 – a master regulator of actin 
cytoskeleton and driver of cell migration (see Introduction, Figure 5) – in caveolin-1-rich 
lipid rafts and, hence, upregulates invasion of A549 adenocarcinoma cells (Rendon et al., 
2007). More specifically, Rendon et al. showed that MIF is pro-invasive in A549 
adenocarcinoma cells and its inhibition either by siRNA or ISO-1 is a viable therapeutic 
approach. Mechanistically, evidence was provided that MIF stabilises Rac1 in the plasma 
membrane and facilitates Rac1 GTP loading and effector binding. That Rac1 from MIF-
deficient cells inherently cannot be loaded with GTP points to the fact that Rac1 cannot 
dissociate from its inhibitor RhoGDI which holds Rho GTPases such as Rac1 in an inactive, 
GDP-bound state (see Introduction, Figure 5). Moreover, MIF depletion redistributes 
flotillin-2 and caveolin, two markers of lipid rafts, to non-raft fractions. Taken together 
these findings suggest that an axis involving MIF-Rac1-caveolae-RhoGDI could explain the 
observed effects in WT COS-7/M6 fibroblasts. Remarkably, RhoGDI, is not only a putative 
MIF interactor (see Introduction, Table 2) but also a negative regulator of Rac1 (see 
Introduction, Figure 5). 
Recently, MIF overexpression has been reported to directly induce caveolin-1 
phosphorylation, which enables HMGB1 release and subsequent CD11b+ cell recruitment 
in the context of breast cancer metastasis (Lv et al., 2016). This finding is interesting 
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because CD11b+ cells are innate immunity cells including monocytes/macrophages, 
providing evidence for a yet another MIF-macrophage signalling pathway. 
Combined, all previous studies on the MIF-caveolin axis (Rendon et al., 2007; Reidy et al., 
2013; Lv et al., 2016) point to the fact that a MIF-caveolin/lipid raft signalling cascade may 
be active independent of MIF’s classical CD74 receptor. 
Alternatively, G-protein coupled receptor (GPCR)-elicited signalling has been implicated in 
MIF-mediated motility and could help to explain some of the findings of this work. As COS-
7/M6 cells are weakly positive for a member of the GPCR family, CXCR4 (Cai et al., 2012), 
it is possible that MIF-mediated upregulation of chemokinesis is due to downstream 
CXCR4 signalling. Moreover, CXCR4-mediated endocytosis followed by MIF release into 
the cytoplasm could explain how MIF is internalised independent of CD44/CD74. In fact, in 
CD74-negative but CXCR4-positive HEK293 cells, a CXCR4-specific inhibitor AMD3100 
inhibits MIF internalisation by 40% (Schwartz et al., 2012). Moreover, CXCR4 resides in 
lipid rafts in human PC-3 prostate cancer cells (Wong et al., 2014) as well as in human 
monocytes described in one report (Triantafilou et al., 2002) but not in similarly obtained 
human PBMCs described elsewhere (Kozak et al., 2002). This line of questioning merits 
further attention as it would explain why WT COS-7/M6 cells are responsive to MIF. 
While D-DT binds CD74, nothing is known about a D-DT-CXCR4 axis. Because D-DT 
upregulates motility of CD44+/CD74+ COS-7/M6 but not WT COS-7/M6 cells, it would be 
unlikely that a receptor such as CXCR4 in WT COS-7/M6 suffices to transduce D-DT-
triggered signalling. In fact, D-DT classically engages its two receptors in CD44+/CD74+ 
COS-7/M6 cells and transduces the signal downstream. This finding is in line with the in 
vitro actin assembly assays where MIF but not D-DT slowed down the rate of actin 
assembly (section 6.4). 
Taken together, WT but not enzymatically-inactive MIF upregulates motility of fibroblasts 
independent of its receptors, and possibly due to lipid raft-mediated endocytosis or 
signalling. Additionally, MIF’s structural and functional homologue, D-DT does require its 
receptors for upregulating motility of fibroblasts, suggesting it uses its orthodox D-DT-
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CD74/CD44-Src-ERK1/2 signalling pathway. Mechanistically, the fact that MIF upregulates 
motility independent of its CD44/CD74 receptors suggests a cytoplasmic rather than an 
extracellular function, or a presence and action of an unknown receptor. Since the 
dynamic rearrangements of the actin cytoskeleton are fundamental to driving cell motility, 
the idea that MIF directly influences actin was further tested. 
6.3. Chemokinesis and actin staining upon MIF stimulation 
Cells maintained under ordinary culture conditions exhibit a variety of actin structures 
such as fibres spanning across the cytoplasm, cortical rims around the plasma membrane 
(Hall, 1998), and nuclear actin playing a role in the serum response (Baarlink et al., 2013). 
Under starvation, stress fibres disappear whereas cortical rims become more prominent. 
Conversely, re-introduction of serum or serum components brings back stress fibres. It 
was hypothesised that MIF may mimic the effects of serum on the fibroblast cytoskeleton. 
To observe whether MIF rearranges the actin cytoskeleton, phalloidin stainings of actin 
stress fibres (filamentous actin) in WT COS-7/M6 cells were employed. MIF rescued the 
starvation-induced loss of actin stress fibres, as compared to the heat-inactivated protein. 
This result is in line with the finding that MIF stimulation of B cells leads to actin 
polymerisation (Klasen et al., 2014) and the fact that MIF–/– bone marrow-derived 
macrophages (BMDMs) exhibit fewer chemokine-induced stress fibres (Fan et al., 2011) 
but extends it for the first time to fibroblast-like cells. 
Heterogeneity of cells is noticeable not only in the random motility assays but also in actin 
stainings. In random motility assays, a certain population of cells was observed to remain 
non-motile with or without stimulus, but a significantly larger amount of cells appeared to 
be responsive to MIF/D-DT. Same holds true for phalloidin-stained actin cytoskeleton, as 
some cells appeared to maintain their starvation phenotype (cortical rim) but statistically 
significantly, more cells exhibited prominent stress fibres. One possible explanation is a 
local auto- or paracrine effect. Enhanced cell motility as well as prominent stress fibres 
might be triggered first by MIF/D-DT, and secondarily by other factors such as secreted 
EGF. 
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All experiments were performed under reduced-serum conditions (0.5% (v/v) FCS) thus 
diminishing proliferation and excluding the effect of cell growth. If starving the cells were 
undesirable, another experimental approach would include the use of mitomycin C to 
arrest the cell cycle – allowing the cells to stay at 10% (v/v) FCS. 
It is worth mentioning that starvation itself can induce morphological changes such as loss 
of stress fibres in cells. Moreover, starvation upregulates endocytosis (Mueller et al., 
2015) and autophagy (Russell et al., 2014). As such, it may facilitate the uptake of 
membrane proteins/extracellular factors such as recombinant proteins, thus partially 
contributing to effects observed here. Notably, D-DT and some MIF substitution mutants 
did not induce chemokinesis in WT COS-7/M6 cells, pointing to the fact that the observed 
phenomena are stimulus-specific. Were they artefacts, any exogenously added 
polypeptide such as MIF point-mutant or D-DT would stimulate motility. 
6.4. Actin and microtubule assembly 
6.4.1. MIF induces F-actin stress fibre formation in WT COS-7/M6 cells 
Encouraged by the findings that (a) MIF steers WT COS-7/M6 cell chemokinesis 
independent of CD44/CD74, (b) MIF promotes actin stress-fibre formation in the same 
cells, and (c) MIF/D-DT putatively interact with many actin cytoskeleton-associated 
proteins in NIH 3T3 fibroblasts, the MIF-actin axis was further investigated by two in vitro 
actin assembly assays. 
The first assay used fully reconstituted components needed for the actin assembly 
including monomeric pyrene-actin, purified seven-subunit ARP2/3 complex, and VCA 
domain as an actin assembly inducer. Hypothesising that MIF/D-DT directly interact with 
one of the ARP2/3 proteins, MIF/D-DT were tested for their ability to alter the rate of 
pyrene-actin polymerisation in vitro. However, neither MIF nor D-DT influenced actin 
polymerisation, making it unlikely that a direct MIF-ARP2/3 or MIF-VCA interaction 
accelerates or slows down the rate of actin assembly occurring in vivo. More importantly, 
when a HEK293 cell extract was used as a source for the ARP2/3 complex instead of 
purified and reconstituted components of ARP2/3, MIF but not D-DT slowed down the 
rate of VCA-induced actin assembly. The conclusion of those experiments can be based on 
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prior research on capping proteins which provides insight into the physiological 
mechanism of how motility might be promoted while the rate of actin assembly is slowed 
down. Once a capping protein binds the fast-growing end of an actin filament, it prevents 
its further out-growth (typically within the lamellipodium, i.e. in the direction of cell 
movement). While this particular pre-existing actin filament is no longer extended, the 
remaining available pool of G-actin can be used to build up new actin filaments. 
Ultimately, the capping of one filament promotes the generation of more branching 
events nearby and thus results in the extension of new filaments within the lamellipodium 
(Mejillano et al., 2004; Akin and Mullins, 2008; Edwards et al., 2014). 
If MIF slowed down the rate of actin assembly by a mechanism akin to that of a capping 
protein, it eventually could also enhance the build-up of new actin filaments and therefore 
promote cell motility, as observed in MIF-triggered (a) upregulation of COS-7/M6 cell 
chemokinesis and (b) actin polymerisation in the same cells. 
This thesis provides a rationale for a new line of questioning in which MIF may function as 
a chaperone for cytoskeletal proteins. Specifically, monomeric MIF has an exposed 
hydrophobic face (Israelson et al., 2015) or patch (Sun et al., 1996) which may have 
affinity towards other proteins and confers a chaperoning role. To illustrate this, MIF was 
shown to be chaperone for superoxide dismutase 1 (SOD1) in the context of amyotrophic 
lateral sclerosis as it prevents aggregation of misfolded SOD1 (Israelson et al., 2015). As 
such, during fast actin turnover at the leading edge of a migrating cell, MIF could help to 
protect certain cytoskeleton-associated proteins from degradation, resulting in a net 
movement forward. 
6.4.2. Actin and microtubule (MT) assembly 
Which cytoskeletal components drive cell motility is cell-specific. In glioblastoma cells it is 
not actin but MTs that are solely responsible for motility (Panopoulos et al., 2011). 
Migration of fibroblast and fibroblast-like cells such as COS-7/M6 is actin-dependent but 
also requires cell polarisation whereby the MT-organising centre is localised between the 
leading edge and the nucleus. In PtK1 cells, Rac1 coordinates both actin and MTs to drive 
cell migration (Wittmann et al., 2003). 
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To broaden our understanding of the mode of action of MIF, a hypothesis could be tested 
that MIF affects the network of MTs. While MIF promotes excessive MT polymerisation 
(Frascaroli et al., 2009; Preau et al., 2013), it remains to be determined whether MIF 
directly modifies MT assembly by performing in vitro MT assembly assays. Earlier studies 
on the MIF-MT axis used crude extracts of MIF derived from guinea pig lymph nodes 
(McCarthy et al., 1979). Today, not only highly purified, endotoxin-free MIF, but also point 
mutants such P2A, Δ4 and C60S can be produced, and tested in in vitro MT assembly 
assays. 
6.5. Future perspectives 
The implications of this work extend into many research areas. 
In a screen for a MIF receptor, a cDNA library originating from a human monocytic 
leukaemia cell line (THP-1) was expressed in COS-7 cells (Leng et al., 2003). While CD74 
was identified as a candidate with MIF binding capacity, that study did not identify any 
other CD44 molecule nor C-X-C receptors on the surface of THP-1 monocytes. In adult T-
cell leukemia 2 (ATL-2) cells, thioredoxin was described to be internalised simultaneously 
with MIF (Son et al., 2009), but the presence of CD74 or CXCRs within that MIF-
thioredoxin complex was not evaluated. In U87 human glioblastoma cells, MIF binds EGFR 
but it is unknown whether a hypothetical CD74/EGFR heterodimer forms as well. In 
addition, COS-7 cells are marginally positive for CXCR4 (Cai et al., 2012) which might 
transduce some of MIF’s actions. Furthermore, not every study evaluated the status of 
MIF receptors (see Introduction, Figure 3A-B). All of this fragmentary evidence points to 
the fact that there exists yet another MIF receptor, or a novel internalisation route. 
If MIF upregulates chemokinesis of WT COS-7/M6 cells, this mechanism could involve (a) 
MIF phosphorylating caveolin-1 (Lv et al., 2016) or (b) MIF being endocytosed via lipid 
rafts, possibly via CXCR4 or a yet-unidentified receptor. MIF could be attracted to a lipid 
raft by its hydrophobic patch in order to bind the plasma membrane, a process similar to 
that observed elsewhere (Bagnat et al., 2000; Peng et al., 2005). Upon MIF recruitment to 
the lipid raft, neighbouring rafts could be recruited (a) to provide a larger platform for 
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downstream cytoplasmic signalling but possibly also (b) to mediate MIF internalisation 
(Simons and Toomre, 2000). 
Provided exogenous MIF is endocytosed and localises within an endosome, it could either 
undergo lysosomal degradation or endosomal escape. While cellular trafficking such as 
endosomal escape has been extensively studied in the context of small-molecule drug 
delivery, gene/siRNA delivery, and viral infections, not much data and technological 
advances exist in terms of polypeptide/protein endosomal escape. Only last year has seen 
a major step forward when aurein 1.2, a 13-residue peptide, has been described to 
increase non-endosomal protein delivery in mammalian cells (Li et al., 2015). It was found 
in a screen using superpositively charged GFP (+36 GFP) based on a premise that 
positively-charged proteins have an intrinsic capacity to be taken up by cells and undergo 
endosomal escape, effectively evading the proteasomal degradation (Li et al., 2015). 
Speculating that MIF has reached the cytosol, MIF could be interacting with a variety of 
actin cytoskeleton associated proteins. In fact, cytoplasmic MIF localises to the cell 
periphery in live epithelial HeLa (Kleemann et al., 2000a) and fibroblast-like NIH 3T3 cells 
(Filip et al., 2009). It also appears to be enriched in the pseudopodial fraction of cells 
undergoing chemotaxis. After mechanical removal of the cell body, pseudopodia 
remaining within a 3-μm Transwell® membrane were washed out and MIF was found 
within the pseudopodial proteome (Lin et al., 2004). However, excimer laser ablation – a 
technique much more precise than mechanical removal of the cell body – did not 
corroborate that finding (Ito et al., 2012). Still one could speculate that such a locally-
available pool of MIF molecules – either cytoplasmic or recently endocytosed – might be 
ready to influence the actin network either at the leading edge or within the pseudopodia. 
Point or deletion mutants of D-DT would shed more light on the action of D-DT. Further 
investigation on D-DTL – a D-dopachrome tautomerase-like protein identified within the 
human proteome (UniPROT ID A6NHG4) – might expand the MIF superfamily. 
Furthermore, four other D-DT genes were recently described (Premzl, 2015). If cells 
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positive for novel D-DTs could be identified, a question could be asked whether altered 
physiological levels of novel D-DTs affect cell motility. 
While current MIF research community largely focuses on novel MIF/D-DT gene products 
such as invertebrate MIF orthologues (Furukawa et al., 2016) as well as novel therapeutic 
approaches in humans (Roger et al., 2016), this thesis emphasises the importance of 
further delineation of MIF/D-DT signalling axes at a cellular level in fibroblasts. Further 
identification of novel MIF receptor(s) or internalisation routes could help to better 
understand the roles of secreted versus intracellular MIF/D-DT. 
6.6. Summary of the discussion 
Full-length, enzymatically-active MIF promotes cell motility independent of CD44/CD74. 
This may be due to the fact that it is endocysed in a novel, perhaps a non-receptor 
mediated way, and thus acts intracellularly. Such an explanation would be in line with the 
MIF/D-DT interactome data (see Introduction, Table 2) which revealed that MIF/D-DT 
putatively interact with actin cytoskeleton-related proteins. Alternatively, there might be 
an unidentified MIF receptor – a GPCR such as CXCR4 or a growth factor receptor such as 
EGFR – that transduces MIF’s downstream signalling in WT COS-7/M6 cells. 
Although D-DT is a functional and structural homologue of MIF, the fact that it requires 
CD44 and CD74 for upregulation of COS-7/M6 cell chemokinesis may stem from the fact 
that it necessarily needs the classical CD44/CD74-Src-ERK1/2 axis to exhibit its biological 
effects. In support of this theory, it may be that unlike MIF, D-DT is not endocytosed at all 
and hence cannot act cytoplasmatically. Such an interpretation is corroborated by the fact 
that unlike MIF, D-DT did not affect the rate of in vitro actin assembly. As an alternative, 
D-DT may be not as robust as MIF with respect to fibroblast-like cells; in other words, 
circulating or other resident MIF receptor-negative cells may be highly responsive to D-DT. 
While MIF and D-DT were both described to synergistically participate in ccRCC wound 
healing (Pasupuleti et al., 2014), these cancer cells may exhibit different features than 
simian fibroblasts. Unlike this thesis, other studies did not address the mode of action of 
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D-DT on motility of fibroblast-like cells, and certainly more studies are needed to elucidate 
the role of D-DT in migrating cells. 
Fibroblasts are accessory cells that migrate towards the wound and secrete ECM 
constituents to promote tissue repair. Stromal fibroblasts are known to steer the 
collective invasion of carcinoma cells – themselves being incapable of invasion – in an 
integrin- and protease-dependent fashion (Gaggioli et al., 2007), and making them an 
attractive therapy target and justifying more research on their migratory capacity. MIF 
promotes the migration of fibroblasts (MEFs) in the migratory phase of wound healing 
(Dewor et al., 2007). More precisely, short-term but not long-term treatment with MIF 
stimulates motility of fibroblasts. Conversely, MIF inhibits cancer-associated fibroblast 
(CAF) in a rhabdomyosarcoma environment (Tarnowski et al., 2010). Based on this thesis, 
a novel piece of the puzzle is added, as MIF does not require its receptors for upregulation 
of COS-7/M6 cell motility. It would be clinically relevant to characterise patient-derived 
CAFs for their CD44/CD74 and CXCRs expression pattern, and subsequently test their 
responsiveness to MIF/D-DT. 
This work builds upon previous studies that showed MIF-mediated upregulation of MEF 
would healing and extends them by investigating MIF’s homologue – D-DT. It also 
broadens the current knowledge on COS-7/M6 as it seems that receptors are required for 
D-DT- but not MIF-triggered two-dimensional cell motility (Figure 25). 
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Figure 25. Hypothetical model of how MIF/D-DT affect cell migration based on data from this thesis. MIF 
but not D-DT facilitates receptor-negative WT COS-7/M6 cell chemokinesis, suggesting either a cytoplasmic 
role for MIF or lipid raft-mediated signalling. Conversely, D-DT engages CD44/CD74 to upregulate WT COS-
7/M6 chemokinesis, consistent with earlier reports (Merk et al., 2011). As not only receptors but also 
clathrin and dynamin are required for MIF-mediated modulation of intracellular signalling (Schwartz et al., 
2009; Xie et al., 2011), inhibitors of clathrin and dynamin abrogated MIF’s and D-DT’s induction of 
chemokinesis in receptor-positive cells. In receptor-negative cells only the inhibition of lipid raft-associated 
endocytosis abolished MIF-induced chemokinesis, again indicative of either a novel MIF internalisation route 
via lipid rafts and subsequent endosomal escape, the presence of a yet-unidentified MIF receptor, or specific 
lipid raft/caveolin-mediated signalling. In line with those cell-culture results, MIF but not D-DT decreases the 
rate of monomeric (globular) actin assembly into filamentous actin in in vitro actin assembly assays using 
HEK293 total cell extracts as ARP2/3 donor, suggesting a novel role for MIF in directly influencing the actin 
cytoskeletal machinery for driving cell motility. 
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7. Appendix 
 
Appendix 1. Summary of all chemokinesis results along with the statistical analyses. 
COS-7/M6 
cell line 
Stimulation Median velocity 
[μm/min] 
Mean velocity ± SD 
(95% CI) [μm/min] 
Significance 
WT NT 0.07 0.10 ± 0.09 (0.09, 0.11) - 
CD44
+
/CD74
+
 NT 0.08 0.10 ± 0.07 (0.09, 0.11) - 
WT EGF (vs. NT) 0.14 0.18 ± 0.14 (0.16, 0.19) *** 
CD44
+
/CD74
+
 EGF (vs. NT) 0.11 0.16 ± 0.13 (0.15, 0.18) *** 
WT MIF (vs. NT/boiled MIF) 0.10 0.14 ± 0.11 (0.13, 0.15) *** / * 
CD44
+
/CD74
+
 MIF (vs. NT/boiled MIF) 0.11 0.14 ± 0.09 (0.13, 0.15) *** / *** 
WT D-DT (vs. NT/boiled D-DT) 0.08 0.11 ± 0.09 (0.10, 0.12) Ns / Ns 
CD44
+
/CD74
+
 D-DT (vs. NT/boiled D-DT) 0.09 0.12 ± 0.10 (0.11, 0.13) * / *** 
WT Boiled MIF (vs. NT) 0.08 0.12 ± 0.09 (0.10, 0.13) Ns 
CD44
+
/CD74
+
 Boiled MIF (vs. NT) 0.08 0.10 ± 0.08 (0.09, 0.10) Ns 
WT Boiled D-DT (vs. NT) 0.07 0.10 ± 0.09 (0.09, 0.11) Ns 
CD44
+
/CD74
+
 Boiled D-DT (vs. NT) 0.07 0.09 ± 0.07 (0.08, 0.90) ** 
WT MIF + D-DT (vs. NT) 0.09 0.12 ± 0.09 (0.11, 0.13) *** 
CD44
+
/CD74
+
 MIF + D-DT (vs. NT) 0.10 0.12 ± 0.10 (0.12, 0.13) *** 
WT Boiled MIF + boiled D-DT 
(vs. NT/MIF + D-DT) 
0.08 0.11 ± 0.10 (0.10, 0.13) Ns / Ns 
CD44
+
/CD74
+
 Boiled MIF + boiled D-DT 
(vs. NT/MIF + D-DT) 
0.07 0.09 ± 0.07 (0.08, 0.10) ** / *** 
WT NT 0.08 0.09 ± 0.05 (0.09, 0.10) - 
WT MIF (vs. NT) 0.10 0.12 ± 0.07 (0.11, 0.13) *** 
WT MIF C60S (vs. NT) 0.08 0.10 ± 0.06 (0.10, 0.11) * 
WT NT 0.07 0.08 ± 0.06 (0.08, 0.91) - 
WT MIF (vs. NT) 0.09 0.11 ± 0.06 (0.10, 0.12) *** 
WT MIF Δ4 (vs. NT) 0.06 0.07 ± 0.05 (0.07, 0.08) Ns 
WT MIF P2A (vs. NT) 0.07 0.08 ± 0.04 (0.07, 0.08) Ns 
WT NT 0.07 0.09 ± 0.07 (0.08, 0.10) - 
WT MIF + EtOH 0.09 0.12 ± 0.09 (0.11, 0.13) - 
WT MIF (vs. NT) 0.08 0.11 ± 0.09 (0.10, 0.12) *** 
WT MIF + 4-IPP (vs. MIF + EtOH) 0.07 0.09 ± 0.06 (0.08, 0.10) *** 
WT MIF + ISO-1 (vs. MIF + EtOH) 0.07 0.09 ± 0.08 (0.08, 0.10) *** 
WT NT 0.09 0.12 ± 0.09 (0.10, 0.13) - 
WT MIF (vs. NT) 0.12 0.16 ± 0.11 (0.14, 0.17) *** 
WT MIF siRNA (vs. NT) 0.08 0.10 ± 0.09 (0.09, 0.11) Ns 
WT MIF siRNA + MIF (vs. MIF siRNA) 0.10 0.13 ± 0.09 (0.12, 0.14) *** 
CD44
+
/CD74
+
 NT 0.11 0.14 ± 0.10 (0.13, 0.16) - 
CD44
+
/CD74
+
 MIF (vs. NT) 0.15 0.19 ± 0.13 (0.17, 0.21) *** 
CD44
+
/CD74
+
 MIF siRNA (vs. NT) 0.09 0.11 ± 0.09 (0.10, 0.13) ** 
CD44
+
/CD74
+
 MIF siRNA + MIF (vs. MIF siRNA) 0.11 0.14 ± 0.10 (0.13, 0.16) *** 
95% CI is the lower and upper 95% CI of the mean. All stimulations with recombinant proteins, MIF’s 
tautomerase activity inhibitors, and ethanol were performed at 0.5% (v/v) FCS. NT denotes 0.5% (v/v) FCS 
without any exogenous compound. The treatments are statistically compared towards respective NT 
controls, not an overall mean of all NT values ever generated (colour coding). Abbreviations: CI, confidence 
interval; EtOH, ethanol; SD, standard deviation. Significance levels: ns, non-significant (p > 0.05); *, p ≤ 0.05; 
**, p ≤ 0.01; ***, p ≤ 0.001. 
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9. Summary in English 
Macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT) are 
paralogous pro-inflammatory cytokines. Whereas cytosolic MIF plays a role in cell cycle 
progression, secreted MIF and D-DT activate second messenger signalling through a CD44/CD74 
receptor complex. Using an interactome screen, cytosolic MIF/D-DT were found to interact with 
many actin cytoskeleton-associated proteins in NIH3T3 fibroblasts suggesting a direct involvement 
of MIF/D-DT in modulating cell motility, but whether the receptors are indispensable for mediating 
motility remains elusive. To differentiate between receptor- and non-receptor-mediated events, 
COS-7/M6 fibroblasts deficient in CD44/CD74 (WT) and stable cell lines expressing CD44 and CD74 
were generated. Chemokinesis (random single-cell motility) was assessed in cells stimulated with 
recombinant MIF/D-DT, mutated forms of MIF, inhibitors of MIF’s tautomerase activity, and 
inhibitors of clathrin- and non-clathrin-dependent endocytosis. Due to low D-DT’s tautomerase 
activity, ISO-1/4-IPP were not tested with D-DT. In the presence of CD44/CD74, both MIF and D-DT 
stimulated chemokinesis but only MIF enhanced chemokinesis in the absence of receptors. The 
stimulatory effect of MIF on migration depended on its tautomerase activity and lipid 
raft/caveolae-mediated – but not clathrin-mediated – endocytosis. To observe a direct effect of 
MIF and D-DT on actin dynamics, actin polymerization was measured in an in vitro actin assembly 
assay. MIF but not D-DT decreased the rate of F-actin assembly. By decreasing the rate of cell 
extract-driven actin assembly, MIF phenocopies the function of F-actin capping proteins. 
Moreover, stimulation with MIF increased the number of prominent F-actin stress fibres in COS-
7/M6 WT. Taken together, MIF stimulates fibroblast chemokinesis independent of the status of its 
cell-surface receptors, likely by directly modulating the actin cytoskeleton. MIF-mediated 
chemokinesis appears to depend on lipid raft/caveolae-mediated endocytosis. D-DT triggers 
chemokinesis only in the presence of MIF/D-DT receptors – CD44/CD74 – implying D-DT requires 
the classical receptor-driven second-messenger transduction pathway. 
 
Summary in German 
132 
 
10. Summary in German (Zusammenfassung auf Deutsch) 
Macrophage migration inhibitory factor (MIF) und D-dopachrome tautomerase (D-DT) sind 
paraloge pro-inflammatorische Zytokine. Zytosolisches MIF spielt bei der Progression des 
Zellzyklus eine Rolle, während sekretiertes MIF und D-DT intrazelluläre Signalkaskaden über eine 
Aktivierung eines CD44/CD74 Rezeptorkomplexes modulieren können. Mittels Interaktom-
Screening in NIH3T3 Fibroblasten wurde gefunden, dass zytosolisches MIF/D-TT mit Zytoskelett-
assoziierten Proteinen interagiert. Darauf basierend wurde postuliert, dass MIF/D-DT die Motilität 
von Zellen moduliert. Ob hier eine Aktivierung der Membranrezeptoren eine Rolle spielt, ist 
bislang unbekannt. Um zwischen Rezeptor-vermittelten und Rezeptor-unabhängigen 
Mechanismen zu unterscheiden, wurden CD44/CD74-defiziente COS-7/M6 Fibroblasten (WT) 
verwendet, sowie Zelllinien erzeugt, welche stabil CD44 und CD74 exprimieren. Chemokinese 
(random single-cell motility) wurde an Zellen untersucht, die mit rekombinantem MIF/D-DT, 
mutierten Formen von MIF, Inhibitoren der Tautomerase-Aktivität von MIF, sowie Inhibitoren von 
Clathrin-abhängiger und Clathrin-unabhängiger Endozytose, stimuliert wurden. Aufgrund der 
geringen D-DT Tautomeraseaktivität, ISO-1/4-IPP wurden nicht mit D-DT getestet. In der 
Anwesenheit von CD44/CD74 stimulierten sowohl MIF als auch D-DT die Chemokinese, allerdings 
war nur MIF hierbei in der Lage, in Abwesenheit der Rezeptoren zu stimulieren einen 
stimulierenden Einfluss auf die Chemokinese auszuüben. Der stimulierende Effekt von MIF 
basierte auf dessen Tautomerase-Aktivität und wurde durch Lipid raft/Caveolae-abhängige – nicht 
jedoch Clathrin-abhängige – Endozytose vermittelt. Um einen möglichen direkten Effekt von MIF 
und D-DT auf die Aktin-Dynamik zu untersuchen, wurde mittels eines Aktin-Assemblierungs-Assays 
die Aktin-Polymerisation in vitro gemessen. MIF, nicht aber D-DT, verminderten die 
Assemblierungsrate von F-Aktin. Wahrscheinlich beruht dies auf einer F-Actin Capping Protein-
analogen Funktion von MIF. Darüber hinaus führte die Stimulation mit MIF zu einer erhöhten 
Anzahl an prominenten F-Aktin Stressfasern in COS-7/M6 (WT) Zellen. Zusammengefasst 
stimulierte MIF die Chemokinese von Fibroblasten, unabhängig von Membranrezeptoren, über 
direkte Modulation des Aktin-Zytoskeletts. Die MIF-stimulierte Chemokinese basierte auf Lipid 
raft/Caveolae-abhängiger Endozytose. Dagegen stimulierte D-DT die Chemokinese nur in 
Anwesenheit der Membranrezeptoren CD44/CD74, was vermutlich auf einer klassischen Rezeptor- 
und second messenger-vermittelten Signalkaskade beruht.  
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